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Introduction 
P eriodic disease was probably mentioned for the first time in medical literature in 1806, when Heberden described a clinical entity in which periodic pain affecting the 
abdomen and sometimes the chest and extremities predominated. (I) These 
patients suffered from "pains which are regularly intermittent, the fits of which return periodically as 
those of an ague, such as I have known in the bowels, stomach, breasts, lans, arms, hips, though it 
be but seldom that such parts suffer in days and recur for years at remarkably regular short 
intervals At that time periodic such a manner" 
In 1895, Osier described a clinical entity in which penodic pain affecting the abdomen and 
sometimes the chest and extremities predominated (2) A few years later, Janeway and Mosenthal 
reported on a case of a 16-year-old Jewish school girl who suffered from birth onwards from 
recurrent attacks of penodic abdominal pain accompanied by fever of short duration (3) These 
reports focussed on the periodic occurence of symptoms but the term "periodic disease" as such 
was first coined by Reimann in 1948 He defined periodic disease as disorders featured by regular 
recurrences of clinical symptoms with recurrent arthralgia, abdominal pain and skin rashes as the 
main manifestations. (4) In his view the symptom of fever within this clinical picture was prominent 
enough to justify the term penodic fever. 
Soon it became clear that the early cases reported by Osier and Janeway and Mosenthal 
constituted a separate syndrome charactenzed by fever, acute abdominal, pleuntic and articular 
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pam (5) It appeared that there was a frequent familial occurrence and that the disease mainly 
affected people from the Mediterranean bassin, hence the name familial Mediterranean fever 
(FMF) (6) Although the first cases were descnbed in the beginning of the 20th century, there are 
indications that FMF is a much older disease and perhaps is even mentioned in the Bible (Leviticus 
26 16) As the number of cases grew its clinical picture became very distinct Familial 
Mediterranean fever (FMF) is an autosomal recessive disorder occurring mainly in Sephardic Jews, 
Arabs and Armenians Although FMF has a preference for people from Mediterranean ancestry, it 
does occur in Turks, French, Germans, Swedes, Italians and Dutch In a landmark paper from 
1967, Sohar and collegues described the clinical picture of FMF (7) The acute febrile attacks, the 
hallmark of the disease, are self-limited febrile episodes lasting from 24 to 48 hours and recurnng 
at irregular intervals, accompanied by peritonitis, pleuritis and synovitis So ailed erysipelas-like 
skin lesions are also very typical for the disease In early senes amyloidosis is mentioned a the 
second major manifestation of the disease Amyloidosis is systemic and of the AA type and leads 
almost invanably to nephropathy and death due to renal failure In 1974 colchicine was introduced 
as mainstay in the therapy of FMF In several double-blind tnals it was shown that colchicine, if 
dosed adequately, was able to decrease frequency and severity of attacks in a substantial number 
of these patients (Θ-10) Subsequently, it was shown that colchicine was also helpful in preventing 
and arresting the development of amyloidosis ( I I ) Ftecently, the FMF susceptibility gene has been 
mapped to the short arm of chromosome 16 (12) 
Over time, other separate syndromes typified by penodic fever have been descnbed. For 
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instance, adult-onset Still's disease, a vanation of Still's disease in children, was for the first time 
described in 1971 as a syndrome with high spiking fever, a typical evanescent rash and arthntis. 
( 13) Familial Hibernian fever has been noted in a large Insh family presenting as attacks of fever 
with localized myalgia and painful erythema ( 14) 
Apart from Still's disease other periodic fever syndromes have been recognized in children such 
as chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome (15,16) and a 
syndrome of penodic fever, pharyngitis and aphtous stomatitis (FAPA). ( 17) This list of penodic 
fever syndromes is far from exhaustive and all have in common that the diagnosis still relies upon 
clinical evaluation. 
In 1979, physicians from the University Hospital in Leiden, The Netherlands were confronted 
with 3 patients with peculiar attacks of fever, occurnng every 2 to 4 weeks and lasting 3 to 7 days. 
Two patients were brother and sister and all patents had a remarkably similar clinical picture. 
From birth onwards, the patients were suffering from febnle attacks accompanied by abdominal 
pain and diarrhoea, impressive swelling of the cervical lymph nodes, skin lesions and joint 
involvement. Laboratory testing revealed an acute phase reaction with leukocytosis, neutrophilia 
and a raised erythrocyte sedimentation rate. A firm diagnosis could not be made in these patients 
but recurrent infections, malignancies, and auto-immune disorders were excluded during the 
frequent and prolonged admissions. Although a few Dutch patients with FMF have been descnbed, 
the abovementioned clinical picture was completely dissimilar from FMF. (18) As part of an 
immunological work-up, 2 patients underwent a bone marrow biopsy. 
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Fluorescence of bone marrow plasma cells was very similar in both patients showed an 
abnormally high percentage of delta positive cells. Subsequent immunoelectrophoresis showed a 
clear IgD precipitation line. (Fig. I) 
Rgl 
Serum immunoelectrophoresis 
showing a high concentration 
of IgD in serum of a patient 
with the hyper-lgD syndrome. 
Comparison with normal 
serum (upper panel), undiluted 
patient's serum (middle panel) 
and a 1:3 diluted patient's 
sample (lower panel). The 
precipitation line represents a 
high concentration of IgD. 
Further quantification of this IgD revealed very high concentrations of this protein. The third patient 
also tested positive for IgD. Within a short period of time 3 other similar patients were found. The 
clinical picture of these patients did not fit with any of the previous described syndromes, especially 
FMF, and it became clear that this constituted a new syndrome. In the Lancet of May 1984, Van 
der Meer et al. presented a series of 6 these patients as a new syndrome called the 
hyperimmunoglobulinemia D and periodic fever syndrome (HIDS). ( 19) 
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Subsequently, reports of similar cases came from United Kingdom, France, Italy and later from the 
United States. (20-23) This firmly established HIDS as a new syndrome. The pathogenesis of this 
syndrome however remained obscure and despite initial enthusiasm for colchicine, no treatment 
proved beneficial Although HIDS can be described as a benign disease because there are no 
potentially lethal complications, the disease has senous personal consequences for patients and 
their families. If the disorder remains undiagnosed, these patient suffer from repeated invasive 
investigations. The prospect of having a disease which cannot be cured and will lead to lifelong 
symptoms is difficult to bear and the recurrent attacks deeply interfere with the social and 
economical lifes of patients and families. In 1992, further research in this syndrome was initiated by 
the establishment of the "International Hyper-lgD study group". This study group consists of 
physicians treating these patients and goal of this study group is to improve awareness of, facilitate 
diagnosis of, and investigate novel therapies for this syndrome. (24) One of the first tasks was to 
gather additional patents in order to descnbe HIDS more accurately and to delineate it from other 
periodic fever syndrome. We were able to collect data for 50 cases and chapter 2 presents the 
clinical and laboratory features of HIDS. 
In the process of collecting the data, it became clear that skin lesions were an important feature 
of the symptomatology dunng the febnle attacks. It must be remembered that all patients were 
diagnostic puzzles and many underwent diagnostic procedures such as skin biopsies. In chapter 3 
the cutaneous manifestations and histological findings of skin biopsy specimens in patents with 
HIDS are presented. 
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Chapter 4 highlights the genetic aspects of HIDS The disease occurs in families, and its mode 
of inheritance appears to be autosomal recessive The discovery of genetic location of FMF on the 
short arm of chromosome 16 allowed us to test whether the HIDS gene differs from that of FMF 
Attacks in HIDS are compatible with activation of the cytokine network In chapter 5 we 
describe the results of cytokine measurements in 22 HIDS patients during, but also in between 
their febnle attacks Moreover, we tested the capability of whole blood to produce cytokine when 
challenged by lipopolysacchande 
Chapter 6 centers on neoptenn which is regarded as a marker of activation of the cellular 
immune system and is produced by macrophages in response to γ-interferon It is completely 
secreted in unne and is easy to measure by high performance liquid chromatography and may 
serve as a more objective parameter In 10 HIDS patients we measured the excretion of urine 
neoptenn and the serum concentration of γ-interferon dunng the first days of febnle attacks 
Chapter /addresses vanous aspects of the acute phase response so typical for HIDS In 11 
patients we measured the concentration and degree of fucosylation of α,-Acid glycoprotein during 
and in between attacks 
Chapter 8 investigates the role of IgD in the pathogenesis of HIDS We incubated normal 
human peripheral blood mononuclear cells to IgD isolated from serum of one of our patients 
After 24 hours we harvested the supernatants and measured the concentration of mterleukm-1 β, 
tumor necrosis factor α and mterleukm-1 receptor antagonist 
16 Introduction 
There are indications that dunng febrile attacks higher concentrations of the acute phase 
proteins are seen in HIDS compared to FMF. In Chapter ?we tested the hypothesis whether this 
is due to a difference in the production of inflammatory products by peripheral blood mononuclear 
cells. Furthermore, we compared the capability of a liver cell line to produce acute phase proteins 
in response to these inflammatory products from FMF and HIDS patients. 
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Chapter 2 
HYPERIMMUNOGLOBULINEMIA D AND 
PERIODIC FEVER SYNDROME. THE 
CLINICAL SPECTRUM IN A SERIES OF 50 
PATIENTS 
JOOST P.H. DRENTH, CEES J. HAAGSMA, JOS W.M. VAN DER MEER, AND THE 
INTERNATIONAL HYPER-IGD STUDY GROUP 
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Abstract 
We studied 50 patients (28 male and 22 female) with the hyper-lgD and periodic fever 
syndrome. Most patients originated from Europe, namely The Netherlands (28 cases; 56%), 
France ( 10 cases, 20%), and Italy (3 cases, 6%) but I patient was from Japan A hereditary 
component is suggested by 18 patents coming from 8 families The syndrome is typified by a very 
early age at onset (median, 0.5 years) and life-long persistence of penodic fever. Characteristically, 
attacks occur every 4-8 weeks and continue for 3-7 days, but the individual vanation is large. 
Attacks feature high spiking fever, preceded by chills in 76% of patents. Lymphadenopathy is 
commonly present (94% of patients). During attacks, 72% of patients complained of abdominal 
pains, 56% of vomrting, 82% of diarrhea, and 52% of headache. Joint involvement is common in 
the hyper-lgD syndrome with poly-arthralgia in 80% and a non-destructive arthrrtis, mainly of the 
large joints (knee and ankle), in 68% of patients. Eighty-two percent of patents reported skin 
lesions with some attacks; these demonstrated vasculits histologically. Serosits has been seen in 
only 3 patents (6%), while amyloidosis has not been recorded in any of the patents with this 
syndrome. Immunizatons precipitated attacks in 54% of patents. All patents had a persistently 
elevated serum IgD level (è 100 U/mL), and in 82% of cases the serum IgAwas likewise elevated. 
Dunng attacks there is an acute-phase response adjudged by leukocytosis, neutrophilia, and 
increased ESR. The etology remains to be eluadated, and treatment is supportive. The hyper-lgD 
syndrome is distnct from other penodic fever syndromes like systemic-onset juvenile rheumatoid 
arthrrtis, adult-onset Stil disease, and familial Mediterranean fever. 
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2.1 Introduction 
I n 1984, Van der Meer and colleagues (53) described 6 patients with periodic fever and a constantly elevated polyclonal IgD and labeled the syndrome the hyperimmunoglobulinemia D (hyper-lgD) and periodic fever syndrome (called 
here the hyper-lgD syndrome) Similar cases of this new syndrome have been reported by others; 
some of these cases have been difficult to diagnose (5, 15, 16, 20, 21, 28, 32, 35,38, 40, 45, 51, 
53, 54) The hyper-lgD syndrome has to be distinguished from other clinical entités with 
recurrent high spiking fever such as systemic-onset juvenile rheumatoid arthritis, adult-onset Still 
disease, familial Mediterranean fever, and familial Hibernian fever (31, 37, 38, 39, 57). The 
patents present with a long history of recurrent attacks of fever, which are frequently preceded by 
chills and accompanied by headache, bilateral cervical lymphadenopathy, and occasionally by 
abdominal pain and diarrhea. Laboratory analysis invariably reveals a markedly elevated serum 
level of polyclonal IgD (22, 38, 53). As yet, little is known about the etology and pathogenesis of 
the syndrome and treatment remains supportive. It has been hypothesized that these patents 
exhibit an uncontrolled type III hypersensitvity reaction possibly with involvement of IgD-containing 
complexes (5, 21, 54). The few isolated case reports illustrate only some of the clinical 
charactenzations of hyper-lgD and penodic fever syndrome, and therefore only an incomplete 
picture of its manifestatons is available currently. The present study was performed to obtain a 
comprehensive descnpton of the clinical features of this syndrome and to clanfy its positon as a 
distinct entity separate from the other penodic fever syndromes. We collected clinical and 
laboratory data for 50 cases, both published and unpublished, of patents with the 
hypenmmunoglobulinerrna D and penodic fever syndrome. 
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2.2 Patients and Methods 
We conducted a search to obtain data on patents known to have hyper-lgD and periodic fever 
syndrome. Patients with the hyper-lgD syndrome referred to the University Hospitals of 
Nijmegen, Utrecht, or Leiden in the Netherlands participated in the study We included patients 
brought to our attention via personal correspondence to I of us (| W M M ) A computer-aided 
literature search (Medline, National Library of Medicine, Bethesda, MD) using the key words 
"fever," "penodic," and "hyper-lgD" was performed for the years 1984 to 1993. The reference lists 
of published reports were examined for additional cases. 
Supplementary information was obtained by questionnaires completed by the attending physicians 
of the cases and, whenever possible, by examining the individual patient charts The International 
Hyper-lgD Study Group was established to improve awareness of, facilitate diagnosis of, and 
investigate novel therapies for this syndrome The group consists of physicians who were treating 
these patients Patients were included if they had a history of recurrent fever, defined as a rectal 
body temperature higher than 38 5°C, and an elevated level of serum IgD (100 U/mL) measured 
when possible at 2 occasions at least I month apart Recurrent microbial infections as a cause of 
the periodic fever were ruled out. Data were collected using questionnaires with special attention 
to the following items, age at onset of the attacks; length and penodicity of the attacks, occurrence 
of chills before an attack; highest recorded body temperature; occurrence of headache, arthralgias, 
abdominal pains, diarrhea, and vomiting; ancestry of patient, and family history with regard to 
periodic fever. The effect of colchicine therapy, when given, was also evaluated. 
Physical signs recorded were lymphadenopathy, defined as the enlargement of lymph nodes at 
2 sites, splenomegaly; serosrtis; arthritis; and cutaneous manifestations. The results from 
histopathologic examination of biopsy specimens, when available, from lymph nodes, rectum, 
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appendix, and skin were collected and reviewed. The corollary from previous abdominal surgery 
was registered with special attention to lymph-node hyperplasia and the possible occurrence of 
serosrtis. Laboratory data included complete blood count, erythrocyte sedimentation rate, 
electrolytes, renal function tests, and liver function parameters. The level of the immunoglobulins 
IgA, IgG, IgG I, lgG2, lgG3, lgG4 and IgM was documented together with the lowest and highest 
available IgD concentration. Data on the presence of circulating immune complexes and 
concentration of complement components as well as the presence of auto antibodies were 
recorded as were the results of urinalysis (proteinuria and erythrocyturia) Patents with alternative 
causes of recurrent fever such as tuberculosis, brucellosis, recurrent cytomegalovirus infectons, 
persisting Epstem-Barr virus infection, and facttous and fraudulent fever were omitted from the 
study 
2.3.1 Results 
Demographic features 
The literature search identified 35 patents (5, 15, 16, 20, 21, 28, 32, 35, 3Θ, 40, 45, 51, 53, 
54). We were informed about another 6 patents by personal correspondence with the following 
physicians: Dr J. Demonty (Liege, Belgium 1990), Prof. Dr C M . Monootti (Padua, Italy 1992), 
Prof Dr M. Alcalay (Portiers, France 1992), Dr D. Jílek (Usti nad Labern, Czech Republic 1992), 
and Dr. Τ Español (Barcelona, Spain 1993). Another 9 patents were referred to members of the 
Intematonal Study Group on Hyper-lgD. The total patent populaton compnsed 50 patents (28 
male and 22 female). Most of the patents were of Dutch origin, namely 28 patents (56%), and 10 
patents (20%) from our senes were bom in France (Table I). 
The mean age was 27 years (median, 25.5 yr) with a range from 3 to 69 years (Table I ). 
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Twenty patients had a positive family history for periodic fever. Eighteen patients, all sets of siblings, 
came from 8 families. There were 3 sets of brother-sister sibs (patients #2-#3, # I 3 - # I 4 , 
#21 -#22). Two patients were sisters (patients #33-#34). Ten patients were brothers, with 4 
brothers in I family (patients # 15-# 16, #27-#30, #35-#36-#44-#45, #47-#48). The mother 
of patient # 6 was diagnosed with familial Mediterranean fever and died of amyloidosis. Two of the 
mother's brothers also had penodic fever, I of them with amyloidosis. The latter had been free of 
attacks since renal transplantation in 1979; his serum IgD was 4 U/mL. The other brother had a 
serum IgD of 99 U/mL. Patient # 6 committed suicide in August 1992. Patient # 14 died as a result 
of stroke due to a large frontal calcified meningioma in November 1993. The grandmother of 
patient #24 had a nephew suffering from recurrent bouts of fever and arthritis which could be 
effectively treated with colchicine. His serum IgD was undetectable. We are not aware of 
individuals with symptoms suggesting the hypenmmunoglobulinemia D and periodic fever 
syndrome in the ancestry of our patients. Indeed, when determined, the serum IgD level in the 
parents and the kin of the patients was without exception normal (100 U/mL). For example, 4 
brothers (patients #35-#36-#44-#45), from a family of 6 sons, had elevated serum IgD levels 
(respectively, 360 U/mL, 398 U/mL, 482 U/mL, 565 U/mL). Two other brothers, the father, and 
the mother did not exhibit periodic fever and had normal IgD levels (respectively, 38 U/mL, 0.4 
U/mL, I I U/mL, and 6 U/mL). There is no evidence that the disease was transmitted by our 
patients to their children; 9 patents had offspring and none of the children showed symptoms of 
periodic fever. Indeed, the serum IgD in the veins of the umbilical cord measured just after 
delivery in I patient (# I) with an extremely elevated serum IgD (1,607-5,300 U/mL) was normal 
(3.3 U/mL), demonstrating that IgD does not cross the placenta. Two brothers (# 15-# 16) were 
mentally retarded and had primary pigmentary retinal degeneration and sensory heanng loss. They 
had been previously descnbed in 1968 as having etiocholanolone fever ( 13). 
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Table I. Characteristics of the hyper-lgD syndrome 
Patent 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
I I 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
Sex 
F 
M 
F 
M 
M 
M 
F 
M 
M 
F 
M 
M 
M 
F 
M 
M 
F 
F 
M 
F 
M 
F 
F 
F 
F 
M 
M 
F 
F 
M 
M 
M 
F 
F 
M 
M 
F 
M 
F 
M 
F 
F 
F 
M 
M 
F 
M 
M 
M 
M 
Nat 
N 
N 
N 
N 
N 
N 
1 
В 
Ν 
Ν 
Ν 
Ν 
UK 
UK 
Ν 
Ν 
Ν 
Ν 
Fr 
Ι 
Ν 
Ν 
Ν 
Ν 
Ι 
Ν 
Ν 
Τ 
Τ 
Ν 
Ν 
Fr 
Fr 
Fr 
Ν 
Ν 
Fr 
Fr 
Fr 
Fr 
Fr 
Fr 
С 
N 
N 
J 
S 
S 
Ν 
Ν 
Age at onset 
M 
1 
2 
0 
0 
53 
8 
2 
3 
12 
"for years" 
4 
3 months 
3 months 
3 months 
0 
0 
0 
1 
6 months 
2 
3 months 
2 months 
3 months 
1 
1 
3 months 
1.5 
5 
5 
4 months 
0 
9 months 
1 months 
5 months 
4-5 
10 
< 1 months 
1 months 
6 months 
< 1 months 
< 1 months 
3 months 
1 
8 
4 
4 months 
8 months 
1 months 
6 months 
5 weeks 
Current 
age(yr) 
32 
30 
44 
34 
69 
26 
27 
45 
29 
42 
49 
23 
45 
61 
35 
36 
24 
43 
23 
33 
20 
16 
19 
22 
14 
13 
21 
20 
14 
8 
12 
21 
28 
25 
31 
33 
27 
27 
24 
25 
30 
25 
23 
27 
22 
16 
13 
3 
7 
3 
Length of 
attacks 
4-5 
3-7 
4-5 
3-4 
13-22 
3-7 
3-6 
4-5 
1-2 
3-4 
3-5 
4-5 
5-6 
5-6 
3-5 
3-5 
7 
3-5 
5 
4-7 
5-6 
5-6 
7 
6 
3-4 
2-3 
2-3 
3-4 
7 
2-3 
7 
3 
3-4 
4-6 
3-4 
7-10 
7-10 
7-14 
7-14 
7 
7-14 
3-5 
2-4 
5-7 
6-7 
4-5 
2-3 
2-3 
2-3 
4-5 
Frequency of attacks 
1 x/4 weeks 
1 x/4-6 weeks 
1 x/4-6 weeks 
1 x/4 weeks 
2x/year 
2x/year 
Ix/I2-I6weeks 
lx/2 weeks 
lx/l-4 weeks 
1 x/4 weeks 
lx/3-12 weeks 
lx/3-4 weeks 
lx/8 weeks 
lx/8 weeks 
1 x/4 weeks 
1 x/4 weeks 
lx/2-3 weeks 
1 x/4 weeks 
lx/2-4 weeks 
1 x/4 weeks 
1 x/4-6 weeks 
1 x/4-6 weeks 
1 x/4 weeks 
1 x/4 weeks 
1 x/4-8 weeks 
1 x/3-4 weeks 
lx/2 weeks 
1 x/2-4 weeks 
lx/3-8 weeks 
1 x/4 weeks 
1 x/4 weeks 
lx/3 weeks 
I x/8-16 weeks 
1 x/4-8 weeks 
lx/7-8 weeks 
lx/8 weeks 
1 x/4-8 weeks 
1 x/4-6 weeks 
3-4x/year 
1 x/4-8 weeks 
1 x/4-6 weeks 
1 x/2-3 weeks 
1 x/2-4 weeks 
1 x/4-12 weeks 
2-3x/year 
several times a year 
lx/8-12 weeks 
1 x/4-6 weeks 
lx/2 weeks 
1 x/2-3 weeks 
Max rectal body 
temperature ( ° Q 
41.3 
41 
40.1 
40.6 
40,3 
> 4 0 
39.5 
39.5 
40.0 
40.1 
40.5 
40.5 
4 0 0 
39.6 
40.1 
40.5 
41.0 
>40 
40 
408 
40 
39 
41.0 
41.2 
405 
41.0 
40.9 
40 
39 
40.3 
39.5 
40 
40 
39 
40 
41 
40.1 
39.5 
40 
40.2 
40 
40.6 
40 
40.3 
39.9 
39 
39.5 
38.5 
40 
41 
Abbreviations: Nat = Nationality; M = Male; F = Female; N = The Netherlands; I = Italy; В = Belgium; UK = United 
Kingdom; Τ = Turkey; С = Czech Republic; J = Japan; S = Spain; Fr = France; yr = year; mo = month. 
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At that time, during and in between fever attacks, a high level of free non-estenfied 
etiocholanolone of the blood had been documented. Measurements on subsequent occasions in 
both patents showed normal values of this hormone. One further patient (# 17) had a,-antitrypsin 
deficiency with moderate liver cirrhosis. 
Characteristics of the attacks. 
The median age at onset was 0.5 years with a range from the first weeks of life to an extreme 
of 53 years (SD 7.θ yr). The age at onset of the disease could not be determined for I patient 
(# 10), who suffered from periodic fever "for years" (54). 
The majority of the patients (34 cases, 68%) developed symptoms of periodic fever at a very 
young age {<, I year) (Table I ). The average length and frequency of the attacks for the individual 
patents are listed in Table I. 
The length of the attacks varied both from attack to attack and from individual to individual, but 
in general, attacks lasted from 3 to 7 days One patent had very short bouts of penodic fever 
lasting I to 2 days. Six patents had attacks lastng longer than 7 days, and I patent had attacks 
lasting for 6 weeks. The frequency of the attacks differed substantally among the individual patents 
(Table I ) While some patients had attacks every 2 weeks or even weekly, others had attacks only 
twice a year. Most patients had attacks once a month or bimonthly. Attacks did not appear at fixed 
intervals, however, although a hidden periodicity was found in I patent using sophistcated 
computer analysis (49). The tme lapse between episodes, even within an individual patent, varied 
considerably. Symptoms did not always resolve completely between frequent attacks. There was a 
tendency among the patents with hyper-lgD toward decreased penodioty and seventy of attacks 
with increasing age. No definite influence of pregnancy on the frequency or seventy of the attacks 
could be identified in our cohort. 
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Fever 
A high spiking fever was present in all 50 patients (100%). The highest m-hospital recorded 
rectal values ranged from 38.5°C to 4I.2°C (Table I). Thirty-eight patients (76%) had fevers 
i40°C. The fever was sustained in all. Typically, at onset of an attack, the body temperature 
rapidly rose within a few hours to ¿39°C. During the attack the body temperature remained high 
and declined only slowly to normal values after several days. The pyrexial period, on the whole, 
indicated the boundaries of an attack. 
Premonitory symptoms 
Most patients could predict the advent of attacks very shortly before a rise in body 
temperature. Prodromal symptoms include nasal congestion, sore throat, backache, severe 
tiredness, vertigo, headache, and, in some cases, even behavioral changes, such as irritability and 
lassitude. Thirty-eight (76%) patients had experienced chills before an attack of periodic fever; 12 
patients never had a chill (Fig. I ). 
number of patients 
R g l . 
S y m p t o m s 
during attacks 
in 50 patients 
with the 
h y p e r - l g D 
syndrome 
Diarrhea Arthralgia Chills Abdominal pain Vomrting Headache 
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Precipitating factors 
In 27 patents (54%), active immunization with either diphtheria toxoid, tetanus toxoid, 
pertussis, influenza, mumps, measles, or rubella vaccine precipitated a typical attack. Viral infections 
could also trigger febnle attacks. No indications were found that certain food ingredients elicited or 
prevented attacks. Some patients indicated stress as a precipitating factor, and minor surgical 
interventions tnggered febrile episodes in some patents. One patient (#1) experienced more 
attacks shortly before the menstrual period (49). Most episodes, however, came unexpectedly and 
were not preceded by specific events. 
2.3.2 Clinical Features 
Abdomina symptoms 
Gastrointestinal symptoms were a prominent feature of the attacks (Fig. I) Thirty-six patents 
had abdominal pain, and 14 did not. In some patents the abdominal symptoms were the mam 
feature of the attack and defined the severity of the attack, resembling an acute abdomen. 
Appendectomy was performed in 17 cases dunng an attack; on histopathologic examination none 
of the removed appendices showed signs of mflammaton. Because of the seventy of the 
symptoms, a laparotomy was performed in a few cases, including 2 brothers (# 15-# 16) who had 
severe attacks of abdominal pain suggestng obstructon of the ileum. For both patents, extensive 
adhesions were found in the abdominal cavity at first laparotomy; these seemed responsible for 
the mechanical ileus, and both patents had swollen intra-abdominal lymph nodes. In 3 other 
patients (#20, #45, #47), laparotomy revealed mesenteric adenits as a cause for the abdominal 
pains. One patent (#47) had a repeat laparotomy I year later because of severe adhesions. 
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Vomiting occurred in 28 patients (56%) dunng the attacks (Fig. I ). Diarrhea was a feature of the 
febnle attacks in 41 patients (82%). Usually the diarrhea occurred the first few days after the onset 
of an attack and was watery in nature; a few patients had transitory bloody stools. 
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Fig 2. 
Physical signs 
during attacks 
in 50 patients 
with the 
h y p e r - l g D 
syndrome 
Lymphadenopathy Skin lesions Arthritis Splenomegaly Serositis 
Headache accompanied the pyrexial attacks in 26 patients (52%). In I patient (#26), headache 
was sometimes the dominant feature of an attack. 
Articular manifestations 
Forty patients (80%) complained of poly-arthralgias during pyrexial attacks; 10 patients denied 
articular symptoms (Fig. I ). Arthritis defined as swollen and painful joints could be demonstrated in 
34 of 50 patients (68%) (Fig. 2). The larger joints, particularly the knee and ankle, were most 
commonly affected (Table 2), and patients sometimes had several joints affected during an 
individual attack. Often, the joint manifestations occurred symmetrically. The articular 
manifestations were strongly associated with the febrile attacks, but did not necessanly follow a 
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disease flare, and joint involvement did occur in the absence of fever Arthritis was not the first 
symptom of the hyper-lgD syndrome to appear, the interval from onset of the disease to the first 
attack of arthritis ranged from 6 months to 13 years Febnle attacks with arthritis occurred more 
frequently in the younger age group, with a gradual decrease of articular symptoms with age The 
arthritis in the hyper-lgD syndrome appears to be benign From long-term follow-up in our 
patients we have no evidence of joint destruction, even in patients with severe recurrent arthritis 
Serologic tests for rheumatoid factors were negative Synovial fluid was drawn from 3 patients 
and yielded yellow turbid fluid with mucin clots 
Table 2. Articular manifestations in 34 cases of hyper-lgD syndrome 
Joint affected" 
Knee 
Ankle 
Wnst 
Elbow 
MCP 
PIP 
MTP 
DIP 
Shoulder 
Hip 
CVC 
No ofafff 
24(71%) 
22 (65%) 
14(41%) 
11 (32%) 
8 (24%) 
5 (15%) 
4 (12%) 
3 (9%) 
2 (6%) 
2 (6%) 
1 (3%) 
Abbreviations MCP = metacarpophalangeal joints, MTP = metatarsophalangeal joints, PIP = proximal 
interphalangeal joints, DIP = distal mterphalangeal joints, CVC = cervico vertebral column Arthritis defined as swollen 
and painful articulations Shoulder, hip or CVC involvement was defined as presence of pain on passive motion 
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There was a high white blood cell count with more than 80% polymorphonuclear cells, but 
cultures from synovial fluid proved sterile. Arthroscopy was performed in I case (patient # 12) and 
showed a thickened synovium without degenerative changes of the articular surface. Biopsy 
specimens from the synovium ofthat patient were'covered with fibnn deposits with macrophages 
and lymphocytes. Immunofluorescence showed endothelial and intimai deposits of C3 together 
with granular deposits of IgM and C3 in the junctional zone between synoviocytes and underlying 
tissue Immunofluorescence was negative for IgD. The picture was compatible with active 
vasoproliferative synovitis. No specific radiographic changes were noted. 
The articular symptoms usually responded to nonsteroidal anti-inflammatory drugs or to 
corticosteroids. Prednisone in doses up to I mg/kg per day for a short penod (i. 2 weeks) was 
successful in most cases 
Manifestations in serous membranes 
Involvement of the peritoneum during the attacks was demonstrated in 3 cases (Fig. 2). As 
mentioned, laparotomy in 2 brothers (patients # 15-# 16) revealed severe adhesions, conceivably 
a consequence of recurrent peritonitis A repeat laparotomy in another case (#47) showed severe 
abdominal adhesions I year after surgery because of mesenteric lymphadenitis. In all other cases 
there was no evidence of peritoneal, pleural, or pericardial serositis. 
Amyloid 
Amyloidosis was not demonstrated in any patients with the hyper-lgD and penodic fever 
syndrome despite long durations of symptoms. Rectal biopsy was performed in 16 patients and 
showed no amyloid. Except for the family of patient #6, there was no evidence of clinical 
manifestations of amyloid in any family members of the patients with the hyper-lgD syndrome 
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Lymphadenopathy and splenomegáy 
Lymphadenopathy during the attacks was an almost pathognomonic finding in our senes and 
was present in 47 patients (94%). Only 3 patents did not show palpable lymph nodes (Fig. 2) 
Charactenstically, the lymph nodes increased in size dunng the attacks, with the cervical region 
most commonly involved. Inguinal and axillary lymph nodes were also affected. The lymph nodes 
were rubbery and/or tender on palpation. In cases where laparotomy or lymphangiography had 
been performed, involvement of mesenteric, iliac, and paralumbar lymph nodes was noted. In 19 
cases, lymph nodes were biopsied, and, in general, specimens showed hyperplasia, presence of 
plasma cells, and signs of aspecific reactive lymphadenitis, that is, nonspecific changes. A palpable 
spleen dunng febrile episode was found mainly in children. This feature was demonstrated in 24 
patients (48%) during the attacks (Fig. 2). In contrast to lymphadenopathy, splenomegaly became 
a rare symptom of the febrile attacks with increasing age. 
Cutaneous manifestations 
An extensive review of skin lesions in the hyper-lgD syndrome has been published elsewhere 
( I I ). In brief, 41 patients (82%) demonstrated skin lesions with pyrexial attacks, and 9 never had 
cutaneous manifestations (Fig. 2). Erythematous macules were the most common skin lesions (26 
patients), followed by papules ( 17 patients) (Table 3). A representative eruption usually consisted 
of multiple erythematous macules which could be solitary or confluent. The larger macules 
sometimes showed annular formation with normal skin centrally and slightly irregular margins The 
lesions were widespread but predominated on the limbs. Biopsies from affected skin sometimes 
showed endothelial swelling and perivascular inflammatory infiltrates. 
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Table 3. Cutaneous manifestations in 41 patents with the hyper-lgD syndrome. 
Cutaneous manifestation* No of affected patients (%) 
Erythematous macules 26 (63%) 
Erythematous papules 17 (4196) 
Urticaria 10(24%) 
Erythematous nodules 9 (22%) 
Morbilliformic rash 8 (19%) 
Non-defined exanthema 8 ( 19%) 
Annular erythema 6 (15%) 
Purpura 5 (12%) 
Petechia 4 (10%) 
* Some patients have more than one skin lesion 
2.3.3 Laboratory Tests 
General 
In all patients, attacks were accompanied by a sharp rise in the erythrocyte sedimentation rate 
(ESR), with a mean ESR of 90 mm/h (range, 20-150). During the episodes, leukocytosis was noted 
in all patients with a mean leukocyte count of 18.7x10 9/L (range, 4.6-42xlO'/L). Twenty-one 
patients (42%) were observed with counts in excess of 20x10 '/L. The leukocytosis was related to 
neutrophilia often with immature neutrophils and toxic granulation. Following an attack, the 
leukocytosis and ESR consistently resolved to normal values. In all 50 patients, the infection surveys 
were nondiagnostic; these included cultures of blood, unne, and other sites as well as serologic 
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tests for viruses. 
Mild transient erythrocytuna, as defined I + by dipstick, was observed in 8 patients during 
episodes with high spiking fever. In between attacks the results of the urinalysis were normal in all 
patients. The renal function remained normal in all patients. In I patent (#17) with concomitant 
α,-antitrypsin deficiency, the hepatic function was moderately impaired. Circulating immune 
complexes, usually by the CI q binding assays, were present dunng and in-between attacks in low 
titers in 10 patients (20%). There were no auto-antibodies. Serum complement was determined 
in 46 patients; it was normal in the majority and slightly reduced in 3 patients C3 levels were 
mildly elevated in 8, and C4 levels were mildly increased in 7 patients. No complement 
deficiencies were found. When tested, the cellular and humoral immunity did not differ from 
normal controls. Thus the hyper-lgD syndrome does not seem to represent an immunodeficiency 
state. 
/mmunogfobu/ins 
An elevated serum IgD is essential for the diagnosis of the hyper-lgD syndrome. Table 4 lists 
the highest and the lowest serum IgD level for a given patent. The concentratons vary from 0 
U/mL to 5,300 U/mL. We could not detect a relationship between the level of the serum IgD and 
either the frequency or seventy of attacks. In 3 patients (#27, # 3 1 , and #48) the onset of 
penodic fever preceded the nse of serum IgD. Symptoms in these patents started early in life, and 
the first analyses revealed normal serum IgD in all 3 (respectively, 11,0, and 39 U/L). After 41 
months, 26.5, and 37 months, respectively, the serum IgD level increased to more than 100 
U/mL (218, 158, and 600 U/mL, respectively). Neither frequency nor intensity of the attacks 
changed in this penod of rising IgD. The serum immunoglobulin concentratons are given in Table 
4. The serum IgG was normal in 31 patents and elevated in 19 patents (г 14.6 g/L). On average 
the serum IgG was 13.5 g/L (range, 6.03-27.2 g/L). 
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Table 4. Levels of immunoglobulins A, G l , G2, G3, G4, G, M and D in patents with 
the hyper-lgD syndrome 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
ΙΘ 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
36 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
IgA 
(g/L) 
11'A 
6 83 
3 65 
57 
29 
33 
5 36 
3 17 
1 85 
37 
1 9 
33 
52 
72 
79 
88 
63 
26 
5 07 
40 
4 97 
2 22 
2 94 
1 5 
7 25 
44 
105 
1 53 
2 74 
105 
7 67 
4 38 
5 08 
5 97 
44 
7 74 
190 
84 
109 
66 
47 
5 82 
13 1 
7 38 
216 
28 
125 
441 
23 
1 4 
IgGI 
(g/L) 
4 17 
7 55 
130 
87 
5 55 
2 86 
7 69 
4 28 
4 75 
5 47 
82 
7 22 
8 33 
II 5 
150 
80 
5 73 
4 82 
7 
7 
9 18 
8 66 
137 
1 64 
188 
II 3 
5 47 
? 
Î 
105 
9 05 
93 
89 
7 25 
9 24 
8 39 
158 
7 
7 
64 
7 
72 
10 
8 59 
7 68 
? 
134 
56 
77 
64 
lgG2 
(g/L) 
051 
2 58 
2 38 
4 05 
4 49 
3 26 
204 
0 85 
218 
3 19 
2 55 
2 02 
47 
0 89 
1 9 
1 3 
2 68 
1 97 
7 
? 
2 76 
0 78 
2 53 
2 02 
1 84 
1 75 
1 06 
7 
7 
1 82 
2 35 
1 3 
1 5 
19 
1 57 
1 67 
3 15 
7 
7 
125 
7 
1 15 
2 54 
2 02 
1 69 
7 
1 38 
30 
1 2 
04 
lgG3 
(g/L) 
0 28 
150 
1 22 
0 85 
0 39 
0 56 
0 86 
0 47 
0 34 
0 59 
071 
0 92 
122 
0 54 
1 17 
0 76 
0 66 
0 97 
7 
? 
1 33 
0 95 
1 74 
0 58 
1 82 
1 3 
1 33 
? 
? 
29 
102 
0 38 
0 72 
0 85 
0 89 
1 32 
1 45 
7 
7 
ON 
7 
0 85 
102 
146 
1 15 
7 
4 56 
0 88 
04 
03 
lgG4 
m 
0 08 
02 
0 27 
02 
0 39 
0 83 
0 97 
0 18 
0 29 
004 
01 
0 24 
0 38 
009 
0 24 
0 15 
041 
0 04 
7 
7 
0 48 
0 04 
0 28 
0 94 
0 25 
0 1 
004 
? 
7 
018 
091 
0 85 
0 13 
0 13 
021 
013 
008 
7 
7 
009 
? 
0 02 
041 
0 14 
0 39 
? 
0 46 
0 76 
0 25 
01 
IgG 
(g/L) 
6 03 
8 72 
108 
125 
106 
II 3 
158 
8 28 
88 
108 
II 4 
143 
133 
147 
162 
97 
108 
96 
II 5 
II 5 
146 
9 82 
109 
166 
190 
121 
6 96 
13 1 
219 
166 
103 
177 
174 
146 
144 
133 
165 
123 
21 5 
79 
130 
19 1 
167 
25 5 
148 
27 2 
165 
103 
102 
93 
IgM 
(g/L) 
0 53 
0 58 
1 75 
1 5 
33 
0 99 
1 78 
013 
1 85 
1 8 
1 1 
1 8 
0 56 
0 17 
06 
05 
1 4 
1 2 
0 79 
0 96 
0 62 
0 78 
0 97 
1 7 
0 27 
09 
0 83 
1 92 
3 39 
4 93 
1 27 
1 9 
2 22 
1 35 
07 
0 66 
1 5 
0 94 
1 36 
1 71 
1 75 
0 49 
0 56 
26 
28 
1 36 
2 28 
3 49 
12 
1 3 
IgD m m 
(U/faL) 
1607 
199 
450 
778 
238 
34 
186 
645 
64 
106 
205 
1450 
318 
1012 
492 
472 
182 
520 
800 
637 
780 
750 
340 
154 
1837 
1445 
230 
? 
? 
0 
II 
100 
231 
432 
302 
266 
283 
637 
849 
134 
141 
632 
15 1 
482 
286 
329 
950 
? 
345 
7 
IgD max 
(U/mL) 
5300 
674 
1383 
991 
280 
196 
1390 
1050 
193 
434 
450 
2000 
900 
3187 
1170 
680 
491 
1470 
950 
680 
2340 
3250 
476 
231 
2805 
4224 
1731 
220 
156 
1898 
656 
145 
936 
636 
398 
360 
1841 
1416 
1203 
414 
793 
1026 
1743 
960 
565 
1310 
1100 
39 
400 
102 
Abbreviations ' = not measured 
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The IgM was within normal range in 21 patients, increased in 17 (> 1.5 g/L), and decreased in 12 
patients (¿0.7 g/L). The mean value was 1.42 g/L (range, 0.13-4.93 g/L). A striking elevation of 
serum IgA levels was noted in our series. As many as 42 patents (82%) had concomitant elevated 
serum IgA levels (¿2.6 g/L). Only 8 patients had normal serum levels of IgA. The mean serum IgA 
in our series was 5.54 g/L with a range from 1.4 to 19.0 g/L. While the IgG I, lgG2, and lgG4 
were virtually within normal limits in our patients, lgG3 was elevated in 13 (31%) of the 42 
patients tested. In I patient the value was below the lower limit 
Management 
The attacks of the fever with the associated symptomatology were self-limiting, and, in general, 
patients were symptom free between attacks. Medical therapy was not convincingly successful, 
since attack-free penods occurred without medication, making the results of treatment difficult to 
assess. Colchicine, which was prescribed for 33 patients, modified the frequency pattern of the 
pyrexial attacks to some extent; in 5 patients it seemed to dimmish the intensity, frequency, and 
duration of the attacks. In 28 patents, the drug was of no benefit and was therefore discontnued. 
In I patient (#8), methylprednisolone at a dose of 8 mg/d was reported to abrogate the attacks 
completely. A few other patents had some benefit from corticosteroids, which ameliorated the 
severity of the attacks. One patent (#3) had been disease free for 6 years with cyclosponn 
(200-300 mg/d), but her brother (#2) did not benefit from this therapy. One patent (#20) was 
treated with intravenous Immunoglobulins administration (0.15 g/kg at 2 week intervals); dunng 
the treatment, the number and seventy of the attacks diminished. This therapy did not influence 
the attack rate in 4 other patents (#33-#34, #47-#48). 
Prognosis 
The hyper-lgD syndrome does not seem to have an appreciable effect on mortality. All patents 
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lived except 2 (patients #6 and # 14). The first patient died of suicide, the other died as a result of 
stroke. As mentioned, the febnle attacks tended to be less frequent and less severe with increasing 
age Apart from age, we could not detect any other factor influencing the attacks of periodic fever 
Patients with this syndrome do not appear to be at great risk for development of amyloidosis. In 
our series, patients with hyper-lgD syndrome did not have an increased nsk of infectons One 
patient (# I ) developed a toxic streptococcal syndrome post partum 
Malignancy was detected in only I case (#3) (limited breast carcinoma, Τ,Ν,,Μ,,). 
2.4 Discussion 
We have performed a clinical and laboratory survey in 50 patents with the hyper-lgD 
syndrome. As with other entités charactenzed by periodic fever the diagnosis of hyper-lgD is 
syndromal. Table 5 lists the features typical for the diagnosis. This discussion will focus on the 
clinical and laboratory features at presentation and on the therapeutic possibilities Furthermore, 
we will demarcate the hyper-lgD syndrome from other penodic fever syndromes like familial 
Mediterranean fever, familial Hibernian fever, systemic-onset juvenile chronic arthritis, and 
aduft-onset Still disease. So far, the hyper-lgD syndrome has been observed predominantly in 
patients from Europe, with the majority of patients originating from the Netherlands (26 patents) 
A considerable number were from France (10 patents) but also from other southern countnes like 
Italy (3 patents), Turkey (2 patents), and Spam (2 patents). This distnbuton probably reflects 
under reporting from other parts of the world. The syndrome seems to be evenly distributed in 
males and females ( Ι Ό.78), and it clusters in families. We found sibs, male as well as female, with 
the disease from 8 different families, suggestng an as yet unknown hereditary pattern. There are 
no indications for the hyper-lgD syndrome in the ancestry of our patents. Our material does not 
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show that either male or female patients will pass the disease to the next generation. 
Typically, the hyper-lgD syndrome has a juvenile-onset and in our series the median age at 
onset of symptoms was 0 5 years Most patients (68%) had their first episode before the age of I 
year. One patient had a very late onset of complaints and had his first attack at the age of 53. The 
frequency of the attacks varied widely among patients Most patients had attacks every 4-8 weeks 
lasting 3-7 days on average. 
The prodromes were rather nonspecific but included nasal congestion, dry throat, severe fatigue, 
vertigo, and headache. At the onset of an attack the body temperature rose within hours to values 
above 39°C, frequently preceded by ngors. Other clinical symptoms may accompany the attacks. 
The majority of patients showed enlarged lymph nodes with cnses, and splenomegaly was 
detected in approximately 48% of patients. The lymphadenopathy could be extensive with 
involvement of not only cervical lymph nodes but also axillary, inguinal, and mesentenc regions. 
On palpation the lymph nodes were rubbery and tender The lymphadenopathy was consistently 
present with subsequent crises in most patients. Splenic and hepatic enlargement was more often 
seen in the younger age group. Abdominal pain was common with attacks; diarrhea occurred in a 
majority of patents (82%), and 56% of patients in our series had vomiting The question remains 
to what extent the abdominal complaints were due to inflammation of the serosal membranes. 
In 3 cases (# 15-# 16, #47) there was evidence for peritonitis with a mechanical ileus caused 
by the formation of adhesions. Laparotomy performed in the acute stage showed gross 
enlargement of the abdominal lymph nodes. It is likely that the abdominal symptoms in the 
hyper-lgD syndrome anse from inflammation of gut-associated lymphoid tissue. Poly-arthralgias 
during attacks were noted in 80% of the cases. Arthritis was reported in 68% of patents in our 
series. In most instances it occurred a few years after the initial attacks. Usually the larger joints 
were affected, and no evidence of destructive arthnts was found (12) 
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Table 5. Features of the hyper-lgD syndrome 
General 
High IgD, (г 100 UAnL), measured at 2 occasions with at least one month apart 
Recurrent attacks 
Elevated lgA(^ 2 6 g/L) 
During attacks 
Elevated ESR and leukocytosis 
Abrupt onset of fever (¿ 38 5°Q 
Lymphadenopathy (cervical) 
Abdominal distress 
- vomiting 
- diarrhoea 
- pain 
Skin manifestations (erythematous macules and papules) 
Arthralgias /Arthritis 
Splenomegaly 
Skin manifestations were a part of the clinical spectrum. In our series, 82% had skin lesions dunng 
attacks, most commonly macular or papular erythematous lesions and histologic evidence of 
vasculitis. 
A characteristic phenomenon of the syndrome is the ability of secondary immunizations to elicit 
an attack (21, 38). This was documented in 54% of patients in this senes and could be a clue to 
early diagnosis. The acute-phase response, reflected by the leukocytosis, neutrophilia, and raised 
ESR, was a consistent finding. The persistently elevated polyclonal serum IgD (* 100 UAnL) was a 
feature shared by all patients. In the bone marrow, the number of IgD-producmg plasma cells was 
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increased (55). As fer as studied, the serum IgD κ/λ ratio was raised (20). Serum IgA was elevated 
in 82% of patents. In 19 patients (38%), serum IgG was elevated. Determination of IgG 
subclasses revealed an elevated lgG3 in only 31 % of the 42 patients tested, in contrast to the study 
by Haraldson et al (20) who studied 5 children (#21-#22, #27-#30, #31) and found lgG3 
elevated in all. 
Serum IgD in normal individuals shows a trimodal frequency distnbution dispersion pattern 
( 14), decreasing slightly with increasing age (50). In normal subjects cigarette smoking is associated 
with elevated serum IgD level, and stopping results in a decline of IgD levels (I); also, maternal 
IgD levels increase with the duration of the pregnancy (24, 25). 
An elevated serum IgD may be found in various diseases, including Hodgkin disease (10), 
sarcoidosis and tuberculosis (8), aspergillosis (29), ataxia-telangiectasia (30, 41) and AIDS (9, 33) 
The role of the elevated serum IgD in the pathogenesis of the hyper-lgD attacks remains 
uncertain. First, there appears to be no relation between the serum concentration of IgD and the 
frequency and/or severity of the attacks; second, the level of the IgD does not fluctuate with attacks 
(35). Third, Haraldson et al (20) observed the onset of the hyper-lgD syndrome before the nse of 
the serum IgD, but that does not necessarily indicate that the elevated IgD is an epiphenomenon. 
It was previously hypothesized that IgD-containmg complexes played a pathophysiologic role (53). 
This theory was supported by the finding of erythrocytuna and the detection of perivascular 
deposits of IgD in lesionai skin from a patient (# I) with the hyper-lgD syndrome (5). Few patients 
(I 1%) in our series showed transitory erythrocytuna with attacks. Thus, the issue of the role of 
immune complexes is still confusing. In a study of a vanety of patients with elevated serum IgD 
levels, polyethylene glycol 6000 complexes containing IgD were noted in patients with and without 
periodic fever (21 ); such complexes were present both during and between attacks. Further 
research is needed to establish whether the elevated IgD should be regarded as a secondary or 
independent phenomenon. Despite the unknown function and role of IgD in the pathogenesis, 
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patients with the hyper-lgD syndrome share a remarkably similar clinical picture, and the elevated 
serum IgD serves well as a marker of the syndrome. The role of circulating IgD in health and 
disease remains equivocal. Studies in normal populations showed that IgD is very low in cord 
blood and that serum levels rise in early childhood and tend to decline with progressing age (23, 
27, 50, 59). 
Antibody activity in the IgD class has been found against insulin (26), against Escherichia coli in 
subjects infected with that organism (46), against wheat in patients with celiac disease (2), and 
against tartrazme in certain patients with chemical hypersensitivity (56). We were unable to detect 
IgD antibodies against milk in 2 of our patients (Van der Meer and Van Nieuwkoop, unpublished 
observations). Interestingly, apart from the elevated IgD, a consistently elevated serum IgA level 
was seen in 41 of our patients (82%) Furthermore, in our patients both humoral and cellular 
immunity appeared normal and there is no increased susceptibility to infections (21 ). 
Drug therapy with colchicine, the first-line drug in familial Mediterranean fever (42), has been 
disappointing in the hyper-lgD syndrome notwithstanding the early impression of benefit (53). 
Nevertheless, the prognosis of patients with the hyper-lgD syndrome is good. Apart from the 
recurrent febnle attacks there are, as yet, no indications of an excess morbidity, for example, the 
development of amyloidosis. 
Differentiation from other periodic fever syndromes such as familial Mediterranean fever, 
systemic type of juvenile chronic arthritis, adult-onset Stil disease, and familial Hibernian fever 
remains difficult since all diagnoses are made syndromally. Most classifications use several clinical 
parameters, and considerable overlap may result. There are nevertheless some clear differences 
between the mentioned periodic fever syndromes and the hyper-lgD syndrome (Table 6). Most 
notably, the serum IgD is normal in the other syndromes. Familial Mediterranean fever (FMF) is 
charactenzed by idiopathic, recurring, self-limited febnle attacks with serosrtis (31 ). There is a 
preference for people from Mediterranean ancestry, particularly Sephardic Jews (48) and 
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Armenians (44), but the disease may also occur in Turks, (36) French people, (47) Germans, (6) 
Swedes, (4) Italians (7) and Dutch people (17, 19, 43) In contrast to FMF, the diagnosis of the 
hyper-lgD syndrome, so far, has mainly been made in Europeans. The question is, of course, 
whether some of the non-Mediterranean patients with penodic fever reported as FMF are actually 
suffering from the hyper-lgD syndrome. We have traced the Dutch patient described by Haex et 
al (19) m 1963 as FMF and could exclude the hyper-lgD syndrome (IgD ar 100 U/mL). The 
hyper-lgD syndrome has an earlier onset than FMF About 50% of the FMF patients had their first 
attack before the age of 10 years (31) In our series, 96% of patients had attacks before the age of 
10. Serositis is a hallmark of FMF. In contrast to FMF, pleuritis has not been encountered as a 
feature of hyper-lgD syndrome Peritonitis, which occurs in over 90% of the cases of FMF, is 
uncommon in the hyper-lgD syndrome (31) Joint involvement with a preference for the large 
joints is a feature of both syndromes The arthritis in FMF may present in a short acute or a 
protracted form (18). The first type resembles the arthritis in the hyper-lgD syndrome, whereas 
the long-standing type does not seem to occur in the hyper-lgD syndrome (3,18) 
Enlargement of lymph nodes, a key finding in the hyper-lgD syndrome is exceptional in FMF (3, 
47) Splenomegaly, which was present in 48% of patients in our series, was found in less than 3% 
in I series of 175 patients with FMF (3). Diarrhea is equally rare in FMF but it occurs in 82% of 
patients with hyper-lgD dunng attacks. Another difference between FMF and the hyper-lgD 
syndrome is the incidence of amyloidosis. In FMF this ranges from 0 to 60%, whereas it is as yet 
rarely if ever encountered in the hyper-lgD syndrome In children, it may be difficult to 
differentiate the hyper-lgD syndrome from the systemic-onset juvenile rheumatoid arthritis (38, 
39). The latter syndrome presents with high spiking, intermittent fever, an evanescent 
maculopapular rash, often with lymphadenopathy and splenomegaly. The articular findings range 
from arthralgia to flond polyarthritis and may only occur weeks after the onset of the first 
symptoms (39). 
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Table 6. Clinical differences between periodic fever syndromes 
Clinical Symptom 
Age at onset (yr) 
Swollen 
lymph nodes 
Carditis 
Arthritis 
Pleuritis 
Peritonitis 
Amyloidosis 
Familial 
IgD 
Country of Ongin 
Treatment 
Abbreviations - = absent, + 
Familial 
Mediterranean 
Fever 
< 2 0 
-
deforming 
+ 
+ 
+ 
+ 
-
Sephardicjews, 
Arabs 
Colchicine 
= often present, + + : 
nonsteroidal anti-inflammatory drugs 
Systemic Onset 
Juvenile 
Rheumatoid 
Arthritis 
< 15 
+/-
+ 
deforming 
+ 
-
± 
-
-
Vanous 
NSAIDs Cortico-
Adult-
Onset Still 
Disease 
> 15 
+ 
+ 
deforming 
+ 
+ 
+ 
-
-
Vanous 
countries 
NSAIDs 
= prominent, ± = occasionally present, ' = 
Hyper-IgD 
< 10 
+ + 
-
benign 
-
-
-
+ 
Tt 
Europe ? 
7 
uncertain, NSAIDs = 
Pericarditis and pleuritis are common in systemic-onset juvenile rheumatoid arthntis; these 
complications have not been seen in the hyper-lgD syndrome. 
In the hyper-lgD syndrome, the fever is more of a remittent type, and the skin lesions are not 
evanescent and persist during the whole febnle episode ( I I ) . Adult-onset Stil disease has a clinical 
picture similar to the juvenile type (34, 52). The average age at onset of adult-onset Still disease is 
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30 years, which is appreciably higher than in the hyper-lgD syndrome. Familial clustenng is not a 
feature of adult-onset Still disease. A sore throat, which can be found in up to 92% of the patients 
with adult-onset Still disease (34,37), is not prominent in the hyper-lgD syndrome. Pleuritis and 
periardrtis occur in 2596-3096 of patients with adult-onset Still disease and not in the hyper-lgD 
syndrome (34, 58) In adult-onset Still disease, swelling of lymph nodes (6096-7196 of patients) 
and abdominal pains (2096-2396) are less frequent than in the hyper-lgD syndrome (34, 58). In 
contrast with the hyper-lgD syndrome, the arthntis in adult-onset Still disease is deforming in 
approximately 30% of cases (34). Both syndromes show an accelerated erythrocyte sedimentation 
rate, a leukocytosis and a neutrophilia An interesting laboratory finding in the adult-onset Still 
disease is an increased serum IgA, which was found in 34% of patents of Ohta et al (34); in the 
hyper-lgD syndrome this occurs in 82% of patients. Disturbed hepatic enzyme levels, common in 
adult-onset Stil disease (up to 71 % of patents) has not been observed in the hyper-lgD syndrome 
(34). Familial Hibernian fever occurs in Irish stock with attacks of fever and localized myalgia and 
painful erythema. Normal serum IgD levels are found in these patients (57). 
2.5 Conclusion 
The hyper-lgD syndrome is a condrtion characterized by recurrent febrile attacks usually of very 
early onset {<. I year). The diagnosis has been made in 50 patents mainly from Europe. There is 
an even male-female distnbuton. Typical attacks occur every 4-8 weeks and last about 3-7 days 
with a large individual vanaton. The attacks feature the acute onset of high spiking fever, 
sometimes preceded by chills. Abdominal pains, vomrting, and diarrhea are associated with the 
episodes. Headache and arthralgias occur frequently with attacks. On physical examinaton dunng 
the attacks, swollen, tender lymph nodes, most often in the cervical region, can be palpated. 
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Especially in the young age-group, splenomegaly may be found. Non-destructive recurrent 
arthritis, mainly in the larger joints, can be demonstrated in many patients. Dunng the attacks, 
most patients have erythematous macules and papules, with histologic signs of cutaneous vasculitis. 
Laboratory testing dunng attacks reveals an acute-phase response (leukocytosis, neutrophilia, 
and a steeply elevated ESR). The diagnosis is based on the clinical picture and a persistently 
elevated serum IgD level (^ 100 U/mL). Most patients also have a elevated serum IgA. The 
occurrence of febrile attacks elicited by various immunizations is a clue to early diagnosis. The 
pathogenesis of the syndrome is unknown. The attacks tend to dimmish with age but patients 
seem to have symptoms from the hyper-lgD syndrome throughout life. Management of the 
syndrome remains unsatisfactory. Colchicine is of value in only a minority of patients. The 
hyper-lgD syndrome clearly differs from other periodic fever syndromes like the adult-onset Still 
disease and familial Mediterranean fever. 
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Abstract 
Background and Design 
The hypenmmunoglobulinemia D (hyper-lgD) syndrome is characterized by recurrent febrile 
attacks with abdominal distress, headache, and arthralgias. Physical examination reveals cervical 
lymphadenopathy in most cases and, sometimes, splenomegaly. Skin lesions have been observed 
in isolated cases during attacks We summarize the features of skin lesions and the histopathologic 
findings in biopsy specimens in the hyper-lgD syndrome. 
Results 
A total of 44 patients with the hyper-lgD syndrome were studied. Thirty-five (79%) of them, 
19 males and 16 females, had skin lesions during febrile attacks. Erythematous macules were the 
most common cutaneous manifestation ( 15 cases), followed by erythematous papules ( 12 cases), 
urticarial lesions (nine cases) and erythematous nodules (seven cases) Skin biopsy specimens of 10 
patents with the hyper-lgD syndrome were available for review. The findings varied considerably. 
Most biopsy specimens showed mild features of vasculitis. Non-specific findings, were noted in five 
biopsy specimens, Sweet-like features in two, cellulitis-like findings in one, and deep vasculitis 
characteristics in one. 
Conclusions 
Skin lesions are common in the hyper-lgD syndrome suggesting that they are a true 
manifestation of the disease. 
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3.1 Introduction 
T he hypenmmunoglobulinemia D (hyper-lgD) and periodic fever syndrome were first described by Van der Meer et al in 1984. (I) Until now, the disease has been 
recognized in patients of Dutch, French, Italian, English, Turkish (2-9) and Belgian 
origin (J. Demonty, MD Liege, Belgium, personal communication, 1990) The syndrome is 
characterized by recurrent attacks of high spiking fever (>38.5°Q, and abdominal pain together 
with diarrhea, vomiting, and arthralgias. Generally, it has a juvenile onset and a clustering in 
families has been reported. On physical examination, lymphadenopathy and splenomegaly are 
noted in a majority of patients. In some cases, arthritis is present Laboratory analysis reveals a 
constant raised serum IgD level (> 140 mg/L). The febrile cnses are accompanied by a vigorous 
acute-phase reaction, as reflected by leukocytosis and an increased erythrocyte sedimentation 
rate. The cause and pathogenesis of the disorder are unknown. Treatment is supportive; in some 
instances, use of colchicine seems to prevent and ameliorate attacks. Isolated articles describe the 
association between attacks and the development of cutaneous manifestations. (2,7,10) Except for 
these case reports, little is known about the cutaneous manifestations and corresponding 
histopathologic features of the hyper-lgD syndrome. In this article we describe the skin lesions in a 
senes of patients with the hyper-lgD syndrome. Furthermore, the histopathologic details of 17 
biopsy specimens, which were available for review, are discussed. 
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3.2 Materials and Methods 
The study group entails several sets. We included patients with the hyper-lgD syndrome who 
were referred to the University Hospitals of Nijmegen, Utrecht, or Leiden in the Netherlands. 
Patients brought to our attention via personal correspondence to one of us (| W.M.M ) were also 
selected. Furthermore, we searched for additional cases in the literature. A thorough computer -
ided literature search (Medline) using the keywords fever", "periodic" and "hyper-lgD" was 
performed for the period 1984 through 1992. The reference lists of published reports were 
examined for additional cases. Supplementary information was sought by correspondence with the 
principal authors of the case reports. Patients were included if they had a history of recurrent 
fever, defined as an elevation of body temperature (>38 5°C), and had a sustained elevated level 
of serum IgD ( > 140 mg/L) measured on two occasions with at least I-month interval One or 
more additional features join the attacks: (cervical) lymphadenopathy, arthralgia/arthntis, 
abdominal distress, diarrhoea, and headache. Tuberculosis, brucellosis, recurrent cytomegalovirus 
infections, adult-onset Still's disease, familial Mediterranean fever (FMF), familial Hibernian fever, 
and persisting Epstem-Barr virus infection were ruled out as an alternative cause of recurrent fever. 
Data were collected with special notice to the manifestations of cutaneous symptoms, but also 
information concerning age, sex, laboratory data, and features of the episodes was obtained. The 
characteristics of the skin lesions with their localization were retrieved. The skin biopsy specimens, 
when available, were recollected and reviewed light microscopically. Furthermore, results of 
immunofluorescence studies of lesionai skin were also evaluated. 
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3.3 Results 
Paùent profiles 
Twelve patients were referred to one of the University hospitals. We were informed about 
another three cases by personal correspondence fl. Demonty, MD Liege, Belgium, 1990); CM. 
Monciotti, MD, Padova, Italy, 1992, and M. Alcalay, MD, Portiers, France, 1992) The literature 
search further identified 29 patients with the hyper-lgD syndrome and periodic fever. ( I -9) In 
total, 44 patients (22 males and 22 females), with hyper-lgD and periodic fever were identified. 
The majority of the patents were of Dutch ongin, (24 patients, 55%). Twelve patents (27%) 
were born in France. Three patents onginated from Italy, two from Great Britain, another two 
from Turkey and one patent from Belgium. The mean age was 28 years with a range from 7 to 
68 years. All patents had a long history with recurrent attacks of penodic fever. Dunng attacks the 
body temperature rises above 38.5°C. The median age at onset of the crises was 5 months with 
a wide range (first weeks of life to 53 years) The frequency of the episodes could vary appreciably 
between the patents: from once every week to twice every year. The mean interval between 
attacks was estimated as once every 5 to 7 weeks. The average length of the attacks was 
calculated as 5 to 8 days (with a range from I to 42 days). Laboratory testng dunng attacks 
invariably displayed leukocytosis and an increased erythrocyte sedimentaton rate. All patents had 
a constant elevated serum concentraten of IgD with values exceeding 140 mg/L. There was no 
correlaton between the level of the serum IgD and the occurrence of skin lesions. 
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Table 2. Clinical features of 10 patients with the hypenmmunoglobulinemia D 
syndrome from whom a skin punch biopsy was taken 
Patient/ 
Sex/Age® 
l/F/29 
2/F/38 
3/M/30 
4/M/40 
5/M/I2 
6/M/I0 
7/M/7 
8/M/I5 
9/M/29 
I0/M/I5 
Age# 
1 
0 
0 
4 
0 
0 
0 
2 
4 
II 
Periodicity of 
attacks 
1 x/4 weeks 
1 x/4-6 weeks 
lx/4-6 weeks 
lx/3-12 weeks 
lx/3-4 weeks 
lx/4-6 weeks 
lx/3-4 weeks 
1 x/2 weeks 
Ιχ/7-θ weeks 
1 x/8 weeks 
Temperature 
during attacks 
(°Q 
41.3 
40.1 
40.6 
40.5 
40.5 
40.0 
41.0 
40.9 
40.0 
41 0 
Leukocyte 
count" 
(10'xL) 
25 
20.6 
16.9 
13.7 
30.0 
11.4 
20 9 
199 
2Θ.8 
32.8 
IgD" 
(mg/L) 
7483 
1953 
1400 
635 
2824 
3304 
5964 
1948 
562 
508 
® means: age at time of last biopsy. 
* means: year of onset of penodic fever. 
° means highest recorded leukocyte count during attacks. 
* means highest recorded serum IgD level. 
Skin manifestations 
Thirty-five patients ( 19 males and 16 females, 79%) had skin lesions during pyrexial attacks, 
while seven patients never had cutaneous manifestations. The data on cutaneous manifestations 
could not be recollected for two patients. The manifestations of skin lesions seen in the 35 patients 
are listed in Table I. Most commonly, the lesions were erythematous macules (15 patients), 
followed by papules (12 patients). Nine patients presented with urticarial lesions, (Fig. I) Seven 
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patents had erythematous nodules Annular erythema and palpable purpura were encountered in 
six and four patients, respectively. Erythematous pustules and petechiae were noted in only one 
patient each. Most patients presented with a consistent pattern, and identical skin lesions were 
seen with successive crises Patients could present with different types of skin eruptions at one 
stage of the attack, eg, erythematous macules and papules. The skin lesions do not necessarily 
appear with every febrile attack, but may skip episodes. The distribution of the lesions can be 
widespread, but they are mostly localized on the limbs and, in some cases, on the trunk Few 
lesions were found on the nates, loin, thigh, or in the neck. In our senes, the lower legs were not 
a predilection site. Typically, the skin lesions occurred with the fever and disappeared between 
episodes A representative eruption usually consists of multiple red solitary and confluatmg slightly 
raised erythematous macules with a size varying from 0.5 to 2 cm (Fig. 2) The greater macules 
may show annular formation with normal skin centrally. The margin of the efflorescence may be 
slightly irregular. Small solitary papules may also be present. In very few cases are the cutaneous 
manifestations accompanied by symptoms such as pain or itching, but the majority of patients does 
not have complaints. 
Histopathologic^ manifestations 
Seventeen biopsy specimens from 10 patients with skin lesions and the hyper-lgD syndrome 
were available for histopathologic examination The characteristics of these patients are listed in 
Table 2 The histologic picture varied considerably among the biopsy specimens, even when 
taken from the same patent (Table 3). Five biopsy specimens showed rather non-specific findings, 
with an unaffected epidermis and minimal penvascular lymphocyte infiltrates, sometmes with few 
neutrophils. Epidermal changes were usually inconspicuous. 
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Figi: 
Urticarial papules and 
plaques in the neck area in 
the hyper-lgD syndrome 
Fig 2: 
Erythematous papules and 
macules on the lower 
aspect of the arm in the 
hyper-lgD syndrome 
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Table 2. Reported dermatological findings in 
hyperimmunoglobulinemia D syndrome 
35 patients with the 
Erythematous 
ι 1 
macules papules nodules urbcana annular purpura non specified morbilli petechia pustules No of 
erythema erythematous rash form patents 
exanthema 
x x x I 
x x x 2 
x x χ I 
χ χ χ χ 2 
x x 3 
x x χ I 
χ χ I 
x x x I 
x x 2 
χ I 
χ 3 
χ χ I 
χ χ I 
χ χ I 
χ I 
χ 3 
χ χ I 
χ 3 
χ 4 
χ χ I 
χ I 
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In a few patients, slight acanthosis was observed. In one patient (patient I), focal spongiosis and 
infiltration by lymphocytes were present in one of biopsy specimens obtained from this patient; in 
three other biopsy specimens epidermotropism of small numbers of lymphocytes was seen 
without spongiosis. Marked infiltration of the epidermis by polymorphonuclear neutrophils 
(PMN's) could be observed in two patients, whereas in two others only a few PMN's were found 
in the epidermis. (Fig. 3) The main abnormalities were found in the upper part of the dermis. 
There, capillaries and post-capillary venules showed features of vasculitis to some extent, that 
could vary considerably even within one biopsy specimen. 
Fig3: 
Detail of dermal infiltrate 
in the hyper-lgD 
syndrome, showing few 
lymphocytes with num­
erous polymorphonuclear 
neutrophils in the upper 
aspect of the dermis and 
also intra-epidermally. 
(hematoxylin-eosin, origi­
nal magnification χ 400) 
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Fig 4: 
Sweet-like features in the 
hyper-lgD syndrome 
showing marked edema of 
the epidermis, diffuse 
infiltration by lymphocytes, 
and numerous poly­
morphonuclear neutro­
phils without clear signs of 
leukocytoclasia. 
(hematoxylin-eosin, origi­
nal magnification χ 100) 
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Fig 5: 
Broadened septum with 
extravasation of erythro­
cytes and numerous 
lymphocytes and poly­
morphonuclear neutro­
phils extending into the fat 
lobules in a patient with 
erythematous nodules, 
(hematoxylin-eosin, origi­
nal magnification χ 100) 
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Swelling of endothelial cells was a feature of all biopsy specimens, while penvascular edema was 
present in seven biopsy specimens. Extravasation of erythrocytes was present in five biopsy 
specimens. Fibrinoid changes of vessel walls were not a prominent sign, and they were seen in 
two patients only. Discrete penvascular deposits of nuclear dust as a result of leukocytoclasia were 
seen in 10 biopsy specimens, All biopsy specimens showed perivascular inflammatory infiltrates 
composed of varying numbers of lymphocytes and a mixture of PMN's. Diffuse infiltration of the 
surrounding collagen by PMN's was seen in four biopsy specimens. In two patients (patients 4 and 
9) numerous PMN's were found in perivascular and diffuse dermal positions mimicking Sweet 
syndrome (Fig. 4). Also, nuclear dust was abundantly present, without clear signs of vasculitis. 
Marked subepidermal edema was also a prominent feature. Eosinophils were only sparsely 
present in two biopsy specimens. In two patients (patients I and 7), the infiltration of lymphocytes 
and PMN'S extended into the subcutaneous tissue. In another patient, (10) extensive infiltration of 
the subcutaneous septa occurred wrth secondary extension into the fat lobuli by numerous PMN'S, 
also with marked signs of vasculitis of the septal vessels (Fig. 5). Moreover, the overlying dermis 
showed only minimal perivascular lymphocyte infiltrates with small numbers of PMN'S. 
Immunofluorescence studies had been done in nine patients. The mam results are summarized 
in Table 3. Because screening for deposits of IgD was performed in three patients only, few data 
on its occurrence could be obtained from this retrospective study In one patient, testing was 
negative, in another clear perivascular deposits were visible; and another showed deposition along 
the basal membrane. There was no clear correlation between the serum IgD concentration and 
deposits of IgD C3 deposits along the basal membrane were seen in three biopsy specimens, 
while perivascular deposits were noted in four biopsy specimen. Three biopsy specimens were 
featured by IgM deposits. Penvascular fibrin deposits were demonstrated in lesionai skin of one 
patient. 
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3.4 Comment 
The present study describes the clinical and histopathologic features of skin lesions in a senes of 
patients with the hyper-lgD and penodic fever syndrome. Skin manifestations in this periodic fever 
syndrome have occasionally been descnbed making their relevance difficult to interpret. 
( 1,2,7,9,10) This study shows that 79% of the 44 patients developed skin lesions during attacks at 
some stage of the disease Most commonly, they consisted of erythematous macules and papules 
followed by urticarial lesions and erythematous nodules The high frequency of occurrence 
suggests that these are true manifestations of the syndrome The skin lesions become manifest in 
the course of feverish episodes, indicating that they are an integral part of the disease. 
We have not found any relationship between the magnitude of the serum IgD concentration and 
the frequency or extent of the skin lesions. 
There was quite some variation of the histopathologic findings among the 17 biopsy specimens 
obtained from 10 patients Nevertheless, nearly all biopsy specimens showed penvascular 
inflammatory infiltrates composed of variable number of lymphocytes and PMN'S. Seven biopsy 
specimens were featured by clear signs of vasculitis, while two biopsy specimens showed Sweet­
like changes. 
There are few reports in the literature on the histopathologic changes in skin lesions in this 
syndrome. (1,7,10) In the onginal article of Van der Meer et al, a patient was descnbed with a 
transient erythematous painful "rash" on the distal parts of her extremities (I) One biopsy 
specimen showed lymphocytic vasculitis with mononuclear infiltrates around vessels, swelling of 
the endothelium, and extravasation of erythrocytes and nuclear debns. Immunofluorescence 
studies showed perivascular depositions of IgA and C3 but no IgD. ( I ) In an extended account on 
this patient, the cutaneous manifestations were described as erythematous macules and papules 
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occurring during an attack and lasting for 5 to 10 days. (10) Histologic examination revealed 
endothelial cell swelling, fibrinoid changes of vessel walls, and a mixed neutrophilic and lymphocytic 
perivascular infiltrate with minor leukocytoclasia. Direct immunofluorescence demonstrated 
perivascular IgD and C3 deposits ( 10) An immune complex nature of the attacks involving IgD 
was suggested. Specimens from two other patents with hyper-lgD syndrome showed "capillarrtis" 
in one and "non specific dermatitis" in the other patient. (7) 
The febrile attacks in the hyper-lgD syndrome are accompanied by a vigorous acute- phase 
response reflected by a steeply elevated erythrocyte sedimentation rate and leukocytosis Although 
not established in the hyper-lgD syndrome, manifestations like fever and leukocytosis are thought 
to be mediated by the cytokines interleukm I, mterleukm 2, and tumor necrosis factor. ( I I ) These 
pro-mflammator' cytokines could be responsible for the vascular wall destruction, the perivascular 
inflammatory infiltrates, and the cutaneous manifestations. 
The cutaneous manifestations in hyper-lgD have to be distinguished from skin lesions in other 
periodic fever syndromes like FMF and adult-onset Still's disease. The major characteristics of these 
three periodic fever syndromes are listed in Table 4. 
In FMF, the erysipelas-like erythema is considered to be one of the most specific and 
characteristic cutaneous manifestation. It does not seem to occur in the other syndromes These 
lesions are described as sharply bordered red patches with a diameter of 10 to 15 cm, and they 
appear on the lower extremities on the dorsa of the feet, over the ankle, and sometimes over the 
knee. (12) On palpation, the affected skin is hot, tender, and swollen. The erysipelas-like skin 
lesions seem to appear only in association with arthritis in FMF. ( 13) The reported incidence of 
the erysipelas-like erythema ranges from 3% to 46%, depending on the study cited. (13-16) The 
histopathologic examination shows a dermal edema with an infiltrate consisting of 
polymorphonuclear leukocytes and lymphocytes. (12) An association between FMF and Henoch-
Schonlem purpura has been observed by several investigators. ( 13,16,17) In a series of 46 children 
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Table 4. Summary of characteristics of periodic fever syndromes 
Characteristics Hyper-lgD 
syndrome 
Adult-onset Still's 
disease 
Familial Mediterranean 
fever 
Ethnic background 
Familial clustenng 
Age of onset 
Abdomina symptoms 
Arthralgia/arthntis 
Serositis 
Lymphadenopathy 
Amyloidosis 
Serum IgD 
Treatment 
Most typical cutaneous 
manifestations 
Distribution of lesions 
European 
+ 
< lOyrs 
+ 
+/+ 
-
+ 
-
1 
? 
erythematous macules 
and papules 0.5-2 cm 
limbs and trunk 
Histopathologic findings 
апаЫе: mainly 
vasculitis, varying 
numbers of PMN's, 
sometimes Sweet-like 
seldom deep vasculitis 
Amencans, Japanese, French, 
South- amencans 
> l 6 y r s 
+/+ 
+ 
+ 
nsaid/prednisone 
salmon-pink macules or 
papules up to 3 mm 
limbs and trunk sometimes 
on (ace and neck 
mainly perivascular infiltration 
with PMN's 
Sephardic |ews, Armenians 
and Arabs 
+ 
<IOyrs 
peritonitis, constipation 
+/+ 
+ 
colchicine 
erysipelas-like erythema 
below the knee; on dorsa 
of lower legs, ankles and 
feet 
dermal infiltration with 
PMN's 
PMN's = polymorphonuclear cells; NSAID = nonsteroidal ant-inflammatory drug; + = present; - = absent; ± = 
present but unremarkable 
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with FMF, this type of purpura it occurred m 13% (13), but it was desenbed m only 3.6% in a 
study with 470 patients. (16) Histological examination of the lesions shows leukocytodastic 
vasculitis. (13,17) Other cutaneous manifestations like purpunc rash, angioneurotic edema, 
subcutaneous nodules, and bullous skin lesions have also been reported in FMF, but their 
significance is less clear. (13,16,18,19) Interestingly, treatment of FMF with colchicine significantly 
reduces the frequency of all cutaneous manifestations ( 13) In adult-onset Still's disease, a transient 
salmon-colored rash is a major cutaneous feature of the disease. The typical rash is mildly pruritic 
or nonprutrtic, occurs pnmanly on the trunk and proximal limbs, and consists of small 
erythematous macules or maculopapules, 3 mm or less in diameter The eruption is usually 
associated with fever, anses in the afternoon and evenings and resolves before the following 
morning (20,21) A Koebner phenomenon has been reported. In a large series, of adult-onset 
Still's disease, the evanescent maculopapular rash was observed in some 87% of the cases. (21,22) 
Histopathologically, a mild penvascular inflammation of the superficial dermis with 
polymorphonuclear and/or mononuclear leukocytes and dermal edema may be demonstrable. 
Treatment with vanous drugs is without much effect. (22) The skin lesions in hyper-lgD can be 
distinguished clinically from those in FMF and adult-onset Still's disease, as is clear from Table 4. 
Cutaneous manifestations are a common feature in the hyper-lgD syndrome and may be 
incorporated with its symptoms. 
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Abstract 
The hypenmmunoglobulinemia D and periodic fever (hyper-lgD) syndrome is typified by 
recurrent febnle attacks with abdominal distress, joint involvements (arthralgias/fcrthntis) headache, 
skin lesions, and an elevated serum IgD level (> 100 U/ml) This familial disorder has been 
diagnosed in 56 subjects worldwide Familial Mediterranean fever resembles the hyper-lgD 
syndrome and it can be speculated that both are caused by mutations in the same gene The gene 
causing familial Mediterranean fever (MEF) has been located on chromosome I6p We have 
studied 10 families with 19 affected and 2Θ non-affected subjects The clinical findings and IgD 
determinations from these families are compatible with autosomal recessive inheritance Using 
highly polymorphic markers surrounding the MEF gene, only negative Lod scores were obtained, 
whereas haplotype analysis excluded this locus as the cause of the hyper-lgD syndrome In 
addition, no indication for linkage was obtained with markers from other candidate gene regions 
on chromosomes 17q and 14q 
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4.1 Introduction 
T he hypenmmunoglobulinemia D and periodic fever syndrome (hyper-lgD) is a rare entity characterized by recurrent attacks of fever ( I ) Symptoms start at an early age and persist throughout life (2). Diagnosis is made by using a list of clinical entena 
allowing it to be distinguished from other periodic fever syndromes such as familial Mediterranean 
fever (FMF), adult-onset Still's disease, and juvenile chronic arthritis (2), Typically, the attacks occur 
every 4-8 weeks and last 3-7 days; they are accompanied by abdominal distress (vomiting, 
diarrhoea, and pain), joint involvement (arthralgia/arthrrtis), skin lesions, headache, and 
lymphadenopathy (1-4). All patients have a constantly elevated polyclonal serum IgD level (> 100 
U/ml) (5). The pathogenesis of the hyper-lgD syndrome is an enigma and consequently therapy is 
only supportive. So far, 56 patients (29 male/27 female) from nine countries have been diagnosed 
Autosomal recessive inheritance is suggested by the finding that in seven families, two or more sibs 
are affected, whereas the parents are unaffected. Serum IgD measurements in one affected family 
revealed high values in patients and low values in unaffected members (< 100 U/ml), supporting 
the concept of autosomal recessive inheritance (4). 
The febrile attacks of the hyper-lgD syndrome and FMF have much in common, despite some 
clinical differences, such as lymphadenopathy (rare in FMF), serosrtis (rare in hyper-lgD syndrome), 
and amyloidosis (not seen in hyper-lgD syndrome). Both syndromes are typified by recurrent 
abdominal distress, articular symptoms, and skin manifestations, There is also sirmlanties in the 
biochemical changes that accompany attacks, namely, high erythrocyte sedimentation rate, 
leukocytosis, and high levels of C-reactive protein (2,6). In the view of these similarities, it could be 
speculated that FMF and the hyper-lgD syndrome are variants of one condition (7,8), and that 
both syndromes are allelic and produced by defects in the same gene. Initially, in Israeli families of 
North African and Iraqi (non-Askhenazi) descent, linkage was indicated between FMF and markers 
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on chromosome I7q22-q24 (9). A maximum Lod score of 3.27 was reached approximately 10 
centimorgans (cM) telomenc to D17S40. Subsequent linkage studies have however failed to 
support chromosome 17q as the location for the responsible gene (9). In the same non-Askhenazi 
Israeli families, the gene causing FMF the MEF gene could been mapped to the short arm of 
chromosome 16(10) Using marker D16S84 ( 16p 13 3). a lod score of 9 17 was reached at a 
recombination frequency (Θ) of 0.04 (10). These results also pertain to Armenian families suffering 
from FMF ( I I ) Refined mapping with highly polymorphic markers resulted in the localization of 
the MEF gene less than I cM centramene from DI6S246 (12,13) Such accurate localization 
allows us to examine the role of the MEF gene in the hyper-lgD syndrome. 
4.2 Materials and Methods 
Patients 
The present study included 10 families with members suffering from the hyper-lgD syndrome 
(Fig. I ). Seven families originate from the Netherlands [nos 2,5,8-10], the other three families are 
from the United Kingdom [no 6], France [no I] and Spam [no 7]. There were no consanguineous 
marriages In total, 19 affected and 28 non-affected family members were investigated. The clinical 
data pertaining to these patients have been published elsewhere and the diagnosis of hyper-lgD 
syndrome was made according to standard entena (2). Briefly, the patients suffer from life-long 
recurrent self-limiting attacks of fever, with no known antigenic triggers, lasting 3-7 days and 
accompanied by one or a combinaton of the following symptoms: abdominal distress (vomiting, 
diarrhoea, pain), skin manifestations, arthralgia/arthntis and/or lymphadenopathy. A detailed family 
history and pedigree were obtained by interviewing each patient; a comprehensive medical history 
was also taken from each unaffected family member. Immunoglobulin D concentrations were 
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measured by enzyme-linked immunosorbent assay with a detection limit of I U/ml. The study was 
approved by the Medical Ethical Committee (CEOM) of our hospital. 
DNA Analysis 
Blood was sampled from relevant family members, and genomic DNA was isolated according 
to the method of Miller et al (14). The markers studied were DI6S4I8, DI6S423, DI6S283, 
^ d DI6S29I (chromosome ІбрІЗ.З), DI7S5I5 (chromosome l7q22-24), and DI4S78 
(chromosome l4q32-33). All markers were analyzed using polymerase chain reaction 
amplification of genomic DNA (50 ng) in a 15-μΙ reaction mixture containing 200 μΜ of each 
dATP, dGTP, dTTP, 2.5 μΜ dCTP, 0.6 μΟ a32P-dCTP (IOmCi/ml, 3000 G/mmol/l), I χ 
Supertaq buffer [10 m/VTns-HCI pH 9.0, 50 mM KCl, 1.5 глЛ7 MgCI2, 0.1% Triton X-IOO, 
0 0 1 % (wA/) gelatin] and 0.06 U Supertaq (HT Biotechnology Limited, United Kingdom) 
overlayed with mineral oil. After initial denaturation for 5 mm at 94°C, amplification was 
performed with 30 cycles of 94°C for I mm, 55°C for 2 mm, and 72°C for I mm, followed by a 
final extension of 6 mm at 72°C (15). The reactions were performed in a 96 wells thermal cycler 
(M.J. Research Inc. Watertown, Mass., USA). After amplification, samples were analyzed on a 
6.6% Polyacrylamide gel (acrylamide: Ν,Ν'-methylene bisacrylamide 19:1) containing 8 3 A7Urea, 
Ι χ TBE ( 100 m/VTns-borate, 2mA/EDTA pH 8 3). Electrophoresis was performed at 60 W for 
2-4 h. After drying of gels, bands were visualized by overnight exposure to Kodak X-OMAT S film. 
Statistica/ analysis 
Linkage analysis was performed using the computer program LINKAGE (version 5.10) (16). 
Lod score calculations were performed on the basis of autosomal recessive inheritance with a 
gene frequency for the hyper-lgD syndrome of 0.00001 and complete penetrance. 
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4.3 Results and Discussion 
Ten families with the hyper-lgD syndrome were studied (Fig. I ) in order to test the hypothesis 
that the hyper-lgD syndrome and FMF are caused by the same gene 
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Ten hyper-lgD families studied for linkage analysis with polymorphic markers In total 19 affected 
patients and 33 non-affected family members were present Results of IgD measurements in UAnL are 
shown for each individual Note the high serum IgD concentrations in patients ( > 100 U/tnl) and the 
low values for unaffected individuals ( < 100 U/mL). 
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The clinical findings from these families supported the 
autosomal recessive mode of inheritance of the hyper-lgD 
syndrome This was further substantiated by the analysis 
of IgD levels in patients and in non-affected family 
members All patients had elevated serum IgD levels 
varying from 266 U/ml to 4224 U^nl, whereas all non-
affected persons had levels below the cut-off point of 100 
U/ml and ranging from 0 4-60 U/ml (Fig I ) 
Highly polymorphic markers surrounding the MEF 
gene were selected for linkage analysis As can be seen in 
Table I, only negative Lod scores were obtained and a 
region of at least 10 cM surrounding each marker locus 
was excluded as the location of the responsible gene (Z¿-
2) Because three of the marker loci have been mapped 
within 5 cM from the MEF gene (Fig 2), our results 
exclude the MEF gene as the cause for the hyper-lgD 
syndrome This finding was further corroborated by the 
construction of haplotypes in two of the largest 
families (nos 2 and 3, Fig. ЗА, 3B) ( 17) 
Fig 2 
Order of polymorphic markers surrounding the MEF gene The genetic distances (sex averaged) are given in cM 
according to the Genome Data Base ( 12) The hatched box indicates the location of the MEF gene The asterisks 
point to the microsatellrte markers examined in the current study 
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Fig. 3 А & В Haplotype analysis of the relevant area of chromosome 16p for family 2 (A) and family 3 (B). 
The orientation of the markers is l6pter-DI6S29l-DI6S283-DI6S423-DI6S4l8-l6cen. 
Haplotypes were assigned in such a way as to minimize the number of crossovers in each family 
(17). 
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Focusing on the chromosomes of mother in family 2, it appears that each copy of the relevant 
segment has been inherited by her affected children. Furthermore, individuals 11.4 and 11.5 have the 
same haplotypes, although only male 11.4 is clinically affected (Fig. ЗА). In family 3, a comparison of 
the haplotypes of sibs 11.2 and 11.4, who are both affected, reveals that they have inherited different 
combinations of parental segments of I6p (Fig. 3B). These findings exclude the MEF gene as the 
cause for hyper-lgD syndrome in these families. 
After the exclusion of the MEF gene, we decided to test two other candidate regions. Markers 
from the region I7q22-q24 have previously shown linkage with the disorder in a subset of MEF 
families (9). Multi-point linkage analysis indicated that the most likely positon of the gene was at 10 
cM telomeric to D17S40. 
Table I. Linkage analysis between the gene for hyper-lgD syndrome and markers of 
candidate regions for the gene 
Marker 
DI6S29I 
DI6S283 
DI6S423 
DI6S4I8 
DI7S5I5 
DI4S78 
Location 
I6ql3.3 
I6ql3.3 
I6ql3.3 
I6ql3.3 
I7q22 
I4q32.3 
0.00 
- 0 0 
-oo 
-OS 
-OO 
- 0 0 
- 0 0 
Lodscores θ 
0.01 
-5.64 
-5.08 
-6 58 
-7.09 
-10.6 
-4.21 
0 05 
-2.36 
-2.43 
-2.72 
-3.17 
-5.19 
-1.62 
0.1 
-1.16 
-1.40 
-1 35 
-1.70 
-3.02 
-0.68 
0.2 
-0.31 
-0.54 
-0.38 
-0.56 
-1.18 
-0.04 
0.3 
-0 07 
-0.18 
-0.09 
-0.16 
-0.41 
0.07 
0.4 
-0.01 
-0.04 
-0.01 
-003 
-0.08 
0.03 
However, linkage analysis in our families with the marker DI7S5I5, which has been mapped at 
this location (18), resulted in a negative lod score (Table I). A region of about 30 cM surrounding 
this marker locus was excluded; this argues against the I7q region as the location of the gene for 
hyper-lgD syndrome. Another candidate locus is the immunoglobulin heavy chain gene cluster on 
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chromosome 14q32 3(19) The high serum IgD concentration persists during non-symptomatic 
periods, and other serum immunoglobulins like IgA and lgG3 can also be elevated in patients with 
hyper-lgD syndrome One could therefore speculate that a mutation at the lg-locus might interfere 
with the regulation of several members of the gene cluster. Although such a mutation would rather 
be expected to act dommantly, we have performed linkage analysis with marker D14S78, which is 
located at an estimated distance of θ cM from the lg-locus Although the lg-locus cannot be firmly 
excluded (Table I), the negative Lod score does not support the presence of a mutation in the 
immunoglobulin heavy chain gene cluster causing hyper-lgD syndrome 
4.4 Summary 
In summary, linkage analysis in 10 families with the hyper-lgD syndrome demonstrates that, 
despite the fact that many of the symptoms of the hyper-lgD syndrome being similar to FMF, the 
MEF gene can be unequivocally excluded as the primary disease locus for the hyper-lgD 
syndrome This finding firmly establishes that the hyper-lgD syndrome and FMF are two distinct 
genetic disorders Furthermore, we have found no indication of linkage with markers on 
chromosome I7q (foregoing evidence suggested linkage with FMF) or I4q (immunoglobulin heavy 
chain cluster) The localization of the gene may require a search with markers equally spaced along 
the entire human genome. 
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Abstract 
The hypenmmunoglobulinemia D and periodic fever (hyper-lgD) syndrome is typified by 
recurrent febrile attacks with abdominal distress, joint involvement (arthralgias/arthntis) headache, 
skin lesions and an elevated serum IgD level (>I00 U/mL). This familial disorder has been 
diagnosed in 59 patients, mainly from Europe. The pathogenesis of this febrile disorder is unknown 
but attacks are joined by an acute phase response, Because this response is considered to be 
mediated by cytokines, we measured the acute phase proteins C-reactive protein (CRP) and 
soluble type II phospholipase \ (Pl_4) together with circulating concentrations and ex-vivo 
production of the proinflammatory cytokines mterleukm (IL)-1 o, IL-1 ß, IL-6, tumor necrosis factor-
α (TNFa), and inhibitory compounds IL-1 receptor antagonist (IL-Ira), IL-10 and soluble TNF 
receptors p55 (sTNFr-55) and p75 (sTNFr-75) in 22 patients with the hyper-lgD syndrome 
during attacks and remission. Serum CRP and PLAj concentrations were elevated dunng attacks 
(mean, respectively 213 mg/L and 1452 ng/mL) and decreased between attacks. Plasma 
concentrations of IL-1 α, IL-1 ß, or IL-10 were not increased during attacks. TNFa concentrations 
were slightly, but significant, higher with attacks (104 vs 117 pg/mL) Circulating IL-6 values 
increased with attacks ( 19.7 vs 147.9 pg/mL) and correlated with CRP and PLAj values dunng the 
febrile attacks. The values of the antiinflammatory compounds IL-Ira, sTNFr p55 and sTNFr p75 
were significantly higher with attacks than between attacks and there was a significant positive 
correlation between each. The ex-vivo production of TNFa, IL-Iß and IL-1ra was significantly 
higher with attacks suggesting that the monocytes/macrophages were already primed m-vivo to 
produce increased amounts of these cytokines. These findings point to an activation of the cytokine 
network and this suggest that these inflammatory mediators may contribute to the symptoms of 
the hyper-lgD syndrome. 
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5.1 Introduction 
T he hypenmmunoglobulinemia D and periodic fever syndrome (hyper-lgD) is a rare entity characterized by periodic occurrence of febrile attacks. (I) All patients have a 
clearly elevated (polyclonal serum IgD (> 100 U/mL). So far we have diagnosed 59 
patients (31 male/28 female) from nine, mainly European, countries. The episodes last 3-7 days, 
occur every 4-6 weeks, start early and persist throughout life, and, between attacks, patents are 
non-symptomatic. (2) Symptoms are not triggered by known infectious agents and include 
abdominal distress (vomiting, diarrhea and pain), joint involvement (arthralgia/arthntis), skin lesions, 
headache, and lymphadenopathy. (2-4) The mam feature of the disease is the abrupt onset of 
fever that parallels with an acute-phase reaction as evidenced by leukocytosis, neutrophilia and a 
raised erythrocyte sedimentation rate. 
The pathogenesis of the hyper-lgD syndrome is unclear, but because fever and the acute phase 
reaction are considered to be mediated by cytokines such as interleukin-1ß (IL-Iß), IL-6, and 
tumor necrosis factor o (TNFct) it can be speculated that symptoms in the hyper-lgD syndrome 
result from a disturbed cytokine synthesis which may be responsible for some of its clinical 
manifestations and could also contnbute to the polyclonal serum IgD elevation. (5-7) Therefore, 
we studied the pattern of circulating and ex-vivo production of inflammatory mediators IL-1 a, IL-
IO, IL-6, TNFa, C-reactive protein (CRP), soluble type II phospholipase Aj (PLAj), and inhibitory 
compounds such as IL-1 receptor antagonist (IL-Ira), IL-10 and soluble TNF receptors p55 
(sTNFr p55) and p75 (sTNFr p75). 
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5.2 Patients and Methods 
Patients 
The study group consisted of 22 Dutch patents, 14 male and θ female patents with the hyper-
lgD syndrome. The mean age at the time of the study was 28.3 years (SD ± 14,4 years) The 
diagnosis was made following standard clinical criteria and a recent review with a pertinent 
description of the clinical and biological features of the hyper-lgD syndrome has been published 
elsewhere (2) Briefly, all patents were suffenng from recurrent febrile attacks accompanied by a 
combinaton of the following features: lymphadenopathy, splenomegaly, arthralgias/arthrrts, 
abdominal pam/vomrting/diarrhoea, skin lesions. The attacks are self-hmitng and last 3 to 7 days. 
The main clinical features of these patents are listed in Table I. 
Blood samples 
Sampling of plasma was performed during attacks as well during remission, using special 
endotoxin-free tubes (Vacutamer Systems, Becton and Dickinson, Rutherford, NJ, USA). The 
plasma was immediately processed in order to avoid ex vivo cytokine excreton. (8) We defined 
attacks if the patent was febnle {t 38°C not caused by infection) and showed signs of active 
disease with symptoms as mentoned before. Remission was defined as the absence of symptoms 
for at least I month. No medicaton, including antpyretcs, were allowed during the study period. 
All patients underwent physical exammaton and results are listed in Table I. Cytokine production 
was measured using a whole blood culture system as descnbed elsewhere. (9) Bnefly, two 4 mL 
tubes containing 48 μι. EDTA-K3 and 250 μι . aprotnm (10000 kallikrem mactvatng units per mL; 
Bayer, Leverkusen, Germany) were drawn. 
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Table I : Main clinical features of 22 patients with the hyper-lgD and periodic fever syndrome 
Patient Sex Age(yr) Lymphade- Spleno- Abdominal Skin Arthritis 
No nopathy megaly distress lesions 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
F 
M 
M 
M 
F 
M 
M 
M 
F 
F 
M 
F 
F 
M 
M 
M 
M 
M 
M 
M 
F 
F 
32 
30 
34 
69 
42 
49 
35 
36 
24 
43 
20 
16 
22 
13 
21 
8 
12 
31 
27 
7 
24 
27 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
-
-
-
-
+ 
+ 
-
+ 
-
-
-
+ 
-
-
-
-
+ 
-
-
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
-
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
+ 
-
-
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
Abbreviations: + , present; -, absent; M, maie; F, female 
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One tube was incubated immediately, the other tube was incubated after addition of 50 μ ι 
lipopolysacchande {Escherichia coli serotype 055:B5, Sigma, St Louis, MO; final concentration 10 
/ig/mL). After 24 hours of incubation at 37°C both tubes are centnfuged at 2,250g for 10 minutes 
and secondly at 15,000g for 5 minutes to obtain platelet-poor plasma. Aliquots were stored at -
70° С until assay. Cytokine production with LPS stimulation was measured and compared to 
production without LPS stimulation. Control values were obtained from 10 healthy volunteers (20 
to 45 years of age) and were 6,847 ±2,175 pg/mL (IL-Iß); 3,344 ± 969 pg/mL (TNFa) and 
9,827 ± 2,597 pg/mL (IL-Ira). TNFa was determined by radio-immuno assay as described by 
Van der Meer et al. (10) (lower detection level 20 pg/mL, upper detection limit 10,000 pg/mL). 
IL-1 α and IL-1 ß were measured by radioimmunoassay (without chloroform extraction) according 
to LISI et al. ( 11 ) (IL-1 α lower detection limit of 5 pg/mL, IL-1 ß lower detection limit of 40 pg/mL). 
IL-1 ra was determined by radioimmunoassay according to Poutsiaka et al. ( 12) (lower detection 
limit 60 pg/mL). sTNFr were measured by an enzyme-linked immunosorbent assay (ELISA 
[detection level, 80 pg/mL for sTNFr p55 and 300 pg/mL for sTNFr p75]; a kind gift of H. Gallat, 
Hoffmann-La Roche, Basel, Switzerland). This assay measures both free and total receptor bound 
concentrations. Since sTNFr is not produced ex vivo, its LPS-stimulated production was not 
assessed in this study. IL-6 was measured by an ELISA as descnbed earlier (detection level 14 
pg/mL). (13) IL-10 was measured by sandwich ELISA with the 4G6 and 5D11 mouse anti-human 
IL-10 monoclonal antibodies for capture and the 5AI0 anti-human IL-10 monoclonal antibodies 
for detection (kindly provided by Medgenix, Amersfoort, The Netherlands). The detection limit 
was I I pg/mL. ( 14) 
CRP measurements were performed wrth an immunoturbidimetric assay using an automatic 
analyzer HITACHI 747 (Hitachi Co, Tokyo, Japan). The measuring range was from 3 to 440 mg/L 
Secreted non pancreatic type-ll PLAj antigen concentrations in plasma were determined with 
an ELISA modified from Smith et al. (15) Two different monoclonal antibodies against human PLA¡ 
(a kind gift from Dr. F.B. Taylor Jr. Oklahoma Medical Research Foundation, Oklahoma City, OK) 
were used as coating and catching antibodies. Because previous experiments showed a very good 
correlation between results from ELISA measurements and with those obtained with cultured 
medium from Hepatoma G2 cells stimulated with human IL-6, only the former method was used. 
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(Schalkwijk CG, unpublished observations) The lower hmrt of detection was I ng/mL 
To minimize analytical errors, all samples from the same patient were analyzed in the same run in 
duplicate 
Statistical analysis 
The paired nonparametric Wilcoxon signed rank test was used for statistical companson of 
values obtained during active disease versus remissions. 
The unpaired nonparametric Mann Whitney U test was used were appropriate In patients with 
multiple samples taken during separate episodes of active disease, the mean value was used. 
Probability (P) values were calculated on the basis of two-tailed tests. A correlation coefficient was 
calculated with the Pearson's correlation test A Ρ value of less than 05 was considered to be the 
lowest level of significancy. Data are given in mean ± standard deviation (SD). 
5.3 Results 
Results of circulating cytokines and other inflammatory mediators are given in Figs. I and 2. 
The CRP concentrations, a reflection of the acute-phase response, clearly modulated with the 
attacks in the patients with the hyper-lgD syndrome. The CRP concentrations were uniformly high 
dunng attacks. 213.3 ± 9Θ.2 mg/L but decreased to low values (22.6 ± 26.Θ mg/L) in between 
attacks (P < 0001 ; see Fig. I A). Concentrations of PLA2 increased to a mean of 1,452 ± 1,665 
ng/mL during the febrile attacks compared to values during non-symptomatc periods ( 113 ± 240 
ng/mL; Ρ < .0001; see Fig. IB). One patient had even a 253-fold elevation (maximum 6,066 
ng/mL) of PLAj during attack as compared with convalescence. The concentrations of PLA and 
CRP obtained dunng febrile attacks showed a very good correlation during attacks ( r = 0.74; Ρ < 
.0001) We could not detect measurable quantités of circulating IL-1 α between and dunng attacks 
in patents with the hyper-lgD syndrome (Table 2). The mean plasma concentratons of IL-113 
during actve disease did not differ from the values obtained during remissions. The TNFa 
concentratons increased from 104 ± 20 pg/mL to 117 ± 15 pg/mL, a small but significant 
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increase (P = .0075). Nevertheless, the TNFa concentrations during attack, remained within 
normal values of our laboratory (106 =t 25 pg/mL). 
IL-6 was also significantly elevated during active disease (147.9 ± 258.3 pg/mL; Ρ < .0001; see 
Fig. 2A). Three patents had values above 150 pg/mL (471 ; 720 and 1,074 pg/mL respectively). 
Exclusion of data from these 3 patients did result in a lower mean IL-6 plasma concentration 
during attacks (54.9 ± 27.2 pg/mL). However, the difference between values obtained during 
attacks and between attacks remained significant despite exclusion. (P < .0001) During febnle 
episodes, there was a moderate, albeit significant, correlation between IL-6 and the acute phase 
proteins CRP (r = 0.47; Ρ = .014) and Р1Д (r = 0.45; Ρ = .018). No correlation could be 
detected between IL-6 and either IL-1 ß or TNFa. 
Table 2. Circulating cytokines in 22 patents with hyper-lgD syndrome 
Circulating concentration (pg/mL) ± SD 
Cytokine Between Attacks Attack 
IL-la < 5 < 5 
IL-1 ß 83.1 ±20.3 80.4 ±21.6 
IL-10® 20.3 ±21.1 14 θ ± 3.7 
θ
 Tested in 8 patients 
IL-10, measured in plasma of 8 patients, remained unchanged regardless the phase of the disease. 
(Table 2) The antinflammatory compounds IL-1 ra, sTNFr p55 and sTNFr p75 were significantly 
increased during attacks compared to remissions (Fig 2B through D). The mean values of IL-Ira 
were 996 ± 329 pg/mL dunng attacks whereas they were 300 ± 167 pg/mL dunng remission (P 
< .0001; see Fig. 2B). 
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Fig I. Individual serum CRP (A) and PLA, (B) for 22 hyper-lgD patients during and in between attacks. For 
(A), the vertical lines indicate mean ( 9 ) ± SD The vertical lines in (B) indicate median (•) and 9 5 % 
confidence intervals. The increase was statistically significant for CRP and PLA¡ ( Ρ < 0001 ) 
The mean sTNFr p55 and sTNFr p75 concentrations during active disease increased to 5,043 ± 
1,703 pg/mL and 7,103 ± 2,378 pg/mL, respectively (both Ρ < 0001; see Fig. 2C-D) The 
sTNFr p75 / sTNFr p55 ratio did not change with attacks (data not shown). We could not establish 
a correlation between either the individual concentrations of IL-1 ra, sTNFr p55 or sTNFr p75 and 
the temperature at the time of blood drawing or the frequency of the attacks (data not shown). 
During attacks there was a significant correlation between circulating plasma concentrations of IL-
I ra and sTNFr p55 (r = 0 48; Ρ = 0231), IL-1 ra and sTNFr p75 (r = 0 67, Ρ = 0006), and 
sTNFr p55 and sTNFr p75 (r = 0.58, Ρ = .0041), however no correlation could be detected 
between individual CRP levels and IL-Ira, sTNFr p55, or sTNFr p75 levels In 3 patients the 
course of the circulating IL-1 ra, STNFr p55 and sTNFr p75 concentrations during first 5 days after 
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onset of the attack was followed as depicted in Fig. 3. The course of the values for the various 
cytokines is as follows. sTNFr p55 and sTNFr p75 only decrease after 3 days after onset of the 
febrile attack. IL-1 ra reaches the highest values on the second day of the attack and normalizes 
wrthm 5 days. IL-6 was rapidly cleared from the circulation similar to the acute-phase proteins CRP 
and PLAj. 
Ex vivo cytokine production 
Figure 4, upper panel, shows the nonstimulated production of the various cytokines tested. 
The unstimulated production of TNFa between attacks was significantly higher compared to 
healthy controls (564 ± 304 vs 225 ± 11 pg/mL). Only the values for IL-1 ra, were significantly 
higher during attacks than during remissions, 3,642 ± 1,708 pg/mL as compared with 2,048 ± 
2,398 pg/mL (P = .015). The production of IL-1 α in whole blood in the presence or absence of 
LPS was negligible, and did not differ between attacks and remission. The LPS-stimulated 
production of IL-1 ß and TNFa in patients with the hyper-lgD syndrome was significantly higher 
dunng attacks compared to remissions and for healthy controls (Fig. 4, lower panel; Ρ < .0001). 
During remissions both the unstimulated and LPS-stimulated production of TNFa, but not of IL-
lß, was significantly higher compared to controls (P < .05). Fourteen patients had TNFa 
concentrations beyond the upper detection limit of 10,000 pg/mL during attacks compared with 
only 6 patients during remission. LPS-stimulated production of IL-6 dunng attacks was similar to 
that measured during nonsymptomatic periods. The LPS-stimulated production of IL-1 ra was also 
significantly higher during attack than in between attacks and than in healthy volunteers (P < 
.0001 ). During attacks there were modest correlations between IL-1 ra and IL-1G production (r = 
0.42; Ρ = 027) and IL-Ira and IL-6 production (r = 0.3; Ρ = .027). The production of IL-Iß 
correlated well with that of IL-6 dunng febrile episodes (r = 0.53; Ρ = .0057). 
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Fig 2. Circulating IL-6 (A), IL-1 ra (B), sTNFr p55 ( Q , sTNFr p75 (D) in 22 hyper-lgD patients. The individual 
values are represented by black dots and were obtained during and between attacks. In (A) the vertical 
lines indicate median (•) and 9 5 % confidence intervals. For (B through D) the vertical lines are mean 
( · ) ± SD. The increase was statistically significant for all four cytokines ( Ρ < .0001 ) 
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Fig.3: Time course of circulating concentrations of IL-6 (A), IL-1 ra (B). sTNFr p55 (C), sTNFr p75 (D), CRP 
(E), and PLA, (F) in 3 individual patients with the hyper-lgD syndrome during the first 5 days of an 
attack 
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5.4 Discussion 
We investigated the pattern of circulating cytokines and the ex vivo production of cytokines in 
22 patients with the hyper-lgD syndrome. We found evidence for a vigorous acute-phase 
response in the hyper-lgD syndrome, as reflected by the significant increase of CRP and PLAj 
concentrations that subsided during remission. The significant elevation of the proinflammatory 
cytokines IL-6 and, albeit very modest, TNFa together with the elevation of the natural cytokine 
inhibitors IL-1 ra, sTNFr p55 and sTNFr p75 point to activation of the cytokine network during the 
attacks of the hyper-lgD syndrome. Although it is not clear to what extent these cytokines 
contribute to the clinical features of the hyper-lgD syndrome, many of its symptoms are 
compatible with the effects of proinflammatory cytokines However, it is unlikely that only one 
factor can cause the clinical picture; instead, activation of the cytokine network and involvement of 
various cytokines probably contnbute to the pathogenesis of the attacks 
The elevation of these inflammatory mediators occurs regardless of the seventy of attacks as 
reflected by body temperature and CP\P concentrations or the frequency of attacks The absence 
of any elevation of IL-10 concentration, a potent inhibitor of synthesis of cytokines, argues against 
an important role for this cytokine in the pathogenesis of the hyper-lgD syndrome, (16) Lastly, 
there is increased ex vivo production of IL-lf3, TNFa, and IL-Ira dunng attacks compared to 
nonsymptomatic penods, as measured in a whole blood culture system. 
The acute-phase response in humans is considered to be mediated by the proinflammatory 
cytokines, and we detected a modest but significant elevation of IL-6 together with a significant 
correlation between IL-6 and the acute-phase proteins CPP and PLAj in the blood during the 
febrile attacks. 
In view of these findings, it can be speculated that the increased plasma IL-6 concentration 
results from overproduction rather than underutilization, because renal function was normal in all 
patients In addition, the elevated IL-6 values are associated with increased CP\P and PLA, values. 
Underutilization would probably have resulted in low concentrations of these acute-phase 
proteins. 
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IL-6 and IL-1 га in a whole blood culture system incubated for 24 hours. Data are shown as the mean 
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with values obtained between attacks. 
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IL-6, as the major mediator for the regulation of acute-phase protein synthesis in humans also 
influences the glycosylation of these proteins. (7,17,18) In recent studies in the hyper-lgD 
syndrome, we have demonstrated elevated a,-3 fucosylation of the acute-phase protein α -acid 
glycoprotein (AGP), and this finding is compatible with a role of IL-6 during the recurrent febrile 
attacks. (19) In addition, IL-6 is a stimulus for PLA, synthesis in the liver, and the strongly elevated 
(13-fold) PLA, concentrations found during the febnle attacks, together with the correlation 
between IL-6 and РІД, corroborate with these findings. (20) By cleavage of arachidomc acid from 
cell membrane, PLAj in its turn is able to elicit an inflammatory response. Enhanced PLAj activity in 
serum propagates tissue damage through membrane digestion and liberation of cytotoxic fatty 
acids (21) For example, when administered intra-articulary in rats, it causes synovitis (22) and 
serum PLAj concentrations correlate well with activity of juvenile rheumatoid arthritis in humans. 
(23) Furthermore, intradermal injection of РІД causes local dermal inflammatory infiltrates. (24) 
These biological effects of PLAj may be responsible for some of the clinical features of the hyper-
lgD syndrome, because arthritis and cutaneous vasculitis are mam symptoms of the disease. (2,3) 
Despite our efforts, we have not been able to establish which endogenous pyrogen is 
responsible for the fever m the hyper-lgD syndrome. A possible reason for our failure to trace 
appreciable elevations of pyrogenic proinflammatory cytokines such as IL-1 ß and TN Fa may be 
the delay between onset of attack and sampling. Although, we sampled all our patients on their 
first day with fever, this may already have been too late. The slight elevation of TNFa dunng 
attacks perhaps reflects the descending slope of an earlier peak. The increased CP\P levels at time 
of drawing of blood, indicate an already ongoing acute-phase response, thought to be the 
consequence of the action of cytokines, and these may have already disappeared from the 
circulation. 
This hypothesis is in line with the finding of increased cytokine inhibitors such as IL-1 ra, sTNFr 
p55, and sTNFr p75, of which it is known, from expenmental endotoxinemia, that they can still be 
detected in the circulation hours after the disappearance of IL-1 ß and TNFa. (25-27) The same 
holds for PLAj, which peaks Ι θ to 24 hours later than TNFa after endotoxin infusion in human 
volunteers. (28) 
In our study, elevation of IL-1 ra, sTNFr p-55 and sTNFr p-75 was present at the first day of an 
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attack, and appreciable concentrations were found on the second and third day of the attack. 
Endogenously produced IL-Ira, a major natural inhibitor of IL-1, may ameliorate the seventy of 
attacks in the hyper-lgD syndrome. (29-31) Because we did not find clear elevations of IL-1 
concentrations, it is impossible to judge whether the amount of IL-1 ra is adequate to alleviate the 
acute inflammation. Our finding of predominant concentrations of IL-1 antagonist recalls the results 
obtained in systemic JRA, another periodic febrile disorder. In JRA, inhibition of IL-1 bioactivity by 
serum and unne during febrile attacks was found (32) Also, for TNFot we merely find inhibition, as 
judged by the elevated concentrations of soluble receptors for TNF. (33) sTNFr bind TNF and 
form a biological inactive complex, blunting the deleterious effects of TNFot. (26) 
How do our results of circulating cytokines compare to measurements in another penodic fever 
syndrome such as familial Mediterranean fever (FMF)? In FMF patents, TNF and IL-1 activity has 
been investigated. In a study with Sephardic Jews with FMF there was no evidence of TNFa bio­
activity in plasma obtained during attack and remission (34) The authors nevertheless suggested a 
role for TNFa in FMF and impute the lack of elevated circulating plasma TNFct to the short half life 
(6 minutes) and the possible binding to soluble receptors. In a similar study of Turkish FMF 
patents, using ELISA, TNFa was detected, albeit in modest concentratons (33 I pg/mL in 
between attacks compared with 62 2 pg/mL during attacks) (35). Here, again, one may wonder 
whether the values measured dunng an attack represent a tail of initially elevated TNF 
concentratons. The higher concentratons we found during remissions ( 104 ± 20 pg/mL) and 
attacks ( 117 ± 15 pg/mL) in the hyper-lgD syndrome are most likely due to detection of both free 
TNF and TNF bound to sTNFr. 
The role of IL-1 was tested in a study of Ι θ FMF patents, 9 symptomatic and 9 asymptomatc, and 
mean IL-1 activity in patents (either during attack or remission) was comparable to the values 
obtained in controls. (36) 
We studied the effect of bacterial LPS on the cytokine production as generated in whole blood. 
In contrast to T-cell mitogens like concavalm A, LPS is a reliable simulator of cytokine production.. 
The effect of LPS is dose dependent, and dosages up to 10 pg/mL as used in our study have 
yielded in reproducible results. (37) It is of interest that we detected an augmented LPS-stmulated 
ex vivo producton of TNFa, IL-1 ß and IL-1 ra in our whole blood culture system dunng attacks. 
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This enhanced production capacity in the hyper-lgD syndrome during attacks is in contrast with 
findings obtained in various infectious diseases such as meningococcal sepsis and typhoid fever, 
where the ex vivo production of TNF, IL-1 and IL-6 is depressed dunng the acute stage and 
gradually restores dunng recovery. (38,39) Also, TNFo and IL-1 production, as stimulated by LPS, 
has been reported to be markedly decreased during attacks in FMF. (34,36,40) We could confirm 
these results in three FMF patents, and detected decreased ex vivo production of TNFa, IL-1 ß 
and IL-1 ra dunng attacks. (Drenth unpublished observations) These findings clearly differ from the 
increased production dunng the febrile attacks of the hyper-lgD syndrome. It is possible that the 
monocytes/macrophages in the hyper-lgD syndrome are already primed m-vivo to produce 
increased amounts of these cytokines This could be the result of increased concentrations of AGP 
and CRP, because these acute-phase proteins have been shown to potentiate the m-vrtro 
production of cytokines, and of TNFa in particular. (41-43) In addition, CRP and to lesser extent, 
AGP are able to induce the synthesis of IL-Ira in vitro. (43) We have shown earlier that serum 
AGP concentrations are markedly elevated dunng attacks of the hyper-lgD syndrome and 
somewhat elevated during remission. (19) In contrast, lower concentrations of the acute-phase 
protein AGP are found in FMF, and this perhaps contributes to the diminished LPS-stimulated 
cytokine production. (44) These data underscore differences in pathogenesis of the disorders. 
Elsewhere, we have already alluded to the genetic differences between FMF and the hyper-lgD 
syndrome. (45) Additional studies are needed to further elucidate the role of the acute-phase 
proteins in cytokine regulation in the penodic fever syndromes and to delineate the molecular 
basis of the fever. 
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Abstract 
The hypenmmunoglobulinemia D and periodic fever (hyper-lgD) syndrome is typified by 
recurrent unpredictable febrile attacks with abdominal pain, joint involvement (arthralgias/arthritis), 
headache, skin lesions and a polyclonal elevation of serum IgD (> 100 U/ml). Interferon-gamma 
(IFN-γ) is a major proinflammatory cytokine which could play a role in the pathogenesis of the 
attacks There is a need for parameters (if possible non-invasive) to monitor disease activity. A 
potential candidate is neoptenn which is released by monocytes/macrophages when stimulated 
with IFN-γ, excreted unchanged in urine, and appears to be an early and sensitive marker for 
activation of the immune system, We measured rectal body temperature, serum IFN-γ, and unne 
neoptenn in 10 hyper-lgD patients both dunng and between attacks. The body temperature rose 
to a mean of 38.9°C on the first day of the attack and normalised within 5 days. Serum IFN-γ 
during the first day of the attack was 2 98 lU/ml and was significantly lower during remissions. The 
unne neoptenn excretion was 268 ± 170 μπτοΙ/mol creatinine between attacks and was 
significantly increased to 638 ± 275 μπηοΙ/mol creatinine on the first day of symptoms. Maximal 
urine neoptenn values were reached on the fourth day of the attack (1051 ± 387 μπτοΙ/mol 
creatinine) and excretion gradually declined and attained values below 400 μπηοΙ/mol creatinine 
after 9 days. There was a good correlation between serum IFN-γ and unne neoptenn. The 
increases in serum IFN-γ and urine neoptenn suggest activation of the cellular immunity during the 
febrile attacks of the hyper-lgD syndrome. Furthermore, the activation of the cellular immune 
system appears to persist several days after normalisation of the body temperature. Our study 
shows that unnary neoptenn is a good quantitative and qualitative parameter to monitor disease 
activity in patents with the hyper-lgD syndrome 
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6.1 Introduction 
T he hypenmmunoglobulmaemia D and periodic fever syndrome (hyper-lgD) is characterized by recurrent attacks of fever associated with persistently elevated polyclonal serum IgD levels (> 100 U/ml). ( I ) An autosomal recessive inheritance is 
typical (2) Symptoms commence at an early age and persist throughout life and the febrile attacks 
occur every 4 to 8 weeks, lasting 3 to 7 days During these episodes the patients may suffer from 
abdominal distress (vomiting, diarrhoea and pain), skin lesions, joint involvement, headache and 
lymphadenopathy. (3,4) The cause of the syndrome is unknown but since attacks are featured by 
an important inflammatory reaction, IFN-γ as a major proinflammatory cytokine could play a role 
in the pathogenesis Therefore, we measured IFN-γ as well as neopterin, a ptendme derivative, 
which is released by monocytes/macrophages when stimulated with IFN-γ. (5) Neoptenn, is 
conveniently excreted in urine and can be measured easily. It appears to be an early and sensitive 
marker of activation of the immune system (6) In inflammatory diseases such as rheumatoid 
arthritis and systemic lupus erythematosus urinary neoptenn levels correlate closely with the 
disease activity (7,8) The present study investigates whether IFN-γ and urine neoptenn are 
increased during the febrile attacks of the hyper-lgD syndrome and assesses the clinical utility of 
urinary neoptenn as marker of disease activity in these patients. 
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6.2 Patients and Methods 
Patients 
Ten patients, six female and four male, with the hyper-lgD syndrome were included in the 
study and the diagnosis of hyper-lgD syndrome was made according to standard entena. (3). The 
mean age at time of sampling was 28.8 years (range 8-61 years) Patients were instructed to 
commence sampling on the first day of attack and to continue until at least the fever subsided, with 
a maximum of 10 days sampling. Each day the first morning urine specimen was sampled in a 
special container, shielded from light, and frozen at -20°C until analysis. The rectal body 
temperature was measured daily, using a digital thermometer. Samples for unne neopterin 
concentrations were obtained in each patent between attacks to give baseline values. Sampling of 
serum for IFN-γ measurements was performed on the first day of the attack and during remission. 
Laboratory measurements 
The IFN-γ concentration was determined by a commercially available immunoradiometnc 
assay. (Medgenix, Amersfoort, the Netherlands). The microtiter plate wells are coated with 
monoclonal anti IFN-γ. After washing, radiolabeled (ШГ) anti IFN-γ was added. Bound 
radioactivity was determined in a gammacounter and the IFN-γ concentrations were calculated 
from standard curves. The lower limit of detection of the assay was 0.2 lU/ml. The mean value 
obtained in healthy controls is 0.55 ± 0.14 lU/ml. (manufacturers information) 
Determination of neoptenn was by reversed-phase-high-performance liquid chromatography with 
minor modifications. (9) 
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Briefly, unne samples were centrifugea to remove debns, diluted in I to 10 with water containing 
dimethylptenne as an internal standard and injected directly onto a Techsphere 5 ODS column 
(HPLC Technology Ltd). A binary gradient elution was used with an initial mobile phase of 2% 
methanol in 15 mmol/L phosphate buffer, pH 6.4, increasing to 25% methanol after 12 minutes, 
and creatinine was detected separately using a kinetic alkaline picrate (Jaffe) method. The ratio of 
neopterin to creatinine was calculated to compensate for variations of urine density. The median 
urine neopterin value for a group of 65 healthy controls was 149 jumol/mol creatinine (range 62-
273). (8) 
Statistica analysis 
The paired non-parametnc Wilcoxon test was used for statistical comparison of values obtained 
during active disease compared to remission values. Probability (F) values were calculated on the 
basis of two-tailed tests A correlation coefficient was calculated with the Pearson's correlation test. 
A Pvalue of < 0.05 considered to be the lowest level of significance. Data are given in mean ± 
standard deviation 
6.3 Results 
The attacks in the hyper-lgD were featured by an increase of the mean body temperature to 
38.9°C on the first day of the attack which returned to normal by day 5. (Fig I) 
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For 10 hyper-lgD patents a total 69 urine samples (mean 6 9 per patent) were collected dunng 
attacks. Three patents collected the complete set of urine samples for the 10 days. 
The control unne neoptenn excretion for the 10 patents was 268 ± 170 (median 199) μητοΙ/ιηοΙ 
creatnme, significantly lower than values obtained on the first day of symptoms: 63Θ ± 275 
(median 604) μπηοΙ/mol creatnme. (Fig 2) (P = 0 002). Serum for IFN-γ measurements was 
obtained from 9 patents during an attack. The IFN-γ concentraton during the first day of the 
attack was 2.98 ± 3.55 (median 1.33) lU/ml and was significantly lower, 0.59 ± 0.39 (median 
0.44) lU/ml during remissions. (Fig 2) 
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Rg2: 
The left panel indicates the individual unne neopterin values for 10 patients between and during attacks of the 
hyper-lgD syndrome. The mean and standard error of the mean are displayed at either side. Note the significant 
elevation of urine neopterin during attacks. (P = 0.002) The right panel refers to the individual concentrations of 
circulating IFN-γ in nine patients during and in between attacks of the hyper-lgD syndrome. The mean and 
standard error of the mean are displayed at either side IFN-γ concentrations were significantly higher during 
active disease compared to remission, (p < 0.05) 
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All patients had higher total urine neoptenn during attacks compared to between attacks. The 
mean unne neoptenn increased in the first days of the attack and maximal values were reached on 
the fourth day of the attack (1051 ± 3 8 7 μπτοΙΛποΙ creatinine), The unne neoptenn gradually 
declined and attained values below 400 μπτοΙ/mol creatinine after 9 days. (Fig 3) One patient 
started sampling 2 days before the onset of the febnle attack. In the days preceedmg the attack 
neoptenn excretion values were 245 and 2Θ0 μπηοΐ/глоі creatinine The excretion increased 
respectively to 345 and 780 μηηοΙ/mol creatinine on the first 2 days of the febrile attack. There 
was a good correlation between serum IFN-γ and unne neoptenn excretion: г = 0 6675 (ρ < 
0.05). The decrease in body temperature and thus the end of an attack, anticipated the decrease 
of urine neoptenn by 4 to 5 days. In five patients the activation of the cellular immune system 
(urine neoptenn > 200 μπτοΙ/πτοΙ creatinine) persisted dunng remission despite apparent clinical 
wellbemg 
6.4 Discussion 
Serum concentrations of IFN-γ and unne excretion of neoptenn correlated well with the 
clinical condition of the hyper-lgD patients. IFN-γ increased five-fold over remission values dunng 
active disease. IFN-γ participates in the human inflammatory response, partly through its ability to 
induce production of TNFa and other cytokines. ( 10) IFN-γ itself may be a pyrogenic compound, 
but its presence does not explain all signs and symptoms in the hyper-lgD syndrome. ( I I ) Other 
proinflammatory cytokines possibly involved in the pathogenesis are currently being studied by us. 
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Fig3: 
Urine neoptenn in μιηοΙ/mol creatinine ratios during the first 10 days of an attack in 10 patients with the hyper-
lgD syndrome. Day I denotes the first day of the attack as defined by the symptoms. Data are expressed as mean 
and standard deviation. 
We found that urine neoptenn values are low between attacks of the hyper-lgD syndrome but 
increase significantly dunng attacks. Neoptenn is a non-specific marker of cellular activation being 
produced by human macrophages in response to IFN-γ. (5) Neoptenn is a stable compound, 
readily detectable and easy to measure. Since neoptenn is not metabolized, the urine excretion 
reflects the integrated release of neoptenn. (12) Furthermore, serum IFN-γ and urine neoptenn 
correlate significantly in the hyper-lgD syndrome which is in line with these expenmental data in 
vitro suggesting that IFN-γ is the dominant factor involved in the release of neoptenn. (5) The 
course of the unne neoptenn excretion during the attacks demonstrates that maximal values are 
attained within 4 days. Data from one patent indicate that neoptenn excretion values are normal 
in the days immediately before an attack. This may suggest that the value of neoptenn as a 
predictor of attacks is rather limited. The end of the attack, as indicated by the normalization of the 
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rectal body temperature and disappearance of the symptoms occurs in 5 days, but at the same 
time unne neoptenn still continued to be elevated above individual reference values Thus, the 
activation of the cellular immune system appears to persist after normalization of the temperature. 
Our study shows that unnary neoptenn is a good quantitative and qualitative parameter to 
monitor disease activity in patients with the hyper-lgD syndrome A reliable non-invasive 
parameter is needed in the management of the hyper-lgD syndrome because many patients are 
young ( < 10 years), and because of the outpatient basis of the treatment. Moreover, evaluation 
of drugs in a disorder charactensed by unpredictable febnle attacks requires a dependable 
parameter In studies evaluating the effect of colchicine in familial Mediterranean fever, another 
periodic fever syndrome, patents were requested to keep records of their attacks with symptom 
diaries and/or postcards (to be sent to the investigators when having an attack) (13-15) Symptom 
dianes depend to a large extent on self-interpretation by the patent and consequently more 
objective and accurate parameters are clearly needed The use of urine neoptenn to monitor 
disease activity has great advantages; the patents can sample and store urine at home in their 
home freezer for up to 6 months contrastng with serum that requires processing. 
6.5 Conclusion 
In conclusion, unne neoptenn appears to be a good monitor of disease actvity in the hyper-lgD 
syndrome. Neoptenn measurements can be useful when evaluatng the effect of therapy for the 
hyper-lgD syndrome. Our data suggest that attacks of the hyper-lgD syndrome are associated 
with macrophage actvaton as evidenced by increased serum IFN-γ and unne neoptenn 
excreton 
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Abstract 
Crossed affinoimmunoelectrophoresis using concavalin A and Aleuria aurantia lectin as 
diantennary glycan- and fucose-specific affinocomponents, respectively, was applied to study 
changes in the concentration of the acute phase protein α,-acid glycoprotein (AGP) in sera 
obtained from patients with hypenmmunoglobulmemia D and periodic fever syndrome. Increases 
in concentration of AGP compared to control values were found not only during attacks, but also 
during remissions. Compared to healthy controls, the presence of diantennary glycan-contaming 
glycoforms of AGP also increased during febrile attacks, while no changes were found during 
remissions. A continuous high degree of a,,
 3 fucosylation was accompanied by a continuous high 
expression of sialyl Lewisx on AGP. Despite the clinical picture of recurrent febrile attacks with 
asymptomatic intervals, these studies indicate that hypenmmunoglobulinemia D should be 
considered a condition of persistent inflammation. 
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7.1 Introduction 
Hypenmmunoglobulinemia D and periodic fever (hyper-lgD syndrome) is a syndrome characterized by recurrent febrile attacks, usually of very early onset (during the first year of life) and a constantly elevated polyclonal serum IgD level Since the first 
description of the hyper-lgD syndrome (I), the diagnosis has been made in up to 56 patients 
mainly from Europe in a collaborative study by the International Hypenmmunoglobulinemia D 
Study Group. (2-4) The attacks are charactenzed by an acute onset of high spiking fever, often 
preceded by cold chills. Abdominal complaints, vomiting, diarrhea, headache and arthralgias are 
associated with the episodes. During the attacks, swollen, tender lymph nodes are often found. 
Especially in the young age group, splenomegaly may be found. Nondestructive recurrent arthritis 
can be demonstrated in more than 60% of the patients (4) During the attacks, most patients have 
skin lesions due to cutaneous vasculitis (3) Typical attacks occur every 4 to 8 weeks and last 3 to 7 
days each. Laboratory testing during attacks reveals an acute phase response (leucocytosis, 
neutrophilia and increasing erythrocyte sedimentation rate (ESR)) The diagnosis is based on the 
clinical picture and the elevated serum IgD level (> 100 U/ml). The pathogenesis of the syndrome 
remains to be elucidated and no treatment is known. 
Dunng remissions, the concentration of C-reactive protein, a well-known marker of acute 
phase reaction, returns to normal levels, although it is elevated during attacks. (4) It is unclear as 
yet whether the syndrome is charactenstic for an acute state of inflammation, or whether there is a 
state of persistent inflammation. It has been shown in several types of inflammation that the 
glycosylation of acute phase proteins changes during acute and chronic inflammatory processes (5) 
α|-Acid glycoprotein (AGP, orosomucoid) is a positive acute phase protein with five N-lmked 
glycans. At least 12 glycoforms of AGP can be detected in normal human serum diffenng m degree 
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of branching, fucosylation, and sialylation of the glycans. The glycoforms containing one or more 
diantennary glycans are increased in concentration during acute inflammation. This occurs after 
acute trauma (6-9), or can appear with intercurrent infections, as have been described in 
rheumatoid arthntis (10,12). In chronic inflammation such as rheumatoid arthritis, however, only 
minor changes could be established (10,1 I ) Cytokines like IL-1, IL-6 and TNF are involved in the 
inflammatory response, and have been shown to affect the glycosylation process in the liver. 
(12-14) Besides the changes in diantennary glycan content, we have recently reported increases in 
the ct|,3 fucosylation of AGP, both during acute (15) and chronic inflammation (16,17) The high 
degree of α μ ] fucosylation in patients with rheumatoid arthritis could be returned to a lower level 
by treatment with methotrexate ( 17) This increase in fucosylation has also been described for 
haptoglobin (17-19) and a,-antitrypsin (AT) (17) The increased fucosylation was accompanied by 
an increased expression of blood group determinant sialyl Lewisx (SLeX, NeuAca2-3Galßl-4 
(Fucal-3)-GlcNAc-R) (16) Therefore, the type of glycosylation of the acute-phase protein AGP 
can give more information about the state of inflammation and can serve as a better marker for 
discrimination between acute and chronic inflammatory states than the CIV concentration alone 
To gam a better understanding of the nature of the inflammatory response occurring in the 
hyper-lgD syndrome, the serum concentration of the acute-phase protein AGP and its type 
glycosylation, including the expression of SLeX, were investigated in sera from patients with this 
syndrome, dunng both febrile attacks and remissions. Crossed affinoimmunoelectrophoresis 
(CAIE) was used to determine the presence of diantennary containing glycoforms of AGP using 
concanavahn A (Con A) as affino component in the first dimension gel. The presence of glycoforms 
with aM fucosylated glycans was determined using CAIE with Aleuna auranùa lectin (AAL) as affino 
component. AAL is the only lectin to date, that will react with the fucosylated lactosamine units 
present on AGP [15,20,21]. 
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7.2 Patients and Methods 
Source of sera 
Eleven patients (nine males, two females) suffering from the hyper-lgD syndrome were studied 
The diagnosis was in accordance with the guidelines of the "International Hyper-lgD Study Group", 
and these patents represented the numbers 2, 5, 9, I I , ΙΘ, 21, 24, 26, 27, 35 and 36 in a recent 
clinical review. (4) The mean age at the time of the attacks and collecting of blood was 30 years 
(range 13-69 years) and all patients were Dutch. Sampling of serum was performed during attacks 
and remissions. Attacks were defined when the patients were febrile > 38°C (not caused by 
infection), experiencing symptoms compatible with the hyper-lgD syndrome. Remission was 
defined as the complete absence of symptoms for at least 2 weeks. No medical treatment was 
allowed during the study period. In addition, sera from two patients suffering from the hyper-lgD 
syndrome, who had been asymptomatic for at least 2 years, were studied. Sera were stored at 
-20°C until analysis Sera from healthy individuals were used for the determination of control 
values. 
(Glycoprotein concentraùon 
Concentrations of CRP were determined by rocket Immunoelectrophoresis according to 
Laurell [22], using rabbit anti-human CRP IgG (RAH-CRP-IgG) for precipitation. AGP 
concentrations were determined by single radial immunodiffusion, according to Mancini et al. (23), 
using monospecific anti human AGP IgG (RAH-AGP-IgG) for precipitation. All antibodies were 
purchased from Dakopatts, Denmark. Human serum C-reactive protein (HS-CRP) calibrator, 
consisting of a dehpidated pool of human serum enriched in CRP, was used as a standard for the 
determination of the CRP concentration; according to the manufacturers information the 
124 AGP in hyper-lgD syndrome 
CRP-concentration in this preparation was 0.162 mg/rnl. Human serum protein calibrator (HSPQ, 
consisting of pooled sera from healthy blood donors, was used as a standard, according to the 
manufacturer's information that AGP concentration in this preparation was 0.76 mg/ml Both 
HSPC and HS-CRP calibrator were from Dakopatts. 
Crossed affino Immunoelectrophoresis (CAIE) 
CAIE was performed according to the method of Bag-Hansen (24), using 2.5 mg/ml (with a 
hemagglutination titer of 512) Aleuria aurantia lectin (AAL) as the fucose specific affino component, 
or 2 mg/ml concanavalm A as the diantennary-speofic affinocomponent as descnbed previously 
[15] AAL was isolated from fruiting bodies of the Aleuna auranba mushroom as descnbed earlier. 
In short 0 5-2.0 μΙ of serum was electrophoresed through a lectin containing 1% agarose gel, 
resulting in a separation of the differently glycosylated AGP forms. In the second, perpendicular 
dimension, these glycoprotein forms were immunoelectrophoresed against the precipitating 
monospecific antiserum (RAH-AGP-IgG). The resulting precipitation curves were visualized by 
staining with Coomassie Briljant Blue R250 (Sigma St. Louis, MO) The areas under the curves 
indiate the relative amounts of glycoprotein, which were determined using a Summagraph 
(ACECAD D-9000) coupled to a 386 SX PC equipped with a area measurement programme 
(developed by D. Philips, Department of Physiology, Faculty of Medicine, Vrije Universiteit, 
Amsterdam, The Netherlands). 
Partial purification of AGP from serum and detection ofSLeX<ontent of AGP 
In order to obtain preparations ennched with AGP for a better interpretation of immunoblots, 
AGP was isolated from serum by immunoaffinity chromatography, as descnbed in (25), using an 
anti-AGP-Sepharose 4B column. Serum (75-100 μ\) was applied to the column (0 8 χ 1.3 cm; 2 
ml/h) The glycosylation profiles of AGP before and after affinity purification were identical, 
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indicating that no glycosidases were present during the procedure. The concentration was 
determined by radial immunodiffusion, according to Mancini et al. (23) Ten percent SDS-PAGE 
was performed according to Laemmli (26) using the Mini Protean II dual slab gel apparatus from 
Bio-Rad. Gels were loaded with equal amounts of partially purified AGP; AGP isolated from Cohn 
fraction V from pooled human serum, a kind gift from Dr. D.H. van den Eijnden, was used as a 
standard. Proteins were blotted onto nitrocellulose by electrophoretic transfer using the Mini 
Transblot Cell from Bio-Rad. SLeX determinants on AGP were detected as previously described 
(15) by incubating AGP containing nitrocellulose strips with mouse monoclonal anti-SLeX IgM 
(CLSEX-I, 25 ^gAnl in 10 times diluted PBS ATCC HB Θ5Θ0, [27]), followed by alkaline 
phosphatase-conjugated goat antimouse IgM ( I : 250 dilution, Zymed, San Fransisco, CA) for 
detection. An AAL-non-reactive fraction from pooled human serum by means of preparative 
affinity electrophoresis (25) was used as a negative control. 
Statistics 
All values were tested for significance using the Student ¿test. 
7.3 Results 
Concentrations of CRP and AGP in hyper-lgD sera 
The CRP concentrations in the sera of hyper-lgD patents were below 0.02 mg/ml during 
remission, and increased to 0.10-0.30 mg/ml dunng an attack. In contrast, the AGP concentrations 
during remission, were higher than those in control sera ( 1.98 mg/ml compared to 0.79 mg/ml in 
control sera, Ρ < 0.05), with large mtenndividual differences. These concentrations increased to 
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an average value of 2.31 mg/hnl during a febnle attack, also with large intenndividual différences 
(Table I ). For the two patients who had been asymptomatic for at least two years, all protein 
concentrations had returned to control values (results not shown). 
Table I. Concentrations of CRP, AT and AGP, and reactivities with Con A and AAL of 
AGP in hyper-lgD and control sera. 
АО AAL 
CRP (mg/Wil) AGP(mg/ínl) Ν CO(%) DR 
(C2+C3)/a 
DR 
(АЗ+А4+А5У 
(Al +A2) 
Control <0.02 0.79+0.17 10 46.0±8.0 0.33±O.II 38.0±I3.0 0.92±0.36 
HigD 
remission 
HigD 
fever 
<0.02 
(ll/D) 
0.18+0. IO"* 
(0/1 1) 
l.98±0.72a 
(0/11) 
2.31 + 1.10a 
(0/1 1) 
40.6±5.6 0.37±0 10 
(7/4) (9/2) 
I6.6±8.2a 3.51 ±2.17a 
(1/10) (0/11) 
35.3±4.7a-b 0.51 ±0.15a b I5.8±8.8a 3.64±2.06a 
Q-P) (4/7) (3/8) (0/11) 
Values are given as the mean ± S.D. DR, degree of reactivity; this is a measure for the intensity of the interaction 
between the lectin and AGP. The degrees of reactivity were determined by dividing the sum of the strongly reactive 
glycoforms by the sum of the moderately reactive glycoforms. CO and A0, fraction of AGP non-reactive with Con A and 
AAL respectively. Values given in parentheses are the rato of values that fall within the control range over the values that 
fall outside it. 
a: significantly different from control value ρ < 0.05; 
ь: significantly different from HlgD-remission value ρ < 0.05 
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Reactivity of AGP wrth Con A and AAL 
To establish whether changes in the diantennary glycan content and
 a W fucosylation of AGP 
occurred in the sera of patients with the hyper-lgD syndrome dunng remission and febrile attacks, 
CAIE was performed with Con A and AAL as affino components, respectively. In Fig. lb, le, le, 
and If, precipitation curves of AGP are illustrated for one hyper-lgD patient, produced by CAIE 
with Con A and AAL, respectively. 
^ ^ 
AiL_J / \ 
C O C 1 C S C 3 
I I I I 
А О A 1 Α Ξ Α 3 Α 4 Α 5 
I I I I I I 
fig I. Reacüvrty of AGP wrth Con A (a-c) and AAL (d-f) in control serum (a,d), hyper-lgD serum during 
remission (b,e) and dunng a febnle attack (c,f). 0.5-2.0 μ I of serum from the same patient was 
subjected to CAIE as described in Materials and Methods. Only the second dimension gels are shown. 
The lower right corner of each gel corresponds with the site of application in the first dimension gel. 
Electrophoresis was performed in the directions right to left for the first dimension, and bottom to top 
for the second dimension. CO and АО: AGP-fractions that are non-reactive wrth Con A and AAL 
respectively; CI-C3 and AI-A5: forms of AGP that are increasingly reactive with Con A and AAL, 
respectively 
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During a febrile attack, the reactivity with Con A was significantly increased compared to 
control and remission values (P < 0.05), since the percentage of the Con A non-reactive fraction 
(CO) was decreased from 40.6% during remission to 35.3% during an attack (Table l).The 
degree of reactivity ((C2+C3)/CI) was concomitantly increased from 0 37 during remission to 
0 51 during an attack. During remission, the reactivity of AGP with Con A returned to the control 
value (Table I ). 
The reactivity of AGP with AAL showed more distinct differences when compared to control 
values for both states of disease (Table I). The degree of reactivity ((A3+A4+A5)/(AI +A2)) of 
AGP with AAL for hyper-lgD patients was extremely high, both during a febrile attack (3 64) and 
remission (3.51) Although the values expressed large intenndividual differences, they were 
significantly different from the degree of AAL reactivity of the control (0.92, Ρ < 0.05). These 
increases in degree of reactivity corresponded with low percentages of unreactive component (АО) 
for AGP, both during remission (16.6%) and fever (15.8%) compared to the control value 
(38 0%). The glycosylation of AGP in the sera from patients who had been asymptomatic for at 
least 2 years had returned to control values, both with respect to the diantennary glycan content as 
the ot|_3 fucosylation. (results not shown) 
Expression ofSiäyi Lewis* (SLeX) on AGP in hyper-lgD sera 
In order to determine if the increases in ο μ 3 fucosylation also coincided with an increased 
expression of SLeX, partially purified AGP from 4 of the II different patient sera (chosen at 
random) was subjected to SDS-PAGE, blotted and subsequently stained with a monoclonal 
antibody directed against SLeX (CSLEX-I). A representative Western blot of AGP isolated from 
one patient is shown in Fig. 2. Upon staining of AGP-contaming nitrocellulose strips with CSLEX-1, 
a weak positive staining of AGP from sera obtained from healthy individuals was observed (Fig. 2, 
lane I). 
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A strongly enhanced positive staining was observed for AGP isolated from hyper-lgD patients 
during remission and febrile attack (Fig. 2, lanes 3 and 4 respectively), indicating a significant 
increase in the expression of SLeX on AGP in the hyper-lgD syndrome. No staining was observed 
for an AAL-nonreactive fraction isolated from the serum of healthy individuals (Fig. 2, lane 2), 
which was used as a negative control 
M me 1 
8 3 4 
Fig. 2. 
Expression of SLeX on partially purified AGP from hyper-lgD 
sera. Equal amounts of affinity purified AGP (3 μ% as 
determined by radial immunodiffusion (23)) were subjected to 
SDS-PAGE, subsequent blotting and detection of SLeX with a 
specific monoclonal antibody (CSLEX-I) as described in 
Materials and Methods. A representative Western blot of AGP 
from one hyper-lgD patient is shown; only the part of the blot 
containing AGP-bands is reproduced. I, AGP from control 
serum; 2, AGP non-reactive with AAL; 3, AGP from 
hyper-lgD serum during remission; 4, AGP from hyper-lgD 
serum during an attack. 
7.4 Discussion 
Although the hyper-lgD syndrome is characterized by short febrile attacks followed by 
asymptomatic intervals, the present study is indicative of both acute and chronic inflammatory 
responses within this disease. The concentration of the acute phase protein AGP is significantly 
increased during both febrile attacks and remissions, as compared to concentrations in serum of 
healthy individuals. The concentration of CRP is increased only during febrile attacks. The α μ 3 
130 AGP in hyper-lgD syndrome 
fucosylation of AGP, as indicated by the high reactivity with AAL and the CSLEX-1 -staining, in 
serum of hyper-lgD patients is increased during both attacks and remissions, The increases in a,,, 
fucosylation are extreme compared to the value for healthy individuals, with a concomitant 
increased expression of SLeX Previously, it has been shown that for chronic inflammation such as 
rheumatoid arthritis, the percentage of non-fucosylated AGP (АО) was approximately 18 (17), 
whereas for acute inflammation induced by laparotomy, this percentage was found to be 
approximately 30. (15) Therefore, the low percentages of non-fucosylated AGP (АО) continuously 
present in hyper-lgD patients are compatible with chronic inflammation. The continuously high 
<xU3 fucosylation in rheumatoid arthntis can be decreased by treatment with methotrexate, and 
this coincides with a decrease in disease activity. (17) Possibly, the relatively high frequency of 
febnle attacks (once every 4-8 weeks) in the hyper-lgD syndrome does not allow the a M 
fucosylation to return to a basic level, since after an asymptomatic penod of 2 years, the 
concentrations of CRP and AGP and the glycosylation of AGP returned to control values. This 
would be in agreement with our previous finding that in the case of severe bums, the a,,3 
fucosylation can remain extremely high for at least 30 days after the event (15), indicating a 
persistent state of inflammation. 
With respect to the Con A reactivity of AGP, significant increases occurred dunng a febnle 
attack, returning to control values dunng remission. These increases in Con A reactivity of AGP 
may be interpreted as increases in diantennary glycan content, since it has previously been shown 
that the glycans of AGP are of a complex type, both in healthy and diseased states. (9) This 
supports the previous findings that the febnle attack is accompanied by an acute phase response, 
which is further corroborated by the steeply elevated CRP plasma concentrations found in these 
patients dunng attacks. 
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7.5 Conclusion 
In conclusion, our studies indicate that the hyper-lgD syndrome seems to be a disorder of 
persistent inflammation On the one hand the concentration of AGP is continuously increased 
during attacks and remissions, as does the a w fucosylation of AGP, indicating a chronic state of 
inflammation. On the other hand the concentration of CRP is increased only during attacks, as 
does the diantennary glycan content of AGP, indicating an acute state of inflammation within the 
persistently inflamed state These patterns are also found during intercurrent infections in patients 
with rheumatoid arthntis ( I I ) , but are unique for a non-infectious disorder like the hyper-lgD 
syndrome. Proinflammatory cytokines (IL-1, IL-6, TNF) have been shown to modify the 
glycosylation of acute phase proteins such as AGP. (12-14) The changes reported here for the 
hyper-lgD syndrome, suggest a role for such cytokines in the pathogenesis of this syndrome. 
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Abstract 
Immunoglobulin D (IgD) is normally present in only low concentrations in serum. In the hyper-
IgD and penodic fever syndrome (HIDS), however, serum levels exceed 140 mg/l. Clinically, this 
syndrome is further characterized by recurrent inflammatory febrile attacks together with an acute 
phase response and appearance of cytokines in the circulation. The role of IgD in the pathogenesis 
of HIDS and its relation to the increased cytokine concentrations is unclear. Therefore, we tested 
whether IgD, IgG and α,-acid glycoprotein (AGP) isolated from human serum influence the 
synthesis of IL-1 β, TNFct, and IL-1 ra, as measured by specific radio immunoassays, in human 
peripheral blood mononuclear cells (PBMQ. Incubation for 24 h of PBMC with IgD and AGP led 
to increased release of IL-1G, TNFa, and IL-1 ra. The magnitude of stimulation of IgD exceeded 
that of AGP, the effect by IgD was dose-dependent and showed a 30-fold (TNFa) to almost 150-
fold (IL-1 ß) increase at the highest concentration (50 mg/l), while AGP (750 jUg/ml) only increased 
the cytokine secretion 4-fold (TNFa) to almost 30-fold (IL-Iß). The effect of IgD on IL-Ira was 
less dramatic but a 5-fold increase was observed at 50 mg/l compared to a 2.5-fold increase with 
AGP IgD potentiated the effect of LPS on secretion of both IL-1 ß and TNFa, although the effect 
was most apparent for TNFa. Apart from inducing IL-1 ra synthesis, IgG did not influence cytokine 
release in human PBMC. These data indicate that IgD is a potent inducer of TNFa, IL-1 β and IL-
I ra and thus may contribute to the pathogenesis of HIDS. 
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8.1. Introduction 
I mmunoglobulin D (IgD) was first discovered by Rowe in 1965 ( I ) and it is the major antigen receptor isotype coexpressed with IgM on the surface of human peripheral 
В cells (2) Its biological function has not been not fully elucidated, but IgD may be 
involved in the early antibody response by augmenting antibody secretion. (3) In serum, IgD is 
present only in minor quantités and it constitutes only some 0.2% of all immunoglobulins. (4) In 
normal individuals concentrations vary from undetectable to 140 mg/l. Elevated serum IgD may be 
found in several clinical conditions such as IgD myeloma, Hodgkm's disease, sarcoidosis and 
tuberculosis, aspergillosis, ataxia-telangiectasia, AIDS and the hyperimmunoglobulmemia D and 
periodic fever (HIDS) syndrome. (5) The latter clinical entity is characterized by recurrent febrile 
attacks with abdominal complaints, arthralgias/arthntis, skin lesions and an elevated serum IgD 
concentration beyond 140 mg/l. The serum concentration of IgD remains elevated throughout life 
and does not change with disease activity. The attacks are accompanied by an acute phase 
response with high circulating concentrations of α,-acid glycoprotein (AGP), C-reactive protein 
(CRP), soluble type II phospholipase A¡ and serum amyloid Л (6,7) Inflammatory cytokines such as 
interleukm-1 ß (IL-1 ß), IL-6 and tumor necrosis factor-α (TNFa) are thought to play a central role 
in multiple effector functions and cellular interactions in inflammation and immune response. (8) 
Uncontrolled secretion leading to high levels of inflammatory cytokines may lead to an intense 
inflammatory response as noted in the HIDS. Indeed, elevated circulating concentrations of the 
inflammatory mediators TNFa, interleukm-1 receptor antagonist (IL-Ira), IL-6, interferon-γ, and 
soluble receptors for tumor necrosis factor (sTNFr) have been detected dunng the febrile 
episodes. (6,9) Upon stimulation with bacterial lipopolysacchande (LPS, endotoxin), monocytes / 
macrophages are able to produce a wide array of cytokines such as IL-1 G, IL-6, and TNFa. ( 10) 
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During attacks of HIDS, incubation of whole blood with LPS for 24 hr, resulted in augmented ex-
vivo secretion of TNFoc, IL-1 β and IL-Ira in the supernatants compared to convalescence. (6) 
Taken together, these data suggest that inflammatory cytokines such as IL-Iß, IL-6, and TNFa 
could play a pathogenic role in the febnle attacks of the hyper-lgD syndrome. Furthermore, it can 
be speculated that soluble compounds present during an attack are responsible for this up 
regulated cytokine secretion. For example, the acute phase protein CPP is able to potentate the 
secretion of IL-1ß, IL-1га, and TNFa by isolated human monocytes. (I I) On the other hand, the 
effect of IgD on cytokine secretion is not known. These observations prompted us to investigate 
the capacity of serum IgD, IgG, and AGP to modulate the release of cytokines in human 
mononuclear cells 
8.2 Patients and Methods 
Sera and plasma. 
Serum for IgD isolation was obtained from a patient with the hyper-lgD syndrome (patient 
represents # I in a recent review). (5) Dunng the 13-year follow up ( 1981 -1994) she had IgD 
concentrations varying from 2269 mg/l to 7484 mg/l. Sera were stored at -20° С after the addition 
of e-ammocaproic acid (final concentration 0.5%) to prevent "spontaneous' degradation of IgD. 
( 12) Sampling of expenmental plasma was performed during remission, defined as the absence of 
symptoms for at least two weeks. The patient did not use any medication at the time of the study. 
Enzyme linked immunosorbent assay for IgD. 
Determination of IgD was performed using a specific enzyme linked immunosorbent assay 
(ELISA). Microtiter plates (Nunc, Roskilde, Denmark) were directly coated for the titration of 
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human IgD with 1:5000 dilution of rabbit anti-human IgD in 200 μΙ bicarbonate buffer, pH 9.5 
(Dako, Copenhagen, Denmark) Since there was no nonspecific binding detectable in our assay, 
we did not block the plates with albumin. After overnight incubation at 4°C, plates were washed 
with phosphate buffered saline containing 0 01 % Tween 20 (PBS), and samples was added to the 
wells. Plates were incubated again overnight at 4°C. A standard human serum (Behnng, Marburg, 
Germany), calibrated against the British Research Standard No 67/37, was used as a reference. 
( 13) The plates were washed and 100 μΙ mouse monoclonal anti-human IgD, diluted 1.200 in 
PBS, was added and incubated for 90 mm at 37°C. After a washing step, 100 μΙ HRP rabbit anti 
mouse anti IgD (diluted 1:4000 in PBS) (Dako, Copenhagen, Denmark) was added and incubated 
at 37°C for 90 mm. After a washing step, IgD was measured by incubation with 100 μΙ ortho-
phenylenediamme (Sigma, St Louis, MO). The reaction was stopped by 4M H2SO< and 
absorbance was read at 492 nm using a Titertek MuHskan ELISA reader (Eflab, Oy, Helsinki 
Finland). The lower limit of detection was 1.4 mg/l. 
Preparation and purification of IgD. 
IgD was prepared from hyper-lgD sera by chromatography on DEAE-cellulose and CM-C50 
columns followed by gel filtration on Sephacryl S-300. All steps were performed at 4°C. Serum 
was precipitated with polyethyleneglycol (PEG) 6000 (final concentration 7%). The precipitate was 
then dissolved in 0.01 M tnshydroxymethylaminomethane (TRIS), 2 mM ethylenediamine-
tetraacetic acid (EDTA), I mM phenylmethylsulfonyl fluoride (PMSF), and finally 0.5 U/ml 
aprotinin, pH 7.8 to prevent proteolysis. The solution was applied to a column of DEAE-cellulose 
(1.5 cm χ 60 cm) equilibrated in the same buffer. The column was eluted with a linear gradient 
(0.01 to 0.05M) of the TRIS buffer. IgD containing fractions were pooled, dialyzed against 0.01 M 
sodium acetate, 2 mM EDTA, I mM PMSF and 0.5 U/ml aprotinin, pH 6.0 and applied to a CM-
C50 column (2.5 cm χ 15 cm) equilibrated in the same buffer. The IgD positive fractions were 
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again pooled and finally applied to a Sephacryl S-300 column (2.5 cm χ 90 cm) equilibrated with a 
buffer containing veronal buffered NaCI, 2mM EDTA, 0.15 M NaCI, I mM PMSF and aprotinine, 
pH 7.4 The punty was checked by sodiumdodecylsulphate (SDS) Polyacrylamide gel 
electrophoresis. The final IgD product contained 150 mg/l IgD as measured by the described 
ELISA and no detectable IgG, IgA or IgM as detected by immunoturbidimetnc assay (Cobas Fara, 
Roche Diagnostics, Basle, Switzerland). The IgD preparation was dissolved in PBS and stored at -
70°C until use. The purified IgD preparation was tested for endotoxin using the limulus 
amoebocyte lysate assay (Sigma, St. Louis, MO) and was shown to contain less than 6 pg/ml 
endotoxin. 
SDS-PAGE and detection of proteins on membranes. 
The purity was checked by SDS-PAGE gel electrophoresis following the method of Laemmli. 
(14) Briefly, the IgD product was subjected to SDS-PAGE and proteins were stained with 
silvernitrate using a PhastSystem development unit. (Pharmacia, Uppsala, Sweden). The silver 
staining is able to detect 0.3 ng/μΙ protein. (15) Proteins were blotted on nitrocellulose and the 
blots were incubated with a polyclonal anti-lgD antibody (DAKO A093, Dako, Copenhagen, 
Denmark). After a washing step a specific secondary biotinylated antibody was added. Bands were 
visualized with a streptavidin complex and photographed. 
Preparation of IgG. 
Punfied human serum IgG preparation (Globuman Berna) was kindly provided by Pnmmed 
BV, The Netherlands. The preparation contained more than 95% IgG and no IgA and IgM as 
examined by an automatic immunoturbidimetnc assay (Cobas Fara, Roche Diagnostics, Basle, 
Switzerland) and no IgD as assessed wfth ELISA The IgG preparation was dissolved in PBS and 
stored at -70°C unti use. 
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Preparation and purification of AGP. 
AGP obtained from Cohn fraction V of pooled human serum was a gift of Drs. E. Havenaar and 
W. van Dijk, Free University of Amsterdam, the Netherlands. Purification was performed following 
the method of Hao and Wickeshauser using 2 purification steps with absorption on DEAE-
sephadex and chromatography on a CM cellulose column. ( 16) The purity was checked by SDS 
Polyacrylamide gel electrophoresis and by crossed Immunoelectrophoresis using rabbit ant-human 
serum and rabbit anti-human AGP antisera. (Dako, Copenhagen, Denmark) The final preparation 
was dissolved in PBS and stored at -70°C until use. 
Isolation of peripheral blood mononuclear cells (PBMC). 
Peripheral blood from healthy, medication-free donors (25-45 years of age) was drawn into 
sterile 10 ml tubes containing 0.2 mg EDTA. PBMC were isolated by buoyant density gradient 
centrifugation on Percoli. (17) The cells from the interphase were aspirated and washed 2 times in 
sterile saline. After the last washing, the cells were resuspended at a concentration of 5 χ 106/ml m 
RPMI 1640 medium (Dutch modification, Flow Labs, Irvine, Scotland) supplemented with 2 mM 
L-glutamme, I mM pyruvate and 500 /ig/ml gentamicm (Essex, Amstelveen, The Netherlands). 
Medium was subjected to ultrafiltration to remove endotoxin and other cytokme-inducing material. 
(18) Depending on the experiments, either heat-inactivated (30 mm at 56°C) or untreated pooled 
human sera (5%) was added after filtration (complete medium). PBMC were resuspended at a 
concentration of 5 χ l06/ml in round bottom 96-well plastic tissue culture plates (Greiner GMBH, 
Fnckenhausen, Germany) and incubated at 37°C in a humidified atmosphere containing 5% C 0 2 
for 24 hr. PBMC cultures set up in the presence of complete medium served as controls. After 
incubation for 24 hours, the culture plates were centnfuged at 4000 g for 10 minutes to remove 
cellular material. Then, the cell supernatants were aspirated and cytokine content was determined. 
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Isolation of monocytes by adherence. 
PBMC were suspended in complete medium at a concentration of 5 χ 106/ml and allowed to 
adhere on 96-well plastic tissue culture plates (Gremer GMBH, Fnckenhausen, Germany) for I h 
at 37°C in a humidified atmosphere containing 5% C 0 2 Non-adherent cells were removed by 
gently aspiration, and were incubated in adjacent wells. 
Cell stimulation. 
All experimental preparations were dissolved in complete medium before use. PBMC were 
incubated with various concentrations with or without the presence of punfied LPS, final 
concentration 100 ng/ml, (lipopolysacchande prepared from Escherichia coli serotype 055-B5, 
Sigma St Louis, MO). 
Source of antiserum. 
Polyclonal antibodies for IL-1 ß were kindly provided by Sciavo (Siena, Italy). Antibodies for 
TNFct were a gift of Dr. C A Dmarello (New England Medical Center, Boston, MA) and were 
obtained by immunizing New Zealand White rabbits with recombinant human TNF. (19) A 
polyclonal anti-IL-Ira antiserum was raised in New Zealand White rabbits immunized with 
recombinant IL-1 ra kindly provided by Synergen (Boulder, CO). (20) 
Radioimmunoassay for cytokines. 
IL-Iß, TNFot and IL-Ira in plasma were measured in duplicate by non-equilibnum 
radioimmunoassay (WA). Rabbit polyclonal antibodies (ΙΟΟμΙ) were raised against recombinant 
cytokines as described elsewhere [final dilution IL-Iß (I : 210.000), TNFa (I : I5O0O0) and IL-
I ra ( I : 60.000) giving a binding with tracer of approximately 25%]. The antibodies were dissolved 
in WA buffer containing 13 mM Na2EDTA, 0.02% sodium azide, 0.25% bovine serum albumin 
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(Behring, Marburg, Germany), 0.1% Triton X-100, 3 mM Na2HP04, and 250.000 kalhkrem 
inactivating units apoprotinme (Bayer, Leverkusen, Germany), pH = 7.4 were added to sample 
and standard. (21) All reagents were prepared with this buffer. For circulating cytokine 
measurement 100 μΙ and for measurement of ex-vivo cytokine production 25 μΙ (TNFa) and 10 
μΙ (IL-1Q and IL-1 га) of sample and standard were added. The mixture was incubated for I day at 
room temperature. Subsequently, tracer (- 7000 dpm/100 μΙ) was added, and incubation was 
continued for another 2 days. To separate bound and free tracer from the free fraction, 100 μΙ of 
a separation agent ( 10% (vol/vol) sheep antirabbit immunoglobulin G and 0 01 % [(wt/Vol) rabbit 
immunoglobulin G (Sigma, St. Louis MO)] was added to each tube and incubated for 30 mm at 
room temperature. The antibody complex was completely precipitated by the addition of I ml 
7.5% polyethylene glycol 6000 (Merck, Darmstadt, Germany) For IL-Iß, TNFa and IL-Ira the 
range of the standard curve was 20 pg/ml to 3000 pg/ml The sensitivity of the assay with 100 μΙ 
sample was 60 pg/ml (IL-Ira), 40 pg/ml (IL-Iß) and 20 pg/ml (TNFa). There was no cross 
reactivity between IL-Ira and IL-1 β (<0.00l %), TNFa and IL-1 β (<0.0I%) and IL-Ira and 
TNFa (<0.0I%). To minimize analytical errors, all samples were analyzed in the same run, in 
duplicate. 
Statìstica! analysis. 
All results are shown as the mean ± standard error of the mean (SEM) Cytokine 
concentrations were compared with the non-parametnc Fnedman two-way ANOVA and the 
unpaired nonparametnc Mann Whitney U test, where appropiate. A ρ value of < 0.05 was 
considered to be the lowest level of significance. 
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8.3. Results 
SDS-PAGEanalysis of IgD. 
Fig. ι . 
Silver nitrate stained SDS-PAGE of isolated human 
IgD (lane I) showing a band of M r 185,000 
indicating that the purified protein had not 
undergone aggregation or breakdown during 
isolation. The sample was then ¡mmunoprecipitated 
with polyclonal anti-lgD antibodies, separated on a 
SDS-PAGE on a 10% acrylamide gradient gel and 
then visualized by autoradiography, (lane 2) The 
right margin indicates the molecular weight of the 
molecule (Mr χ 10"3) 
185 
IgD product was resolved by SDS-PAGE analysis on a 10% Polyacrylamide gel to observe its 
integrity and purity. Silver nitrate staining showed a band of Mr 185,000 indicating that the purified 
protein had not undergone aggregation or breakdown during isolation. Immunoblotting with 
polyclonal anti-lgD antibodies indicated that the isolated protein indeed consisted of IgD. (Fig. I.) 
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Rg.2. IgD induces IL-IO (panel A), TNFo (panel B) and IL-Ira (panel Q synthesis by PBMC. PBMC were 
stimulated by 0 to 50 mg/ human IgD in the absence (•) or presence (/// ) of E. Coli LPS (100 
ngAnL). After 24 hours, the cultures were harvested and assayed for IL-IO, TNFo, and IL-Ira. Data 
are expressed as means ± standard errors and are derived from 7-11 different experiments, (p < 
0.001 (IL-IO and TNFa), and ρ < 0.005 (IL-1 ra) when comparing PBMC treated with different 
concentrations of IgD in the presence or absence of LPS compared to untreated PBMC) 
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Induction of IL - Iß, TNFa and IL - Ina synthesis in human PBMC and adherent monocytes 
by IgD and IgG. 
The induction of IL-Iß, TNFa and IL-Ira by IgD after a 24-h incubation period is shown in 
Fig.2. IgD was able to stimulate PBMC to a significant increase of the secretion of IL-1 ß, TNFa (p 
< 0.0001), and IL-Ira (p < 0.005). Compared to results from control medium, a concentration 
as low as 0 05 mg/1 IgD induced more IL-Iß (1.01 ± 0.86 ng/ml vs 0.16 ± 0.03 ng/ml), IL-Ira 
( 10.3 ± 1.91 ng/ml vs 2.4 ± 0.09 ng/ml), and TNFa (1.09 ± 0.33 ng/ml vs 0.25 ± 0 08 ng/ml) 
Induction of IL-1 ß and TNFa by IgD was dose-dependent and continued to increase with the 
maximum concentration used (50 mg/l), while the stimulation of IL-Ira release did not increase 
appreciably with concentrations above 0 05 mg/l. The amount of IL-1 ß produced by PBMC at a 
concentration of 50 mg/1 was nearly 150-fold the amount in control samples, while TNFa 
secretion increased almost 30-fold. IgD at a concentration of 50 mg/1, induced maximal IL-1 ra 
secretion (13.1 ± 1.94 ng/ml) Incubation of IgD with LPS ( 100 ng/ml) enhanced IL-1 ß and TNFa 
release by PBMC (p < 0.05). Addition of IgD to LPS, did not influence IL-1 ra secretion from 
PBMC. 
Table I a. Comparison of effect of a 24 hr incubation of IgD on TNFa release (ng/ml) 
from PBMC, adherent monocytes and nonadherent cells 
IgD (mg/l) 
PBMC 
adherent monocytes 
non adherent cells 
0 
0.08 
0.13 
0.08 
0.05 
0.2 
0.505 
0.125 
0.5 
7.4 
4.1 
2.25 
5 
10 
6.95 
3.95 
50 
10 
10 
1.7 
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In order to delineate which cells were most responsive to IgD stimulation, monocytes were 
separated by adherence and cytokine secretion after 24 h IgD stimulation was estimated. 
As shown in Table la & lb monocytes secreted more IL-ß and TNFa compared to non-
adherent cells. This emphasizes the critical role of monocytes with regard to cytokine release in 
response to IgD stimulation in our system with a mixed cell population. 
Table I b. Comparison of the effect of a 24 hr incubation of IgD on IL-1 β release (ng/ml) 
from PBMC, adherent monocytes and nonadherent cells 
IgD (mg/) 
PBMC 
adherent monocytes 
non adherent cells 
0 
0.085 
0.075 
0.065 
0.05 
0.5 
0.4 
0.4 
0.5 
3.3 
2.05 
0.65 
5 
10 
16.5 
2.95 
50 
20 
25.5 
4 
The time-course of IL-Iß, TNFa and IL-Ira production from PBMCs in response to IgD (5 
mg/l) was studied next and compared to that of LPS-stimulated PBMC. (Fig.3.) Measurable 
amounts of IL-10 (0.28 ± 0.09 ng/ml), TNFa (0.82 ± 0.04 ng/ml) and IL-1 ra (0.76 ± 0.1 ng/ml) 
were detected after 2-h incubation with IgD. After 2-h and 4-h incubation PBMC released more 
IL-1 ß but not TNFa or IL-1 га with IgD than with LPS. observed after prolonged incubation (at 24 
hr, 2.73 ± 0.48 ng/ml). 
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Fig.3. Effect of time of addition of human IgD or LPS on IL-10 (panel A), TNFo (panel B) and IL-1 га 
(panel Ç). PBMC were treated with human IgD ( • ) (5 mg/1) or LPS ЦЦ χίΟΟ ng/mL) At 2, 4, 
6, 8, 12 or 24 hours cultures were harvested and cytokines were measured in the 
supernatants. Data are depicted as the mean ± standard error of 5 different donors, (p < 
0.005 when comparing PBMC treated with IgD compared to PBMC untreated with LPS) 
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After 12-h incubation, both IL-10 (12 4 ± 1.56 ng/ml) and IL-Ira (7.8 ± 2.1 ng/ml) reached 
maximal concentrations with cytokine release from PBMC slightly diminishing after prolonged 
incubation. 
To investigate the possibility that the effects observed with IgD were due to endotoxin 
contamination, PBMC were incubated with polymyxin В (25 μg/ml). As shown in Table 2, 
polymyxin В did not influence the effect of IgD but gave a reduction of the LPS-induced IL-1 ß and 
TNFa release. The incubation with polymyxin В did not influence the IL-Ira release by IgD or 
LPS. As an additional control for endotoxin contamination, the IgD preparation was heated in a 
polypropylene tube incubated in a waterbath at I00°C for I h. Exposure of PBMC to the IgD 
preparation resulted in substantial reduction of IL-1 β (360 pg/ml) and TNFa (100 pg/ml) release, 
to values comparable to those from cultures incubated without stimuli. This excludes the possibility 
that the stimulation by the IgD preparation was caused by endotoxin, which is relatively heat 
stable 
Table 2. PBMC were incubated for 24 h. Data represent mean ± SEM from four 
experiments. Polymyxin В was used at a concentratori of 25 /ig/mL. 
Stimulus 
IgD (5 mg/L) 
IgD (5 mg/L) 
LPS(IOOng/mL) 
LPS(IOOng/hnL) 
Inhibitor 
-
Polymyxin В 
-
Polymyxin В 
IL-Iß (ng/ml) 
26 ± 3 I 
21.5 ±4 .5 
31.1 ± 13 
11.4 ±6.11 
TNFa (ng/ml) 
4.7 ± 0.3 
5.8 ± 1 
6 ± 1.6 
1 7 ± 0.57* 
IL-Ira (ng/ml) 
9 5 ± 1.7 
9.8 ± 2.7 
8.35 ± 1.6 
8.32 ±2.1 
"P < 0 05 from LPS alone 
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As shown in Fig.4., human IgG was a potent stimulator for IL-1 ra production, (p < 0 005) 
As little as 0 05 mg/l IgG was able to release appreciable IL-Ira concentrations compared to 
baseline (8 1 ± 13 ng/ml vs 2 4 ± 0.17 ng/ml). The maximal effect was observed at 
concentrations of 0.5 mg/l, but the effect was smaller compared to IgD In contrast, the presence 
of up to 50 mg/l IgG had little effect on IL-1ß and TNFa release in the same cultures Also, IgG did 
not influence the LPS induced cytokine production by PBMC 
Effect of complement-containing serum 
Since C5a induces TNFa and IL-1 ß messenger RNA from PBMC in vitro (22), we investigated 
the contribution of complement to the IgD induced cytokine release. Since the complete medium 
used in all previous expenments contained serum deprived of complement by heat inactivation (30 
mm at 57°Q, nontreated complement-containing serum was added to complete medium. This 
did not change the IgD-induced IL-1 ß, TNF« and IL-1 ra release from PBMC. (data not shown.) 
Induction of IL-1 ß, TNFa and IL-1 ra synthesis in human PBMC by AGP. 
AGP was also tested for its potential to elicit IL-Iß, TNFa and IL-Ira release from PBMC. 
(Fig. 5) PBMC from 5 different donors incubated with AGP produced about 2-4-fold more 
cytokines compared to unstimulated controls (p < 0.05). The maximal effect of AGP on 
production of the vanous cytokines was observed with 750 /ig/ml and higher concentrations did 
not yield different results. PBMC were also incubated with 100 /Jg/ml LPS and increasing 
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Fig.4. Effect of increasing concentrations of human IgG on the induction of IL-Iß (panel A), TNFe 
(panel B) and IL-Ira (panel C) synthesis by PBMC. PBMC were stimulated by 0 to 50 mg/l 
human IgG in the absence ( • ) or presence (/// ) of E. Coli LPS (100 ngAnL). After 24 hours, 
the cultures were harvested and assayed for IL-10, TNFo, and IL-Ira. Data are expressed as 
means ± standard errors and are derived from 4 different experiments, (p < 0.005) (IL-1 ra) 
when comparing PBMC treated with different concentrations of IgD in the presence or absence 
of LPS compared to untreated PBMC) 
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Hg.5. Effect of increasing concentrations of human AGP on the induction of IL-1В (panel A), TNFo 
(panel B) and IL-1 ra (panel C) synthesis by PBMC. PBMC were stimulated by 0 to 1000 ^g/mL 
human AGP in the absence (O) or presence ( · ) of E. Coll LPS (100 ngAnL). After 24 hours, 
the cultures were harvested and assayed for IL-IG, TNFo, and IL-Ira Data are expressed as 
means ± standard errors and are derived from 5 different experiments, (p < 0.005 when 
comparing PBMC treated with different concentrations of AGP in the presence or absence of 
LPS compared to untreated PBMC) 
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concentrations of AGP. The LPS-stimulated synthesis of IL-1 га was significantly enhanced in the 
presence of AGP, whereas no such effect was detectable for TNFa and IL-1 ß (ρ < 0 05) 
8.4. Discussion 
This study demonstrates for the first time that human serum IgD enhances cytokine secretion 
from PBMC in vitro. The effect was dose-dependent and showed an almost 150-fold (IL-1 ß) and 
30-fold (TNFa) increase at the highest concentration of IgD used (50 mg/l) The effect on IL-1 га 
was less dramatic but a 5-fold increase was observed at 50 mg/l Moreover, IgD enhanced the 
effect of LPS on production of both IL-1 ß and TNFa, although the effect was most apparent for 
TNFa These findings suggest a role of IgD in the pathogenesis of HIDS IgD, being present in 
increased concentrations in these patients, could participate in the activation of the cytokine 
network during febrile attacks in these patents by the virtue of its cytokine inducing capacity (6) 
The cytokine releasing effect of IgD is impressive and similar to that of LPS, which is regarded as 
one of the most potent biological stimuli for cytokine release from PBMC. It is unlikely that the 
effect of IgD is mediated via complement activation, since addition of complement containing 
serum did not influence the cytokine release. Preliminary results also indicate that IgD is able to 
induce IL-6, IL-10, soluble TNF receptor p75, and leukaemia inhibitory factor release from PBMC 
(Drenth JPH unpublished observations) It is unlikely that the observed effects of IgD are due to LPS 
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contamination First, we detected an endotoxin concentration of less than 6 pg/ml in our IgD stock 
solution ( 150 mg/l) In our experiments, IgD in a concentration of 0 05 mg/l already induced 
cytokine secretion, and since this represents a dilution of I 3000 of the stock solution this sample 
cannot contain over 0 002 pg/ml LPS It has been shown that the LPS concentration must exceed 
10 pg/ml in order to observe a significant induction of cytokine secretion from human PBMC (23) 
In addition, incubation with polymyxin В did not affect its cytokine-ehciting effects in PBMC Lastly, 
exposure of the IgD preparation for I hour to a temperature of I00°C resulted in complete 
disappearance of the cytokine-ehoting effect Endotoxin degrades only after 4 hours exposure to 
I80°C (24) 
Human IgD is a 185 kD protein with a heavy chain consisting of 4 domains, an Fc region that is 
highly resistant to proteolysis, and a more labile Fab It has been postulated that it may serve as a 
signalling mechanism to the Τ cell population and expenmentally, it augments the antibody 
response to a vanety of antigens Peripheral blood CD4+ and CD8+ lymphocytes from healthy 
donors express receptors for IgD and are denoted as TO cells (25) In contrast to other 
immunoglobulin receptors, such as those for IgG, IgA, IgE and IgM, the IgD receptor is not specific 
only for the Fc region of IgD (26) There is strong evidence that munne IgD receptors are lectins 
which bind not only to the Feo receptors but also to N-lmked IgD-assooated, carbohydrates (27) 
Exposure to oligomenc IgD and IL-2, IL-4 and IFN-γ results in upregulation of these receptors 
(28) IgD may thus play a role in the regulation of immune responses via rts recognition of these 
IgD-receptor positive cells Most probably, effective binding of IgD to these cells is needed to 
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induce the cytokme-producing machinery and to explain the impressive and rapid cytokine release. 
Our data suggest that monocytes are the mam producers of cytokines in the presence of IgD. The 
cooperation of lymphocytes and monocytes does not seem to play a role. It would be interesting 
to know whether IgD affects the transcription of mRNA for the various cytokines or that 
posttranscriptional mechanisms play a role. Further studies are underway to elucidate this issue. 
From our studies we cannot conclude whether the cytokine inducing effect is specific for IgD 
isolated from hyper-lgD patents, or that it also applies to IgD isolated from other sources such as 
patients with IgD myeloma. The structure of IgD from both diseases however differs, and more 
than 90% of the IgD myelomas consist of lambda light chains, while the kappa/lambda light chain 
ratio is elevated in the hyper-lgD syndrome. (29,30) Whether this structural difference results in a 
distinct cytokine inducing effect will be addressed in a future study. 
The cytokme-releasing effect of another immunoglobulin, IgG, has been investigated to some 
extent. 
Our finding of increased IL-1 ra production with virtually absent production of proinflammatory 
cytokines in PBMC cultures incubated with IgG is in accordance with other studies. (31 ) Culture of 
monocytes on adherent IgG specifically increases IL-1 ra production but cells fail to release IL-1 ß. 
(32) In our study, incubation with IgG failed to elicit either IL-1 ß or TNFa secretion but enhanced 
IL-Ira release. 
During the febnle attacks of the HIDS, a variety of acute phase proteins (serum amyloid A, and 
CFtf3) are produced and can be found in appreciable concentrations in the circulation. Moreover, 
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during, but also between attacks, there are high circulating concentrations of AGP and the 
fucosylation of this protein dramatically changes during the febrile episodes. (7) Incubation of AGP, 
in our study, resulted in a dose-dependent increase of release of IL-1 ß, TNFa and also IL-1 ra; the 
effect was most evident at a concentration of 750 yug/ml. Human AGP significantly enhanced the 
LPS-mduced secretion of IL-10 but did not affect TNFa and IL-1 ra release. AGP has been shown 
to induce the synthesis of IL-Iß and IL-Ira in human PBMC. (33) In other studies AGP acted 
synergistically with low concentrations with LPS in the induction of IL-1 ß, TNFa, IL-6 and IL-1 ra. 
(33,34) However, compared to IgD, the cytokme-enhanang effect of AGP is only moderate. 
Dunng the acute phase response AGP undergoes extensive posttranslational modification, with the 
acquisition of sialyl-Lewis-X containing glycans and shift of glycosyiation with increase of biantennary 
glycans. (7) We used AGP obtained from Cohn fraction V of pooled human serum. It is possible 
that the induction of these cytokines depends on the extent of glycosyiation of AGP, but this 
requires further investigation. Another acute phase protein, CRP, seems to be a more potent 
producer of IL- Ια, IL-1 ß, IL-6, TNFa and IL-1 ra and also potentates the LPS-mduced secretion of 
these inflammatory mediators. (I 1,33) All in all, these findings imply that the acute-phase proteins 
may serve an immunomodulatory role in attacks of the hyper-lgD syndrome by augmenting the 
cytokine release from PBMC. 
From our results it is apparent that IgD stimulates human PBMC to secrete proinflammatory 
cytokines such as IL-Iß but also of an inhibitor like IL-Ira. The amounts of IL-1 β by far exceed 
those of IL-Ira. Excess concentrations of IL-Ira (100 to 1000-fold excess) must be present in 
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order to yield a significant inhibition of IL-1-induced responses and thus the amount may be 
inadequate in the acute inflammation. 
8.5. Conclusion 
Although IgD is a potent stimulator of cytokines, its precise role in the pathogenesis of the 
syndrome remains to be clarified further. For example, a clear correlation between the serum 
concentration of IgD and the frequency or seventy of the attacks is absent (5) However, it is 
possible that attacks in the hyper-lgD syndrome are precipitated by the inactivation of an (as yet 
unidentified) inhibitory compound which allows IgD to elicit an exaggerated cytokine response In 
this respect IgD may function in a dual role, amplifying the inflammatory response by release of 
pro-inflammatory cytokines but also serving a down-regulating role by eliciting the production of 
IL-Ira. In this way IgD can act as a factor in maintaining the inflammatory response dunng the 
febrile attacks of the hyper-lgD syndrome. 
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Abstract 
The hyper-lgD and periodic fever syndrome (HIDS)1 and familial Mediterranean fever (FMF) 
are both characterized by attacks of penodic fever accompanied by acute phase responses which 
are substantially higher in HIDS than in FMF To determine whether this difference could be due 
to differences in production of acute phase protein-inducing mediators, we studied peripheral 
blood mononuclear cells (PBMC) from HIDS and FMF patients in the inactive phase of disease 
Unstimulated PBMC from patients with inactive HIDS released significantly more IL-1 β, IL-6 and 
TNF-a than did PBMC from patients with FMF Conditioned medium (CM) derived from PBMC 
of patients with inactive HIDS induced significantly greater CP\P production and significantly higher 
mRNAs for СРчР and SAA in НерЗВ cells than did CM denved from the PBMC of patients with 
inactive FMF Stimulation of PBMC with LPS led to further increases in cytokine production and 
in acute phase protein inducing ability in both patient groups and in controls These findings 
suggest that the greater acute phase response seen in HIDS compared to FMF reflects greater 
production of acute phase protein-inducing cytokines in the former patients and indicate that 
PBMC from inactive HIDS patients are already activated in vivo Finally, the finding of both 
quantitative and qualitative differences in cytokine production by unstimulated PBMC from HIDS 
and FMF patents supports the likelihood of different pathogeneses of these diseases 
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9.1 Introduction 
T he hyper-lgD and periodic fever syndrome (HIDS) is a rare disease characterized by recurrent febrile attacks with abdominal complaints, lymphadenopathy, skin lesions, and joint involvement. Up to now, some 65 patents, mainly of European 
origin, have been recognized (I) A clinically similar entity, familial Mediterranean fever (FMF), is 
an autosomal recessive inflammatory disorder charactenzed by short episodes of fever, peritonitis, 
pleuritis and arthritis (2) which predominantly affects non-Ashkenazi Jews, Armenians and Arabs 
The pathogenesis of these penodic fever syndromes is unknown, but it is probable that attacks 
arise from deregulation of the inflammatory response in both For example, a lack of C5a 
inhibitor has been incriminated as a cause of the recurrent attacks of serosrtis in FMF (3) 
Inflammatory states are often accompanied by increased plasma concentrations of a group of 
acute phase proteins, including C-reactive protein (СГЯР), serum amyloid A (SAA), fibrinogen and 
α|-acid glycoprotein (AGP). (4) A number of inflammation-associated cytokines, particularly 
mterleukm IL-1, IL-6 and tumour necrosis factor-α (TNF-a) are considered the mam inducers of 
their synthesis, (5) Febnle attacks in both HIDS and FMF are accompanied by an acute phase 
response, which however, differs in intensity In HIDS, substantially higher serum concentrations 
of acute phase proteins are achieved during attacks than is seen in FMF. (6,7) This vanation in 
acute phase response between the two syndromes could theoretically be due to different quality 
of a hypothetical inflammatory stimulus, to differences in production of inflammatory mediators 
influencing plasma protein synthesis, or to different responses of hepatocytes 
Peripheral blood mononuclear cells (PBMQ produce a wide range of cytokines capable of 
acute phase protein induction after exposure to bacterial lipolysacchande (LPS) (8), and 
conditioned medium (CM) from such LPS-stimulated PBMC has been shown to induce acute 
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phase reactants in human hepatoma cell lines. (9,10) 
Accordingly, we explored possible differences between these two periodic fever syndromes in 
production of acute phase protein-inducing mediators by companng the abilities of PBMC from 
HIDS and FMF patients to produce three inflammation-associated cytokines In addition, we 
compared the abilities of their CM both to induce production of the protein CRP and to induce 
expression of the mRNAs for the two major human acute phase protein genes, CRP and SM, in 
the human hepatoma cell line НерЗВ. 
9.2 Patients and Methods 
Patients 
Eight patents with HIDS (4 male, mean age 25 9 yrs), 6 patents with FMF (3 male, mean age 
25 3 years) and 7 healthy Dutch volunteers (7 males, mean age 30.3 yrs) took part in the study 
The diagnoses of HIDS and FMF were made according to standard criteria listed elsewhere (1,2). 
The patients with HIDS were all of Dutch origin, while 5 patents with FMF came from Turkey and 
one from Greece. The patents refrained from taking any medicaton during the study, and all 
patients were asymptomatc at the tme of blood drawing. The FMF patents had normal renal 
function and were, apart from the study period, receiving continuous treatment with colchicine ( I -
1.5 mg/day). 
Isolation of peripheral blood mononuclear cells (PBMC) and preparation of conditioned 
medium 
Peripheral blood was drawn into stenle 10 ml tubes containing 0.2 mg EDTA PBMC were 
isolated by buoyant density gradient centnfugaton on Percoli. ( I I ) The cells from the interphase 
were aspirated and washed twice in stenle saline. After the last washing, cells were resuspended 
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at a concentratori of 5 χ 106/ml in RPMI 1640 medium (Dutch modification, Flow Labs, Irvine, 
Scotland) supplemented with 2 mM L-glutamine, I mM pyruvate and 500 mg/ml gentamycin. 
Medium was subjected to ultrafiltration to remove endotoxin and other cytokine-mducing material 
Heat-inactivated (30 mm at 56°C) pooled human sera (5%) was added after filtration PBMC 
were resuspended at a concentration of 5 χ 106/hnl in round bottom 96-well plastic tissue culture 
plates and incubated either with or without 100 ng/ml £ Co//LPS at 37°C in a humidified 
atmosphere containing 5% C 0 2 for 24 hr. After incubation, the culture plates were centnfuged at 
4000 g for 10 minutes to remove cellular matenal. Cell supematants (CM) were then aspirated 
and stored at -70°C. A baseline value for CRP was determined for the CM of the patients and 
controls This baseline value was subtracted from the total amount of CRP subsequently released 
into the medium by НерЗВ cells, in order to calculate actual CRP production. 
Cultures of НерЗВ cells 
Human hepatoma cells НерЗВ were maintained in RPMI 1640 medium supplemented with 
10% fetal bovine serum. Cells were subcultured weekly after trypsinization. Induction of acute 
phase proteins was earned out when cells were confluent, usually on day 6 after subculture. 
НерЗВ cells were incubated at 37°C in 35-mm dishes containing a total of I ml RPMI 1640 
supplemented with ΙμΜ dexamethasone and 10% CM. The medium was collected after 24h 
and stored at -70°C until assay. 
ELISA's 
CRP concentrations in media from НерЗВ cells were determined in duplicate by a modification 
of an ELISA previously reported( 12). Immulon III Dividastnp wells were coated overnight at 4°C 
with 1: 1000 dilution of goat anti-human CRP, IgG fraction (Atlantic Antibodies #89134) in 100 μ\ 
Tris-buffered saline (TBS). After three washes with 200 μ\ TBS containing 0.05% Tween 20, 200 
168 Cytokines and acute phase protein production in periodic fever 
μΙ of I % BSA in TBS was added to each well to block nonspecific binding. Samples were diluted 
in glass tubes in RPMI 1640 with I % BSA. Wells were washed before 100 μΙ aliquots of samples 
and standards were added and incubated at 37CC for 2 h. 
After 3 washes, 100 μΙ of PBS containing I ng/ml biotmylated, sheep anti-human CRP (Cappel 
#55122) was added. This antibody was biotmylated using Pierce Immunopure NHS-LC Biotin 
according to the manufacturer's protocol. After incubation for I h at 37°C and washing with TBS-
Tween, 100 μΙ of streptavidm-horseradish peroxidase conjugate (diluted 1: 1000 in PBS) was 
added and incubated for I h at 37°C. Wells were washed before the substrate was added (Sigma 
OPD kit). The reaction was stopped by 2M H2S04 and absorbance was measured at 490 nm 
TNF-a and IL-1 β were assayed by ELISA's developed in our laboratory in Cleveland 
Immulon III plates were coated for 2 h at 37° with 100 μΙ anti-TNF-cc monoclonal antibody 
(Boehnnger) diluted I '40 in a bicarbonate buffrer, pH 9.0, and placed overnight at 4°C. After 5 
washings with TBS containing 0.05% Tween 20, nonspecific binding of proteins to the plastic was 
blocked by 3 h of incubation with 200 μΙ non-fat dry milk in bicarbonate buffer. After 5 washings, 
100 μΙ samples and standards were allowed to incubate for 2 h at 37°C. Each sample was 
assayed in duplicate. After 5 washings, polyclonal rabbit anti-human TNF-a (Endogen) diluted 
1:1000 in PBS containing 2% non-fat dry milk was incubated for 2 h at 37°C. After incubation 
with horseradish conjugated goat anti-rabbit antiserum (Tago) diluted 1: 1000 in PBS with 2% non­
fat dry milk, OPD substrate (Sigma krt) was used. After a few minutes, the color development was 
stopped with 50 μΙ 2N sulfunc acid and absorbance measured at 490 nm. The lower limit of 
detection was 15 pg/ml. 
The ELISA for IL-1 β involved coating Immulon III plates for 24 h at 4°C with polyclonal anti-IL-
I β antibody diluted 1:9000 in PBS. The plates were washed 3 times with PBS containing 0.05% 
Tween 20 and were incubated for 90 mm at room temperature with PBS containing 5% non-fat 
dry milk. After 3 washings, 100 μΙ samples and standards were added and incubated 90 mm at 
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room temperature After washing again, polyclonal rabbit anti-human IL-1 β antiserum diluted 
1.4000 in PBS containing I % non-fat dry milk was added, and after 90 mm at room temperature, 
horseradish peroxidase-conjugated goat anti-rabbit antiserum (Tago) diluted 1.3000 was added 
and the plate was incubated for an additional hour. After washing, OPD solution (Sigma kit) was 
added and the color development terminated after approximately 5 mm with 50 μ\ 2N sulfuric 
acid. Optical density was read at 490 nm. The lower limit of detection with this asay is 7 pg/ml.. 
IL-6 was measured using a commercial sandwich ELISA (R&D systems, Ine, Minneapolis, MN). 
The assays were earned out according to the manufacturers' instructions and all samples were 
tested in duplicate. 
RNA isolation and analysis 
Total RNA was isolated from stimulated НерЗВ cells by guanidinium isothiocyanate lysis 
following a modification of the method of Chomczynski and Sacchi (13). RNA samples ( 15 ¡u.g per 
lane) were heat denaturated at 65°C in a solution consisting of 50% deionized formamide, 2 M 
formaldehyde in 0.2 M 3-(N-Morpholino)propane sulfonic acid (MOPS) buffer, pH 7.0, with 10 
mM EDTA and than fractionated on I % agarose gels containing 2.2 M formaldehyde. After 
transfer to MagnaGraph nylon (Micron Separations Inc., Westboro, MA) by 3 hours of vacuum 
blotting, RNA was UV cross-linked to the membrane. Dried membranes were photographed 
under UV transamination. Pre-hybndization (4h) and hybridization ( 18h) with CRP and SAA 
cDNA probes labeled with 32P-dCTP by the random primer method (ІГІ cpm) were performed 
at 42°C in hybndizaton buffer containing 50% deionized formamide, 5x standard saline solution 
(SSQ, Ix Denhardfs solution, 1% sodium dodecylsulphate (SDS) and 10 mg/ml denaturated 
salmon sperm DNA Following hybndizaton, nonspecifically bound radioactivity was removed 
from membranes by washing twice with 6x SSC, 0.1 % SDS at room temperature for 30 mm, 
followed by two subsequent washes for 15 mm with 0.1 χ SSC, 0.1% SDS at 62°C. The 
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membranes were then exposed at -70°C to X-Omat AR Kodak film Membranes were stnpped 
by 5 mm exposure to 95°C distilled H 2 0 containing 1% SDS before hybridization with the next 
labeled probe The probes used were I) CRP, pCRP5, kindly provided by H R Colten, St 
Louis, MO (14), 2) SM, pAIO (capable of detecting all SAA isotypes) courtesy of J Sipe, Boston 
MA (15) The intensities of I8S RNA bands on photographs of ethidium bromide stained 
formaldehyde gels and of mRNA bands on autoradiographs were measured by using an UMAX 
scanner (Data System Ine , Hsmchu, Taiwan) with the software Intelligent Quantfier for Maantosh 
(Bio Image, Ann Arbor, Ml) Densitometry of 18S rRNA bands was used to correct for minor 
technical variations and the autoradiograph band intensities were adjusted appropnately 
Statistical analysis 
All results are shown as the mean ± standard error of the mean (SEM) Comparison between 
groups was assessed by the unpaired nonparametnc Mann Whitney U test A ρ value of <0 05 
was considered to be the lowest level of significance 
9.3 Results 
Cytokine Production by PBMC 
The concentrations of cytokines in CM, reflecting production by PBMC over 24 hr of 
incubation, are indicated in Table I. CM derived from unstimulated PBMC from HIDS patients 
(HIDS-CM) contained significantly more IL-1 β, IL-6 and TNF-a than did CM denved from PBMC 
of FMF patients (FMF-CM) 
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TABLE I: IL-1 β, IL-6 and TNF-a content of CM from unstimulated PBMC of HIDS and 
FMF patients compared to that of healthy controls as measured by specific ELISA assays. 
HIDS FMF Control 
IL-1 ß 3.2 ± I. I ' 0.64 ± 0.42 0.048 ± 0.4 
IL-6 11.7 + 4.6' 5.1 ± 2.82 0.068 + 0.017 
TNF« l.5±0.75' 0.072±0.04 0.065±0.0l2 
CM was prepared from unstimulated PBMC Data are expressed as mean ± SEM in 
ng/ml 
FMF-CM, in turn, contained significantly more IL-1 β and IL-6, but not TNF-a, than did CM 
derived from PBMC of healthy controls (C-CM). In all 3 groups, cytokine production by PBMC 
stimulated with 100 ng/ml LPS was significantly increased compared to unstimulated PBMCs 
(Table 2). 
TABLE 2: IL-1 β, IL-6 and TNF-ct content of CM from LPS stimulated PBMC of HIDS and 
FMF patients compared to that of healthy controls as measured by specific ELISA assays. 
HIDS FMF Control 
IL-1 ß 63±7.2' I9.8±3.3 22±6.9 
IL-6 I50±23.7' 73±4. l2 I5.3±8 
TNF« 7.4±2.4 5.5±2.9 l.4±0.8 
CM was prepared from PBMC stimulated with 100 ngAnl LPS. Data are expressed as 
mean ± SEM in ng/M. 
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Figi. 
Effect of CM (10%) from unstimulated 
PBMC of patients with HIDS (•), FMF (X) 
and healthy controls (=) (C-CM) on the 
production of CRP from НерЗВ cells. 
Supernatant were harvested after 24 
hours of incubation and CRP 
concentrations determined. Results are 
expressed as mean ± SEM. HIDS-CM 
caused significantly more CRP production 
than did FMF-CM and C-CM ("p < 0.01 ). 
Stimulated HIDS-CM contained 3-fold more IL-1 β and 2-fold more IL-6 than did stimulated FMF-
CM. Unlike unstimulated PBMC, LPS-stimulated PBMC derived from HIDS and FMF patients 
produced comparable amounts of TNF-a. LPS-stimulated FMF-CM contained more IL-6 than did 
C-CM, while IL-1 and TNF-a production did not differ between these 2 groups. 
Acute Phase Response to CM 
Unstimulated PBMC 
Incubation of НерЗВ cells for 24h with unstimulated HIDS-CM resulted in 5-fold greater 
accumulation of CFÑP in culture medium, reflecting greater production, than was observed with 
unstimulated FMF-CM (p<0.00l) or C-CM (p<0.005) (Fig. I). Unstimulated HIDS-CM also 
caused significantly greater increases in levels of mFlNA in НерЗВ cells for СВР (7-fold) and S M 
(50-fold) than did unstimulated FMF-CM (Fig. 2). 
Unstimulated HIDS-CM induced about 2.6-fold higher CRP mRNA and 5-fold higher mRNA 
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Fig '2: Effect of CM from unstimulated PBMC of patients with HIDS (•). FMF (X) and healthy controls (=) on 
levels of mRNA in НерЗВ cells for CRP (left panel) and SAA (right panel). Results are represented as 
fold increase over mRNA levels in unstimulated Hep 3B cells. *p < 0 05 for HIDS compared to FMF 
patients 
levels for S M than did C-CM but neither of these differences could be shown to achieve statistical 
significance. 
LPS-sùmulated PBMC 
For all three groups, stimulation with LPS led to production of CM capable of greater acute 
phase protein inducing ability than was seen with unstimulated PBMC НерЗВ cells incubated with 
stimulated HIDS-CM secreted 5-fold more CRP than did cells incubated with stimulated FMF-CM 
or C-CM (Fig. 3), and 2 4-fold more than cells incubated with unstimulated HIDS-CM (p=0.01 ) 
Following incubation of Hep 3B cells with LPS-stimulated HIDS-CM, CPR and S M mRNA levels 
were significantly greater than was observed following incubation with FMF-CM or C-CM (Fig. 4) 
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9.4 Discussion 
The major purpose of the current investigation was to determine the extent to which clinically 
observed differences in the magnitude of the acute phase response in HIDS and FMF patients, as 
measured by serum levels of acute phase proteins, could be attributed to differences in release of 
inflammatory cytokines by PBMC from these patients. 
Fig3. 
Effect of CM from LPS-sùmulated PBMC of 
patients with HIDS ( • ) , FMF (X) and healthy 
controls (=) on production of CRP from НерЗВ 
cells НерЗВ cells were incubated with 10% 
CM obtained from PBMC stimulated with 100 
ng/M £ Coli LPS. After 24 hours, supernatants 
were harvested and CRP concentrations 
determined. Results are expressed as mean ± 
SEM. Stimulated HIDS-CM caused significantly 
more CRP production than did FMF-CM and C-
C M ( " p < 0 . 0 l ) . 
We found that unstimulated PBMC from patients with inactive HIDS released significantly more 
IL-1 ß, IL-6 and TNF-a than did PBMC from patients with FMF, and that CM from these cells 
induced significantly greater CFAP production and significantly more mRNA for CFIP and S M in 
НерЗВ cells than did CM from FMF patents. These results support the hypothesis that differences 
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in the magnitude of the acute phase response between HIDS and FMF patients reflect differences 
in cytokine production by their PBMC and indicate that these effects on acute phase protein 
production are exerted at the pre-translational level. We studied PBMC rather than monocytes 
because isolation of monocytes involves an adherence step which may itself activate these cells, 
which we wanted to avoid. To the extent to which findings in PBMC reflect the behaviour of 
monocytes and tissue macrophages, our findings raise the possibility that macrophages may also 
produce large amounts of these inflammatory cytokines in patients with HIDS. In addition, our 
findings also indicate that PBMC are already markedly activated in vivo in patients with inactive 
HIDS In contrast, unstimulated PBMC from patients with inactive FMF produced substantially less 
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Fig 4 Effect of CM from LPS-stimulated PBMC of patents with HIDS (•), FMF (X) and healthy controls (=) 
on levels of m RNA in НерЗВ cells for CRP (left panel) and SM (right panel) Results are represented 
as fold increase over mRNA levels in unstimulated НерЗВ cells, 'p < 0.05 for HIDS patients 
compared to FMF patients. 
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IL-1 β and IL-6, and their TNF-a production was indistinguishable from that seen in PBMC from 
healthy controls. Overproduction of cytokines by unstimulated PBMC from HIDS patients could 
be due either to faulty regulation of autonomous cytokine production or to the effects of an 
exogenous stimulatory factor. Recent findings favor the latter explanation; IgD isolated from HIDS 
patients has been found to stimulate normal human PBMC to produce large quantities of IL-1 ß, IL-
6, TNF-ot and leukocyte inhibitory factor (Drenth, unpublished observations) It is reasonable to 
conclude, in light of our current findings, that the high concentrations of IgD seen in these patients 
serve as a continuous stimulus to inflammatory cytokine production, even during clinically inactive 
periods. This conclusion is consistent with our previous observation that increased fucosylation of 
α,-acid glycoprotein (AGP), a phenomenon shown to be due to the effects of cytokines (16), is 
found in HIDS patients during asymptomatic intervals. The finding that CM derived from 
unstimulated PBMC from HIDS patients in the mtercntical phase is able to induce an acute phase 
response in НерЗВ cells, a relatively insensitive bioassay (17), supports this conclusion, as does the 
observation that serum AGP concentrations are persistently elevated between attacks and increase 
slightly during febnle attacks of HIDS ( 16). 
There has been similar interest in the effect of CM derived from circulating cells on the synthesis 
of acute phase proteins in other inflammatory disorders, Patients with active Crohn's disease 
generally have higher circulating CRP concentrations compared with those with ulcerative colitis 
( 18). IL-1 ß and TNF-a production by unstimulated peripheral monocytes was not different in cells 
from patients with Crohn's disease than in those with ulcerative colitis, but LPS-stimulated cytokine 
production was significantly higher in monocytes from Crohn's disease patents (ΙΘ) and this 
difference was even greater during active disease. CM from both unstimulated and stimulated 
monocytes from patients with active Crohn's disease induced greater release of CRP from 
PLC/PRF/5 human hepatoma cells than did CM from patients with active ulcerative colitis ( 19). 
Similarly, CM from unstimulated and LPS-stimulated PBMC from patients with rheumatoid arthritis 
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significantly increased production of arantichymotrypsm and q -proteinase-inhibitor by HepG2 
cells over levels achieved by CM from PBMC of patients with active systemic lupus erythematosus 
(20). 
The differences we observed in the profile of cytokines produced by unstimulated PBMC from 
patients with inactive HIDS and FMF indicate both qualitative and quantitative differences in 
cytokine production in patients with these two periodic inflammatory disorders during mtercntical 
periods. Unstimulated PBMC from FMF patients produced significantly more IL-6 and IL-1 β, but 
not TNF-a, than did PBMC from normal controls, while PBMC from HIDS patients produced 
significantly more of all three cytokines than did FMF PBMC. Taken together with the observation 
that supernatants from both unstimulated and LPS-stimulated PBMC from HIDS and FMF patients 
differed in their capacity to elicit CRP production and acute phase protein mP\NA changes in 
НерЗВ cells, these findings suggest differences in the pathogenesis of these two mtermittant febrile 
disorders. 
Finally, the observation that HIDS PBMC, although already activated, were able to respond to 
LPS-stimulation with further increase in cytokine production and increased acute phase protem-
mducmg capability is consistent with the hypothesis that acute febrile attacks are precipitated by 
unknown stimuli capable of further increasing cytokine production. There is evidence that the 
ability to produce cytokines in HIDS patients increases during febrile attacks. In these patients LPS-
stimulated ex-vivo production of TNF-a and IL-1G, as measured in a whole blood culture system, 
was found to be significantly greater during acute attacks than following defervescence (6). In 
contrast, LPS-stimulated TNF-a and IL-1 β production in supernatants of PBMC from FMF patents 
was markedly decreased dunng febnle attacks but normalized during recovery (21 -23). This 
apparent differential regulation of cytokines during attacks in these 2 syndromes might further 
explain the difference in the magnitude of the acute phase response observed in vivo. 
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IO. I Summary 
T his thesis deals with various aspects of a recent discovered syndrome· the hyper-lgD syndro-me (HIDS). HIDS is a periodic fever syndrome charactenzed by recurrent febrile attacks 
with abdominal complaints, skin lesions and joint involvement. All patients share a high serum 
IgD, hence the name HIDS. In 1992, the International Hyper-lgD Study Group has been established. This 
group consists of physicians from 9 different, mainly European countnes. The studies presented here, have 
been made possible through intensive cooperation wrth this Study Group The first part of this thesis is 
focused on several clinical aspects of the condition such as demographic features, charactenstics of attacks 
and clinical features. The second part deals with genetic aspects of HIDS and the involvement of cytokines 
during the attacks The last part investigates the role of IgD in pathogenesis of the syndrome and studies 
the acute phase reaction occurring in these patients. 
Chapter 2. 
We conducted a search to obtain data on patients known to have HIDS. We were able to collect 
clinical and laboratory data for 50 cases (28 male and 22 female). Most patients onginated from Europe: 
The Netherlands (28 cases, 56%); France ( 10 cases, 20%), and Italy (3 cases, 6%). One patent comes 
from Japan. The syndrome is typified by a very young age at onset (median 0.5 years) and life-long 
persistence of the penodic fever. Characteristically, attacks occur every 4-8 weeks and continue for 3-7 
days, but there is a large inter-individual variation. Attacks feature high spiking fever, and are associated 
with lymphadenopathy, skin lesions, abdominal pains, vomiting, diarrhoea, and headache. Most patents 
report arthralgias and a non-destructive poly-arthntis, mainly of the large joints (knee and ankle). Serosrtis 
was only seen in 3 patents and we did not find amyloidosis. All patents had persistently elevated serum 
IgD concentratons (> 100 U/mL) and in a majority IgA was likewise increased. 
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During attacks there is an acute phase response So fer the pathogenesis remains to be elucidated 
and treatment is only supportive. 
Chapter 3. 
Here we report on the clinical aspects of skin lesions in 44 patients with HIDS. Most common­
ly, erythematous macules and papules were seen but urticarial lesions and erythematous nodules 
were not uncommon. Skin biopsy specimen of 10 HIDS patients were reviewed and most 
showed perivascular inflammatory infiltrates composed of lymphocytes and polymorphonuclear 
cells suggestive for vasculitis. 
Chapter 4. 
HIDS appears to be a familial disorder and we were able to trace 7 families with 2 or more sibs 
affected Serum IgD measurements in these families revealed high values in patients but low values 
in unaffected members supporting the concept of autosomal recessive mhentance. As HIDS does 
resemble FMF in some aspects, our interest in the genetic aspects of HIDS was raised after the 
discovery of genetic location of FMF on the short arm of chromosome 16. No linkage could be 
obtained between markers on chromosome 16p and HIDS and haplotype analysis excluded this 
locus as the cause of HIDS. 
Chapter 5. 
We examined the acute phase protein response and the role of the cytokines and their inhibito­
ry compounds in 22 patients during attacks and remission. The acute phase proteins C-reactive 
protein and phosphohpase A2 modulated with disease activity. Plasma concentrations of 
mterleukm-1 α (IL-1 α), IL-Iß and IL-10 remained unchanged regardless of the phase of the 
disease, but tumor necrosis fector-α (TNFa) and IL-6 concentrations increased significantly during 
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attacks. The values of the antiinflammatory compounds IL-1 receptor antagonist and soluble TNF 
receptors p55 and p75 increased also during attacks The ex-vivo production of TNFa, IL-113 and 
IL-1 ra as tested in whole blood cultures was higher with attacks These data point to an activation 
of the cytokine network and suggest that these inflammatory mediators contribute to the sympto­
matology of HIDS. 
Chapter 6. 
Attacks in HIDS are clearly associated with an important inflammatory reaction and lnterferon-γ 
(IFN-γ), as a major inflammatory cytokine could play a role in the pathogenesis. Neoptenn is 
released by mononuclear cells when stimulated with IFN-γ and secreted unchanged in urine We 
measured IFN-γ and urine neoptenn in 10 HIDS patients dunng and in between attacks. Results 
show that IFN-γ and urine neoptenn increase dunng attacks which suggest activation of the cellular 
immunity dunng febrile episodes. It appears that unne neoptenn is a good quantitative and qualita­
tive parameter to monitor disease activity in HIDS. 
Chapter 7. 
The next study studied the changes in concentration and glycosylation of the acute phase 
protein α,-acid glycoprotein (AGP) from 10 HIDS patients. Compared to healthy controls AGP 
concentrations were increased dunng attacks and remissions. Dunng attacks there was an increa­
sed presence of diantennary glycan-contammg glycoforms of AGP. Moreover, we observed a 
continuous high degree of α μ 3 fucosylation which was accompanied by a continuous high expressi­
on of sialyl Lewis" on AGP. These inflammatory changes were also present dunng asymptomatic 
intervals, which suggests an element of persistent inflammation in HIDS. 
Chapter 8. 
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The role of the elevated IgD in HIDS is unclear. In order to investigate the relation between 
IgD and the inflammatory changes in HIDS, we isolated IgD from a HIDS patient and tested 
whether it was able to influence the synthesis of IL-1 ß, TNFa and IL-1 ra in normal peripheral 
blood mononuclear cells. Incubation for 24 hours resulted in a dose-dependent increase of these 
inflammatory mediators. This suggest that IgD may serve a role in the inflammatory response in 
attacks of HIDS. 
Chapter 9. 
Attacks in HIDS are accompanied by an intense acute phase reaction, and higher concentrations 
of the acute phase proteins are attained in HIDS than in FMF. We examined whether mononu-
clear cells from these patients differ in their capacity in producing acute phase protein-inducing 
mediators. 
Compared to FMF, mononuclear cells from HIDS patients produced more IL-Iß, TNFa and IL-6 
and induced greater CRP production by Hep 3B cells. Furthermore, compared to FMF, the 
mRNA content for CRP, SAA and fibrinogen were much higher in HIDS treated Hep 3B cells. 
10.1 Epilogue 
From the studies outlined in this thesis it can be concluded that HIDS represents a distinct 
clinical entity and differs from previously described periodic fever syndromes. One important goal 
of this thesis was to delineate HIDS from other periodic fever syndromes and especially FMF. 
Although these syndromes are clinically different, doubt remained whether HIDS and FMF are 
variants of the same condition. Using linkage analysis we have shown that the location of the gene 
for HIDS differs from that of FMF. The pathogenesis of the febrile attacks is unclear but it is unlikely 
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that they are caused by any of the known infectious agents. We have tried to identify a pyrogemc 
molecule responsible for the attacks. Although, we found increased concentrations of TNFa, IL-6 
and IFN-γ in plasma samples of HIDS patents dunng febnle attacks it is unsure whether this fully 
explains the clinical picture. The finding of increased serum IgD concentrations is of paramount 
importance to identify HIDS. Initially, it was thought that IgD-contaming complexes played a 
pathogenetic role in HIDS. However, IgD complexes were found in patents with and without 
periodic fever and such complexes were present both during and in between attacks. Furthermo­
re, IgD did not modulate with seventy and frequency of attacks and lastly, the nse of serum IgD 
was heralded by symptoms in HIDS patents. On the other hand, we detected that isolated serum 
IgD is a very potent inducer of a wide array of cytokines by PBMC. In this respect, attacks in HIDS 
could be precipitated by the mactivaton of an (as yet unidentified) inhibitory compound which 
allows IgD to elicit an exaggerated cytokine response. The PBMC from these patents are very 
sensitve and are able to produce large amounts of cytokines even if not stmulated Furthermore, 
most parameters of the acute phase response return to normal values but the α,,3 fucosylation of 
otracid glycoprotein is increased during and in between episodes which illustrates that there is a 
continuous state of inflammaton. Additonal efforts will be needed to identfy the pathogenetc 
inflammatory mediator. The results obtained here may be beneficial for other recurrent inflamma­
tory disorders. Further research will be focused on the locahzaton of the HIDS gene which 
requires an expansion of the number of families with HIDS patents Informaton about the gene 
and gene product will be necessary to provide a more precise definiton of the pathogenesis 
Lastiy, future mvestgatons should deal with the identficaton of new therapeute strategies Since 
vaccinations are able to elicit febnle attacks in HIDS this is a patentai attractive model to test the 
efficacy of vanous therapeute optons. 
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IO.I Samenvatting 
D it proefschrift handelt over verschillende aspecten van een recent ontdekte aandoening genaamd "het hyper-lgD syndroom" (HIDS). HIDS is een van de periodieke koorts syndromen en wordt gekenmerkt door steeds wederkerende 
aanvallen van koorts, buikklachten, huidafwijkingen en gewrichtspijnen. Alle patenten hebben een 
hoog serum IgD gehalte zodat de naam HIDS gekozen werd. In 1992 werd een internationale 
onderzoeksgroep rond HIDS opgericht. Deze groep bestaat uit artsen afkomstig uit 9, 
voornamelijk Europese, landen De onderzoekingen die in dit proefschnft beschreven staan zijn 
mogelijk gemaakt door intensieve samenwerking met de leden van deze onderzoeksgroep Het 
eerste gedeelte van dit proefschrift is gericht op de beschnjvmg van de klinische aspecten van de 
aandoening zoals de demografische kenmerken, de symptomen tijdens de koortsaanvallen, en de 
laboratorium uitslagen verkregen tijdens en buiten de aanvallen. Het tweede gedeelte handelt 
over de genetische aspecten van HIDS. Het laatste deel van het proefschnft gaat in op de rol van 
cytokinen tijdens de aanvallen, de rol van het IgD in de Pathogenese van de ziekte en de 
onderzoekingen rond de acute fase reactie in HIDS. 
Hoofdstuk 2 
Wij hebben een onderzoek verncht teneinde de presentatie en beloop van HIDS in kaart te 
brengen. In totaal konden we de klinische en laboratonum gegevens van 50 patiënten (28 mannen 
en 22 vrouwen) analyseren. De meeste patenten zijn afkomstg uit Nederland (28 gevallen, 
56%), Franknjk (10 gevallen, 20%) en Italië (3 gevallen, 6%), Eén patent komt uit Japan. Het 
syndroom wordt gekenmerkt door een begin van de klachten op zéér jonge leeftijd (mediaan 6 
maanden) en door het levenslang aanwezig blijven van de aanvallen. De aanvallen treden elke 4 
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tot θ weken op en duren gemiddeld 3 tot 7 dagen, maar er is een grote individuele vánate De 
aanvallen met piekende koorts worden begeleid door gezwollen lymfeklieren, huidafwijkingen, 
buikklachten en hoofdpijn. De meeste patiënten hebben pijnlijke en, soms, gezwollen gewnchten 
(met name knieën en enkels). Ontsteking van de weivliezen namen WIJ in slechts 3 gevallen waar. 
Alle patenten hebben een verhoogd serum Immunoglobuline D (IgD) gehalte (> 100 ΙΕ/ml) en bij 
de meerderheid is het IgA ook verhoogd. Tijdens de aanvallen is er een evidente acute fase 
reactie. Tot op heden is de Pathogenese van het ziektebeeld onopgehelderd en is de behandeling 
louter symptomatsch. 
Hoofdstuk 3. 
De huidafwijkingen tjdens de koortsaanvallen nemen een opvallende plaats in. Wij 
bestudeerden de klinische aspecten van de huidafwijkingen van 44 HIDS patenten. 
Erythemateuze maculae en papéis werden het meest gezien maar ook urticaria kwamen voor. De 
huidbiopten van 10 patenten werden onderzocht en de meesten werden gekenmerkt door de 
aanwezigheid van ontstekingsinfiftraatjes rond de vaten die opgebouwd waren uit witte 
bloedcellen. 
Hoofdstuk 4. 
HIDS is een familiaire aandoening en we zijn in staat geweest om 7 families met 2 of meer 
aangedane broers en of zussen op te sporen. Metng van serum IgD concentrates laat hoge 
waarden zien bij patenten maar lage waarden bij niet aangedane familieleden. Drt wijst erop dat 
de aandoening waarschijnlijk autosomaal recessief overerft. Aangezien HIDS tot op zekere hoogte 
overeenkomsten vertoont met FMF werd onze interesse gewekt door het nieuws dat het gen 
voor FMF was ontdekt op de korte arm van chromosoom 16. Wij konden de koppeling tussen 
markers op chromosoom 16 en HIDS uitsluiten, hetgeen het erg onwaarschijnlijk maakt dat dit 
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locus het gen bevat dat cedeert voor HIDS. 
Hoofdstuk 5. 
De acute fase respons en de rol van de cytokmen en hun remmers werden bestudeerd tijdens 
een aanval en daarbuiten. De acute fase eiwitten C-reactive protein en phospholipase Aj waren 
duidelijk verhoogd tijdens een aanval maar namen daarbuiten af. De plasma concentraties van 
interleukme la (IL-la), IL-Iß en IL-10 bleven onveranderd maar de tumor necrosis factor-a 
(TNFa) en IL-6 concentraties namen significant toe tijdens aanvallen. De concentraties van de 
antinflammatoire eiwitten als IL-1 receptor antagonist en de oplosbare TNF receptoren p55 en 
p75 namen toe tijdens een aanval De door LPS gestimuleerde ex-vivo produktie van TNFa, IL-
I ß en IL-1 ra zoals onderzocht in een volbloed kweek methode, waren duidelijk hoger tijdens een 
aanval. Deze gegevens wijzen op een activate van het cytokmen netwerk en wijzen er op dat 
deze ontstekmgs-mediatoren mogelijk een rol spelen bij het ontstaan van de symptomen bij HIDS. 
Hoofdstuk 6. 
Tijdens koorts aanvallen bij HIDS neemt de ontstekingsreactie een belangrijke plaats in. 
Interferon-γ (IFN-γ), een belangnjke ontstekingsmediator, zou mogelijk een rol kunnen spelen in 
de Pathogenese. Neoptenne komt vnj uit witte bloedcellen als deze gestimuleerd worden door 
IFN-γ en verschijnt onveranderd in de urine. Wij hebben IFN-γ en unne neoptenne bij 10 HIDS 
patiënten gemeten tijdens en ook buiten een aanval. De resultaten laten zien dat tijdens de 
koortsaanvallen IFN-γ in het serum en neoptenne in de unne in verhoogde mate aanwezig zijn. 
Dit suggereert dat het cellulaire immuniteitssysteem tijdens een aanval geactiveerd is. Meting van 
het neoptenne in de unne blijkt een goede kwalitatieve en kwantitatieve parameter te zijn om 
koortsaanvallen bij HIDS patiënten te vervolgen. 
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Hoofdstuk 7. 
Hierna onderzochten wij de verandering in concentratie en glycosylering van het acute fase 
eiwit 0|-zure glycoproteine (AGP) bij 10 HIDS patiënten. Vergeleken met gezonde vrijwilligers 
bleken de AGP concentraties bij HIDS patiënten niet alleen tijdens aanvallen verhoogd maar ook 
daarbuiten. Tijdens de koorts episodes was er een verhoogde aanwezigheid van diantennaire 
suikerketens op het AGP. Bovendien namen we een continue verhoogde a b 3 fucosylering met 
een toegenomen expressie van sialyl Lewis" op het AGP waar. Deze inflammatoire veranderingen 
waren ook buiten een aanval aanwezig hetgeen er op wijst dat er een continue, sluimerende 
ontsteking aanwezig is bij HIDS. 
Hoofdstuk 8. 
De rol van het verhoogde IgD bij HIDS is nog onduidelijk. Teneinde de samenhang tussen IgD 
en de ontsteking bij HIDS te bestuderen werd IgD uit het serum van een HIDS patiënte 
geïsoleerd. Incubatie van IgD met normale witte bloedcellen resulteerde in een dosis afhankelijke 
stijging van IL-1 ß, TNFa en IL-1 ra produktie. Deze gegevens wijzen er op dat IgD mogelijk een 
rol speelt bij de aanvallen van HIDS. 
Hoofdstuk 9. 
Aanvallen bij HIDS patiënten worden vergezeld door een intense acute fase reactie. Bovendien 
worden bij HIDS in vergelijking met Middellandse zeekoorts (FMF) hogere concentraties van de 
acute fase eiwitten gezien. Wij onderzochten of witte bloedcellen van deze patiënten verschillen in 
de capaciteit om acute fase eiwit stimulerende mediatoren te maken. Vergeleken met FMF, 
produceerden witte bloedcellen van HIDS patiënten aanzienlijk meer IL-Iß, TNFa en IL-6 en 
stimuleerden Hep 3B cellen tot een grotere CRP produktie. Daarnaast was er in de HIDS 
behandelde cellen meer mRNA voor CP\P, SAA en fibrinogeen aanwezig in vergelijking met FMF. 
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IO.I Epiloog 
Uit de onderzoekingen die in dit proefschrift beschreven staan kan worden geconcludeerd dat 
HIDS een aparte klinische entiteit is en verschilt van eerder beschreven periodieke 
koortssyndromen Een belangrijk doel van dit proefschrift was het in kaart brengen van HIDS en 
het te onderscheiden van andere periodieke koortssyndromen als FMF Hoewel deze syndromen 
klinisch van elkaar te onderscheiden zijn, bleef er twijfel bestaan of beide syndromen varianten zijn 
van dezelfde aandoening Met behulp van koppelingsonderzoek hebben we aangetoond dat het 
gen voor FMF een andere is dan voor HIDS De Pathogenese van de steeds wederkerende 
koortsaanvallen is onduidelijk maar het is onwaarschijnlijk dat deze veroorzaakt worden door een 
(bekend) mfectieus agens We hebben getracht om het koorts verwekkend molecuul dat mogelijk 
verantwoordelijk is voor de aanvallen te identificeren en hebben daarbij onze aandacht gericht op 
de rol van de cytokmen. Ofschoon verhoogde concentraties van TNFct, IL-6 en IFN-γ gevonden 
zijn, is het niet waarschijnlijk dat deze cytokmen alle symptomen by HIDS kunnen verklaren De 
verhoogde serum IgD concentratie is van groot belang bij het vaststellen van de diagnose. Initieel 
werd gedacht dat IgD-bevattende complexen een pathogenetische rol zouden spelen IgD 
complexen werden echter ook aangetroffen bij patiënten zonder periodieke koorts en bij de HIDS 
patenten waren ze niet alleen tijdens maar ook buiten koortsaanvallen in de circulatie aanwezig 
Daarnaast blijkt uit onze gegevens dat de frequentie en ernst van de aanvallen niet afhangt van de 
hoogte van het IgD Bovendien blijkt dat bij patiënten met HIDS de symptomen voorafgegaan 
worden door de stijging van het serum IgD. Aan de andere kant hebben we echter wel 
geconstateerd dat IgD in staat is om witte bloedcellen aan te zetten tot het maken van cytokmen. 
Wellicht wordt de koorts aanval bij HIDS veroorzaakt door de inactivate van een tot nog toe 
onbekende remmer waardoor het IgD in staat is om de cytokmen produktie op gang te brengen 
waardoor vervolgens de symptomen ontstaan. De witte bloedcellen van HIDS patiënten lijken erg 
Samenvatting & Epiloog 193 
gevoelig en produceren ongestimuleerd reeds grote hoeveelheden cytokinen 
De meeste parameters van de acute fase respons normaliseren na een koortsaanval De a,,3 
fucosylermg van het AGP is echter niet alleen verhoogd tijdens de aanvallen maar ook daarbuiten 
hetgeen duidt op een constante sluimerende ontsteking Verder onderzoek zal nodig zijn om de 
ontstekmgs mediator te identificeren die bij dit syndroom een oorzakelijke rol speelt De resultaten 
kunnen niet alleen van belang zijn voor patenten met HIDS maar mogelijk ook voor patiënten 
met andere penodieke koortsvormen, zoals FMF Daarnaast zal toekomstig onderzoek gericht 
moeten worden op het detecteren van de lokalisatie van het gen dat codeert voor HIDS 
Hiervoor is een uitbreiding van het aantal families met HIDS patiënten nodig Informatie over het 
gen en het eiwitprodukt waarvoor dit gen codeert zal ons veel leren over de Pathogenese van dit 
syndroom Tenslotte zal er in de toekomst gezocht moeten worden naar een goede therapie 
voor HIDS Omdat vaccinaties bij de meeste patiënten een aanval lijkt uit te lokken is dit mogelijk 
een goed model om nieuwe therapeutische opties te bestuderen 
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Met de voltooing van drt proefschrift eindigt een uiterst plezierige periode waann ik alle tijd en 
energie in onderzoek mocht steken. Drt werd onder meer gefaciliteerd door de beurs voor 
assistent-geneeskundigen in opleiding tot klinisch onderzoeker die door het NWO verstrekt werd. 
Het hyper-lgD syndroom is voor het eerst als zodanig beschreven door Prof. Dr. J.W.M, van der 
Meer en het is mede aan zijn inzet en enthousiasme te danken dat dit proefschrift nu voor U ligt. 
Het hyper-lgD syndroom is voor de patiënten door de weerkerende en niet te behandelen 
koortsaanvallen een crux. Aan hen draag ik dan ook dit proefschrift op, in de hoop dat nieuw 
onderzoek zal leiden tot een bruikbaar en effectief geneesmiddel. 
In de afgelopen penode heb ik afwisselend onderzoek kunnen verrichten in diverse laboratoria 
en ik wil diegenen die mij de gastvrijheid verleenden dan ook, met name, dankzeggen. In het 
laboratorium Anthropogenetica (Sint Radboudziekenhuis, Nijmegen) verbleef ik enige maanden in 
1993 en 1994. Edwin Manman, Prof. Dr. H.H. Ropers en in het bijzonder Saskia van de Velde-
Visser zeg ik dank. In 1995 ben ik werkzaam geweest in het MetroHealth Medical Center in 
Cleveland, (Ohio, USA) en ik wil dan ook Prof. Dr. I. Kushner en Deborah Rzewnicki bedanken 
voor de mij geboden gastvnjheid. De vrouwen van het laboratorium Algemene Interne 
Geneeskunde tolereerden mij zelfs gedurende de gehele onderzoeksperiode. Zonder meting van 
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